[
  {
    "id": 10,
    "user_query": "You MUST give a detailed answer to the following question: Name synonym of Acrokeratosis paraneoplastica.",
    "llama-7b_response": "verrucous carcinoma",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 47,
    "user_query": "You MUST give a detailed answer to the following question: Is Weaver syndrome similar to Sotos?",
    "llama-7b_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect growth and development, but they are distinct conditions.\n\nWeaver syndrome, also known as synostosis syndrome, is a condition characterized by premature closure of one or more sutures in the skull, resulting in an abnormal head shape and an increased risk of brain damage. This condition is caused by a mutation in the fibroblast growth factor receptor 1 (FGFR1) gene.\n\nSotos syndrome, on the other hand, is a condition caused by a chromosomal abnormality, specifically an extra copy of chromosome 15. This condition is characterized by rapid growth before and after birth, intellectual disability, distinctive facial features, and an increased risk of certain birth defects.\n\nWhile both Weaver syndrome and Sotos syndrome can affect growth and development, they are distinct conditions with different underlying causes and symptoms. Weaver syndrome is caused by a mutation in the FGFR1 gene, while Sotos syndrome is caused by an extra copy of chromosome 15. Additionally, Weaver syndrome is characterized by premature closure of one or more sutures in the skull and an abnormal head shape, while Sotos syndrome is characterized by rapid growth before and after birth, intellectual disability, distinctive facial features, and an increased risk of certain birth defects.",
    "llama-7b_fact_raw": "1. Weaver syndrome is a genetic disorder characterized by premature closure of one or more sutures in the skull.\n2. The cause of Weaver syndrome is a mutation in the fibroblast growth factor receptor 1 (FGFR1) gene.\n3. Sotos syndrome is a genetic condition characterized by rapid growth before and after birth and intellectual disability.\n4. Sotos syndrome is caused by a chromosomal abnormality, specifically an extra copy of chromosome 15.\n5. Weaver syndrome and Sotos syndrome are distinct conditions with different underlying genetic causes.",
    "llama-7b_fact": [
      "Weaver syndrome is a genetic disorder characterized by premature closure of one or more sutures in the skull.",
      "The cause of Weaver syndrome is a mutation in the fibroblast growth factor receptor 1 (FGFR1) gene.",
      "Sotos syndrome is a genetic condition characterized by rapid growth before and after birth and intellectual disability.",
      "Sotos syndrome is caused by a chromosomal abnormality, specifically an extra copy of chromosome 15.",
      "Weaver syndrome and Sotos syndrome are distinct conditions with different underlying genetic causes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Weaver syndrome is a genetic disorder characterized by rapid growth during childhood, distinctive facial features, and developmental delay, not by premature closure of one or more sutures in the skull (this last condition would more accurately describe craniosynostosis).\n2. FALSE [correction]: The cause of Weaver syndrome is most commonly associated with a mutation in the EZH2 gene, not the FGFR1 gene.\n3. TRUE\n4. FALSE [correction]: Sotos syndrome is most often caused by a mutation in the NSD1 gene, not by an extra copy of chromosome 15 (which characterizes another condition, Prader-Willi syndrome, when the extra copy is paternal, or Angelman syndrome, when the extra copy is maternal).\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of JASPAR database",
    "llama-7b_response": "The JASPAR database is a comprehensive database of protein-protein interaction data for eukaryotic proteins. It was first released in 2001 and has since been updated several times. Here are the releases of the JASPAR database:\n\n1. JASPAR 2001: The first release of the JASPAR database was in 2001. It contained information on 10,000 protein-protein interactions for 2,000 proteins from human, mouse, and rat.\n2. JASPAR 2004: The second release of the JASPAR database was in 2004. It contained information on 20,000 protein-protein interactions for 4,000 proteins from human, mouse, and rat.\n3. JASPAR 2007: The third release of the JASPAR database was in 2007. It contained information on 30,000 protein-protein interactions for 6,000 proteins from human, mouse, and rat.\n4. JASPAR 2010: The fourth release of the JASPAR database was in 2010. It contained information on 40,000 protein-protein interactions for 8,000 proteins from human, mouse, and rat.\n5. JASPAR 2013: The fifth release of the JASPAR database was in 2013. It contained information on 50,000 protein-protein interactions for 10,000 proteins from human, mouse, and rat.\n6. JASPAR 2016: The sixth release of the JASPAR database was in 2016. It contained information on 60,000 protein-protein interactions for 12,000 proteins from human, mouse, and rat.\n7. JASPAR 2019: The seventh release of the JASPAR database was in 2019. It contained information on 70,000 protein-protein interactions for 14,000 proteins from human, mouse, and rat.\n8. JASPAR 2021: The eighth release of the",
    "llama-7b_fact_raw": "1. The first release of the JASPAR database was in 2001.\n2. The JASPAR 2004 database release contained information on 20,000 protein-protein interactions for 4,000 proteins from human, mouse, and rat.\n3. The JASPAR 2010 database release contained information on 40,000 protein-protein interactions for 8,000 proteins from human, mouse, and rat.\n4. The JASPAR 2016 database release reported 60,000 protein-protein interactions for 12,000 proteins from human, mouse, and rat.\n5. The seventh release of the JASPAR database was in 2019, and it included data on 70,000 protein-protein interactions for 14,000 proteins from human, mouse, and rat.",
    "llama-7b_fact": [
      "The first release of the JASPAR database was in 2001.",
      "The JASPAR 2004 database release contained information on 20,000 protein-protein interactions for 4,000 proteins from human, mouse, and rat.",
      "The JASPAR 2010 database release contained information on 40,000 protein-protein interactions for 8,000 proteins from human, mouse, and rat.",
      "The JASPAR 2016 database release reported 60,000 protein-protein interactions for 12,000 proteins from human, mouse, and rat.",
      "The seventh release of the JASPAR database was in 2019, and it included data on 70,000 protein-protein interactions for 14,000 proteins from human, mouse, and rat."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The given numbers of protein-protein interactions and proteins are not associated with the JASPAR database. JASPAR is a database of curated, non-redundant transcription factor (TF) binding profiles stored as position frequency matrices for TFs across multiple species, but it does not focus on protein-protein interactions.\n3. FALSE [correction]: Again, the JASPAR database does not provide information on protein-protein interactions. It provides TF binding profiles.\n4. FALSE [correction]: The JASPAR 2016 database release would not have reported on protein-protein interactions, as JASPAR primarily provides data on transcription factor binding profiles.\n5. FALSE [correction]: Though there was a JASPAR release in 2019, the given data on protein-protein interactions and the number of proteins is incorrect as it does not relate to what is included in the JASPAR database. The JASPAR database contains transcription factor binding profiles, not protein-protein interaction data.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the viral KP4 protein?",
    "llama-7b_response": "The KP4 protein is a viral protein that is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV), which is a type of herpesvirus that is associated with the development of Kaposi's sarcoma (KS), an aggressive form of cancer that affects the skin and other organs.\n\nThe KP4 protein is a viral oncoprotein that plays a crucial role in the transformation of normal cells into cancer cells. The KP4 protein is a transcriptional activator, which means that it can bind to specific DNA sequences and activate or repress the transcription of target genes.\n\nThe KP4 protein has been shown to activate the transcription of a number of genes that are involved in cell proliferation, survival, and angiogenesis, which are processes that are critical for the development of cancer. For example, the KP4 protein has been shown to activate the transcription of the vascular endothelial growth factor (VEGF) gene, which encodes a protein that promotes angiogenesis and is a key factor in the development of KS.\n\nIn addition to its role in the transcriptional activation of target genes, the KP4 protein also has been shown to interact with a number of cellular proteins, including histone deacetylases (HDACs), which are enzymes that play a role in the regulation of chromatin structure and transcription. The KP4 protein has been shown to inhibit the activity of HDACs, which allows it to promote the transcription of target genes and contribute to the transformation of normal cells into cancer cells.\n\nOverall, the KP4 protein is an important viral oncoprotein that plays a critical role in the development of Kaposi's sarcoma and other forms of cancer associated with KSHV infection.",
    "llama-7b_fact_raw": "1. The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).\n2. KP4 is a viral oncoprotein involved in the transformation of normal cells into cancer cells.\n3. The KP4 protein functions as a transcriptional activator by binding to DNA sequences and influencing the transcription of genes.\n4. The KP4 protein activates the transcription of genes involved in cell proliferation, survival, and angiogenesis, such as the VEGF gene.\n5. The KP4 protein can interact with cellular proteins like histone deacetylases (HDACs) and inhibit their activity to promote transcription of target genes.",
    "llama-7b_fact": [
      "The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).",
      "KP4 is a viral oncoprotein involved in the transformation of normal cells into cancer cells.",
      "The KP4 protein functions as a transcriptional activator by binding to DNA sequences and influencing the transcription of genes.",
      "The KP4 protein activates the transcription of genes involved in cell proliferation, survival, and angiogenesis, such as the VEGF gene.",
      "The KP4 protein can interact with cellular proteins like histone deacetylases (HDACs) and inhibit their activity to promote transcription of target genes."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without additional specific information about the protein designations in Kaposi's sarcoma-associated herpesvirus (KSHV), it's difficult to confirm the correctness of this statement regarding \"KP4\" as protein nomenclature can vary.\n\n2. FALSE [correction]: It is known that KSHV encodes proteins with oncogenic potential, such as vGPCR, vFLIP, and LANA. However, referring specifically to a \"KP4\" protein requires more context. The primary oncoprotein associated with KSHV transformation is the viral G-protein-coupled receptor (vGPCR).\n\n3. UNKNOWN: Because the correctness of the statement about the \"KP4\" protein is not verified, the functionality attributed to it, including acting as a transcriptional activator, binding to DNA sequences, and influencing transcription, cannot be confirmed.\n\n4. UNKNOWN: Similar to the previous statements, the specific functions of the \"KP4\" protein, such as activating gene transcription involved in cell proliferation, survival, and angiogenesis, cannot be confirmed without further clarification of what \"KP4\" refers to in the context of KSHV.\n\n5. UNKNOWN: The interaction of the \"KP4\" protein with cellular proteins like histone deacetylases (HDACs) and inhibition of their activity is specific information that requires additional context or sources to verify. Without it, the statement remains undetermined.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "You MUST give a detailed answer to the following question: Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-7b_response": "Yes, DITPA (3,5-diiodothyronine) is a thyroid hormone analog that has been studied in both experimental and clinical settings.\n\nDITPA is a synthetic form of the thyroid hormone triiodothyronine (T3), which is produced naturally in the body by the thyroid gland. Like T3, DITPA is a potent regulator of metabolic processes, including energy production, growth, and development.\n\nIn experimental studies, DITPA has been used to investigate the mechanisms of thyroid hormone action and to study the effects of thyroid hormone deficiency and excess. For example, DITPA has been used to investigate the role of T3 in regulating body weight and metabolism, as well as the effects of T3 on various tissues and organs, such as the heart, muscles, and brain.\n\nIn clinical studies, DITPA has been used to treat patients with hypothyroidism, a condition in which the body does not produce enough thyroid hormone. In these studies, DITPA has been used as an alternative to synthetic T4 (levothyroxine) therapy, which is the most commonly used treatment for hypothyroidism. DITPA has been shown to be effective in improving symptoms of hypothyroidism, such as fatigue, weight gain, and depression, and has also been shown to improve metabolic parameters, such as body weight, cholesterol levels, and blood sugar levels.\n\nOverall, DITPA is a promising thyroid hormone analog that has been studied extensively in both experimental and clinical settings. Its use as a treatment for hypothyroidism and other thyroid disorders is still under investigation, and further research is needed to fully understand its potential benefits and risks.",
    "llama-7b_fact_raw": "1. DITPA (3,5-diiodothyronine) is a thyroid hormone analog that has been used in experimental and clinical studies.\n2. DITPA serves as a synthetic form of the naturally occurring thyroid hormone triiodothyronine (T3).\n3. Experimental studies with DITPA have looked into thyroid hormone action and the effects of thyroid hormone deficiency and excess, including its influence on body weight, metabolism, and various tissues.\n4. Clinical studies have used DITPA as a treatment for patients with hypothyroidism.\n5. DITPA has been found to be effective in improving symptoms and metabolic parameters in patients with hypothyroidism, which include fatigue, weight gain, depression, body weight, cholesterol levels, and blood sugar levels.",
    "llama-7b_fact": [
      "DITPA (3,5-diiodothyronine) is a thyroid hormone analog that has been used in experimental and clinical studies.",
      "DITPA serves as a synthetic form of the naturally occurring thyroid hormone triiodothyronine (T3).",
      "Experimental studies with DITPA have looked into thyroid hormone action and the effects of thyroid hormone deficiency and excess, including its influence on body weight, metabolism, and various tissues.",
      "Clinical studies have used DITPA as a treatment for patients with hypothyroidism.",
      "DITPA has been found to be effective in improving symptoms and metabolic parameters in patients with hypothyroidism, which include fatigue, weight gain, depression, body weight, cholesterol levels, and blood sugar levels."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: DITPA is an analog of thyroid hormones but is not a synthetic form of triiodothyronine (T3); it is structurally distinct although it may mimic some actions of T3.\n3. TRUE\n4. FALSE [correction]: Clinical studies with DITPA have been conducted in conditions such as heart failure but not typically for treating hypothyroidism; standard treatments for hypothyroidism include levothyroxine which is a synthetic form of thyroxine (T4).\n5. FALSE [correction]: Because DITPA has been studied more in the context of conditions such as heart failure, the effectiveness mentioned regarding symptoms and metabolic parameters in hypothyroidism lacks accuracy and specificity. Its effects on these parameters have not been well established for hypothyroidism treatments.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "You MUST give a detailed answer to the following question: What is the COUGER tool?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the COUGER tool. Could you provide more context or information about what you are looking for?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 145,
    "user_query": "You MUST give a detailed answer to the following question: Are there drugs for Tick-borne Encephalitis?",
    "llama-7b_response": "Tick-borne encephalitis (TBE) is a viral infection that can affect the brain and nervous system. There are no specific drugs that can cure TBE, but there are several medications that can help manage the symptoms and reduce the risk of complications.\n\nThe mainstay of treatment for TBE is supportive care, which involves managing symptoms such as fever, headache, and muscle weakness. Acetaminophen or ibuprofen can be used to reduce fever and relieve pain. In some cases, antiviral medications such as ribavirin or oseltamivir may be used to help reduce the severity and duration of symptoms.\n\nIn addition to medications, it is important to protect against tick bites and seek medical attention promptly if a tick bite is suspected. Preventive measures such as using insect repellent, wearing protective clothing, and checking for ticks after spending time outdoors can help reduce the risk of infection.\n\nIt is also important to note that there are currently no licensed vaccines available for TBE. However, several vaccines are in development and may offer protection against TBE in the future.\n\nIn summary, while there are no specific drugs that can cure TBE, supportive care and preventive measures can help manage symptoms and reduce the risk of complications. Antiviral medications may be used to help reduce the severity and duration of symptoms, and several vaccines are in development that may offer protection against TBE in the future.",
    "llama-7b_fact_raw": "1. Tick-borne encephalitis (TBE) is a viral infection that affects the brain and nervous system.\n2. There are no specific drugs that cure TBE, but medications can help manage symptoms.\n3. Supportive care for TBE might include the use of acetaminophen or ibuprofen to reduce fever and relieve pain.\n4. Antiviral medications such as ribavirin or oseltamivir may be used in some cases to reduce the severity and duration of TBE symptoms.\n5. There are no licensed vaccines available for TBE as of the knowledge cutoff date.",
    "llama-7b_fact": [
      "Tick-borne encephalitis (TBE) is a viral infection that affects the brain and nervous system.",
      "There are no specific drugs that cure TBE, but medications can help manage symptoms.",
      "Supportive care for TBE might include the use of acetaminophen or ibuprofen to reduce fever and relieve pain.",
      "Antiviral medications such as ribavirin or oseltamivir may be used in some cases to reduce the severity and duration of TBE symptoms.",
      "There are no licensed vaccines available for TBE as of the knowledge cutoff date."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There are currently no antiviral medications proven to be effective for the treatment of TBE. Management remains supportive and focused on relieving symptoms.\n5. FALSE [correction]: There are licensed vaccines available for Tick-borne encephalitis (TBE) in countries where the disease is prevalent.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 151,
    "user_query": "You MUST give a detailed answer to the following question: Which genome browser database for DNA shape annotations is available?",
    "llama-7b_response": "UCSC Genome Browser",
    "llama-7b_fact_raw": "1. UCSC Genome Browser is a database for DNA shape annotations.",
    "llama-7b_fact": [
      "UCSC Genome Browser is a database for DNA shape annotations."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The UCSC Genome Browser is an online tool that provides access to a variety of genomic data, including DNA sequences, annotations, and comparative genomics information, rather than solely a database for DNA shape annotations.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "You MUST give a detailed answer to the following question: Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-7b_response": "22q11.2 deletion syndrome",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 193,
    "user_query": "You MUST give a detailed answer to the following question: List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-7b_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition, which refers to a change in the number of subunits in a protein complex from a dimer (two subunits) to a tetramer (four subunits). Here are some examples:\n\n1. Hemoglobin: Hemoglobin is a protein in red blood cells that carries oxygen throughout the body. It exists in a dimer form (two subunits) in the bloodstream, but undergoes a tetramer form (four subunits) when it binds to oxygen in the lungs.\n2. Immunoglobulin: Immunoglobulins are proteins that play a role in the immune system. They exist in a dimer form (two subunits) in the bloodstream, but undergo a tetramer form (four subunits) when they bind to antigens.\n3. Cytochrome c: Cytochrome c is a protein that plays a role in cellular respiration. It exists in a dimer form (two subunits) in the mitochondria of cells, but undergoes a tetramer form (four subunits) when it is oxidized.\n4. Ferritin: Ferritin is a protein that stores iron in the body. It exists in a dimer form (two subunits) in the bloodstream, but undergoes a tetramer form (four subunits) when it binds to iron.\n\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. There are likely many more proteins that exhibit this behavior, as the dimer-to-tetramer transition is a common structural feature of many proteins.",
    "llama-7b_fact_raw": "1. Hemoglobin is a human protein that undergoes a dimer-to-tetramer transition when it binds to oxygen.\n2. Immunoglobulins are human proteins that exist as dimers but form tetramers when they bind to antigens.\n3. Cytochrome c is a protein involved in cellular respiration that transitions from a dimer to a tetramer upon oxidation.\n4. Ferritin is a protein for iron storage that undergoes a dimer-to-tetramer transition when binding to iron.",
    "llama-7b_fact": [
      "Hemoglobin is a human protein that undergoes a dimer-to-tetramer transition when it binds to oxygen.",
      "Immunoglobulins are human proteins that exist as dimers but form tetramers when they bind to antigens.",
      "Cytochrome c is a protein involved in cellular respiration that transitions from a dimer to a tetramer upon oxidation.",
      "Ferritin is a protein for iron storage that undergoes a dimer-to-tetramer transition when binding to iron."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Hemoglobin is a protein that is already a tetramer and does not undergo a dimer-to-tetramer transition when it binds to oxygen. It is composed of four subunits (two alpha and two beta chains) each capable of binding one oxygen molecule.\n2. FALSE [correction]: Immunoglobulins, or antibodies, are typically Y-shaped molecules that exist primarily as monomers but can also be found as dimers, trimers, or pentamers, depending on the class of the antibody. They do not typically form tetramers when they bind to antigens.\n3. FALSE [correction]: Cytochrome c is a small hemeprotein found loosely associated with the inner membrane of the mitochondrion. It is involved in the electron transport chain and is a monomer, not a dimer or tetramer. It does not transition from a dimer to a tetramer upon oxidation.\n4. FALSE [correction]: Ferritin is a protein that stores iron, but it does not undergo a dimer-to-tetramer transition when binding to iron. It is a multimeric protein composed of 24 subunits that come together to form a hollow sphere for iron storage.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "You MUST give a detailed answer to the following question: Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-7b_response": "Bcl-2",
    "llama-7b_fact_raw": "1. Bcl-2 is a protein that has been found to interact with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.",
    "llama-7b_fact": [
      "Bcl-2 is a protein that has been found to interact with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE",
    "llama-7b_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "You MUST give a detailed answer to the following question: Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-7b_response": "Yes, vitamin D has been shown to reduce the incidence of falls in older people in clinical trials. A meta-analysis of randomized controlled trials (RCTs) found that vitamin D supplementation significantly reduced the risk of falls in older adults by 17% compared to placebo or no treatment. The study also found that higher doses of vitamin D were associated with a greater reduction in the risk of falls. Another RCT found that vitamin D supplementation reduced the risk of falls by 22% in older adults who were at high risk for falls. These findings suggest that vitamin D supplementation may be a useful strategy for preventing falls in older adults.",
    "llama-7b_fact_raw": "1. Vitamin D supplementation has been shown to reduce the incidence of falls in older people according to clinical trials.\n2. A meta-analysis of randomized controlled trials indicated a 17% reduction in fall risk with Vitamin D supplementation compared to placebo or no treatment.\n3. Higher doses of vitamin D were associated with a greater reduction in the risk of falls in the mentioned meta-analysis.\n4. A specific randomized controlled trial indicated that vitamin D supplementation reduced falls by 22% in older adults at high risk for falls.",
    "llama-7b_fact": [
      "Vitamin D supplementation has been shown to reduce the incidence of falls in older people according to clinical trials.",
      "A meta-analysis of randomized controlled trials indicated a 17% reduction in fall risk with Vitamin D supplementation compared to placebo or no treatment.",
      "Higher doses of vitamin D were associated with a greater reduction in the risk of falls in the mentioned meta-analysis.",
      "A specific randomized controlled trial indicated that vitamin D supplementation reduced falls by 22% in older adults at high risk for falls."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN (The specific percentage reduction cannot be verified without more context or the specific meta-analysis reference).\n3. UNKNOWN (Without the specific details of the meta-analysis, it's unclear whether higher doses were associated with a greater reduction in falls).\n4. UNKNOWN (The specifics of the randomized controlled trial including the exact reduction percentage cannot be verified without the actual trial data or reference).",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "You MUST give a detailed answer to the following question: Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-7b_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\n\nmiR-155 is a microRNA that has been implicated in the regulation of Th17 cell differentiation and function. It has been shown to negatively regulate the expression of the transcription factor RORγT, which is a key regulator of Th17 cell differentiation. In addition, miR-155 has also been shown to negatively regulate the expression of Jarid2, a protein that has been implicated in the regulation of cell proliferation and differentiation.\n\nJarid2 has been shown to negatively regulate the differentiation of Th17 cells by inhibiting the expression of the transcription factor RORγT. It has also been shown to negatively regulate the proliferation of Th17 cells by inhibiting the expression of the protein cyclin D1.\n\nTogether, these findings suggest that there is an association between Jarid2 and miR-155 in Th17 cells. miR-155 negatively regulates the expression of Jarid2, which in turn negatively regulates the differentiation and proliferation of Th17 cells.",
    "llama-7b_fact_raw": "1. miR-155 negatively regulates the expression of the transcription factor RORγT, which is crucial for Th17 cell differentiation.\n2. miR-155 also negatively regulates the expression of Jarid2, a protein involved in cell proliferation and differentiation.\n3. Jarid2 negatively regulates the differentiation of Th17 cells by inhibiting the expression of the transcription factor RORγT.\n4. Jarid2 negatively influences the proliferation of Th17 cells by inhibiting the expression of cyclin D1.\n5. An association exists between Jarid2 and miR-155 in Th17 cells, as evidenced by miR-155 modulating Jarid2 expression, which impacts Th17 cell differentiation and proliferation.",
    "llama-7b_fact": [
      "miR-155 negatively regulates the expression of the transcription factor RORγT, which is crucial for Th17 cell differentiation.",
      "miR-155 also negatively regulates the expression of Jarid2, a protein involved in cell proliferation and differentiation.",
      "Jarid2 negatively regulates the differentiation of Th17 cells by inhibiting the expression of the transcription factor RORγT.",
      "Jarid2 negatively influences the proliferation of Th17 cells by inhibiting the expression of cyclin D1.",
      "An association exists between Jarid2 and miR-155 in Th17 cells, as evidenced by miR-155 modulating Jarid2 expression, which impacts Th17 cell differentiation and proliferation."
    ],
    "llama-7b_judge_raw": "1. TRUE: miR-155 is known to negatively regulate various targets including the transcription factor RORγT, which plays an essential role in the differentiation of Th17 cells, a subtype of T helper cells.\n2. TRUE: miR-155 can negatively regulate the expression of multiple genes, and studies have shown that it can target Jarid2, which is involved in several cellular processes including cell proliferation and differentiation.\n3. UNKNOWN: While Jarid2 is involved in the regulation of various cellular processes, the direct impact of Jarid2 on the differentiation of Th17 cells by inhibiting RORγT expression would require specific experimental evidence which is not provided in the given context.\n4. UNKNOWN: Similar to the above statement, the direct relationship between Jarid2 and Th17 cell proliferation via the inhibition of cyclin D1 would need to be supported by specific experimental results.\n5. TRUE: If miR-155 modulates Jarid2 expression as stated, and given that Jarid2 and RORγT are involved in Th17 cell differentiation and proliferation, it can be inferred that there is an association between Jarid2 and miR-155 in the context of Th17 cells.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "You MUST give a detailed answer to the following question: How many genes does the human hoxD cluster contain?",
    "llama-7b_response": "The human HOXD cluster contains 13 genes.",
    "llama-7b_fact_raw": "1. The human HOXD cluster comprises 13 genes.",
    "llama-7b_fact": [
      "The human HOXD cluster comprises 13 genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The human HOXD cluster comprises 9 genes.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "You MUST give a detailed answer to the following question: List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 305,
    "user_query": "You MUST give a detailed answer to the following question: Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-7b_response": "The ASPH (aspartate beta-hydroxylase) gene encodes for the enzyme aspartate beta-hydroxylase, which is involved in the metabolism of amino acids and other compounds in the body. The gene is located on chromosome 11q23.3 and consists of six exons and five introns.\n\nThere are several different proteins and isoforms that are encoded by the ASPH gene in humans. These include:\n\n1. Aspartate beta-hydroxylase: This is the primary protein encoded by the ASPH gene and is responsible for catalyzing the conversion of aspartate to beta-alanine in the urea cycle.\n2. Aspartate beta-hydroxylase long isoform: This isoform of aspartate beta-hydroxylase is longer than the standard isoform and is found primarily in the liver.\n3. Aspartate beta-hydroxylase short isoform: This isoform of aspartate beta-hydroxylase is shorter than the standard isoform and is found primarily in the kidney.\n4. Aspartate beta-hydroxylase 1: This isoform of aspartate beta-hydroxylase is found primarily in the brain and is involved in the metabolism of amino acids and other compounds in the brain.\n5. Aspartate beta-hydroxylase 2: This isoform of aspartate beta-hydroxylase is found primarily in the liver and is involved in the metabolism of amino acids and other compounds in the liver.\n6. Aspartate beta-hydroxylase 3: This isoform of aspartate beta-hydroxylase is found primarily in the kidney and is involved in the metabolism of amino acids and other compounds in the kidney.\n\nOverall, the ASPH gene encodes for several different proteins and isoforms that play important roles in the metabolism of amino acids and other compounds in the body.",
    "llama-7b_fact_raw": "1. The ASPH gene is responsible for encoding the enzyme aspartate beta-hydroxylase.\n2. The ASPH gene is located on chromosome 11q23.3 in the human genome.\n3. The gene structure of ASPH consists of six exons and five introns.\n4. The long isoform of aspartate beta-hydroxylase encoded by the ASPH gene is found primarily in the liver.\n5. The aspartate beta-hydroxylase short isoform, is found primarily in the kidney.",
    "llama-7b_fact": [
      "The ASPH gene is responsible for encoding the enzyme aspartate beta-hydroxylase.",
      "The ASPH gene is located on chromosome 11q23.3 in the human genome.",
      "The gene structure of ASPH consists of six exons and five introns.",
      "The long isoform of aspartate beta-hydroxylase encoded by the ASPH gene is found primarily in the liver.",
      "The aspartate beta-hydroxylase short isoform, is found primarily in the kidney."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The gene structure of ASPH typically contains more than six exons. Human ASPH consists of 16 exons and 15 introns.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "You MUST give a detailed answer to the following question: When was empagliflozin FDA approved?",
    "llama-7b_response": "July 2014",
    "llama-7b_fact_raw": "1. Empagliflozin was FDA approved in July 2014.",
    "llama-7b_fact": [
      "Empagliflozin was FDA approved in July 2014."
    ],
    "llama-7b_judge_raw": "1. TRUE",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "You MUST give a detailed answer to the following question: What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-7b_response": "Loss of the protein Lon1 in the plant Arabidopsis has been shown to result in several phenotypes, including:\n\n1. Increased cell death: Lon1 is involved in the regulation of cell death, and its loss leads to an increase in programmed cell death in Arabidopsis.\n2. Altered stress responses: Lon1 plays a role in the regulation of stress responses in Arabidopsis, and its loss leads to altered responses to various types of stress, including heat, drought, and salt stress.\n3. Changes in gene expression: Loss of Lon1 leads to changes in the expression of a number of genes involved in various biological processes, including cell death, stress responses, and senescence.\n4. Premature senescence: Loss of Lon1 leads to premature senescence in Arabidopsis, which is an accelerated aging process that results in the premature death of plant cells and tissues.\n\nOverall, the loss of Lon1 in Arabidopsis results in a range of phenotypes that are associated with increased cell death, altered stress responses, changes in gene expression, and premature senescence. These phenotypes suggest that Lon1 plays an important role in the regulation of various biological processes in Arabidopsis.",
    "llama-7b_fact_raw": "1. The loss of the protein Lon1 in Arabidopsis leads to an increase in programmed cell death.\n2. Loss of Lon1 in Arabidopsis alters the plant's responses to various types of stress such as heat, drought, and salt stress.\n3. The absence of Lon1 in Arabidopsis causes changes in the expression of genes connected to cell death, stress responses, and senescence.\n4. Arabidopsis plants lacking Lon1 experience premature senescence.\n5. Lon1 protein is implicated in the regulation of several biological processes in Arabidopsis.",
    "llama-7b_fact": [
      "The loss of the protein Lon1 in Arabidopsis leads to an increase in programmed cell death.",
      "Loss of Lon1 in Arabidopsis alters the plant's responses to various types of stress such as heat, drought, and salt stress.",
      "The absence of Lon1 in Arabidopsis causes changes in the expression of genes connected to cell death, stress responses, and senescence.",
      "Arabidopsis plants lacking Lon1 experience premature senescence.",
      "Lon1 protein is implicated in the regulation of several biological processes in Arabidopsis."
    ],
    "llama-7b_judge_raw": "1. TRUE: The loss of the protein Lon1 in Arabidopsis has indeed been linked to increased programmed cell death in various studies.\n2. TRUE: Research indicates that the loss of Lon1 in Arabidopsis can alter the plant's responses to different stress conditions including heat, drought, and salt stress.\n3. TRUE: Studies have shown that the absence of Lon1 in Arabidopsis results in changes in the expression of genes associated with cell death, stress response, and senescence.\n4. TRUE: When Lon1 is absent in Arabidopsis plants, they often show signs of premature senescence, as the protein plays a part in regulation of the senescence process.\n5. TRUE: Lon1 protein is known to be involved in the regulation of various biological processes in Arabidopsis, including but not limited to mitochondrial function, protein homeostasis, and other vital cellular processes.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "You MUST give a detailed answer to the following question: Does a linker histone exist in the yeast genome?",
    "llama-7b_response": "Yes, a linker histone exists in the yeast genome.\n\nHistones are proteins that are found in the nucleus of eukaryotic cells and are involved in the organization of DNA into chromatin. Linker histones are a type of histone that plays a role in the formation of higher order chromatin structures, such as nucleosomes and chromatin loops.\n\nIn the yeast genome, there are several different types of linker histones, including H1, H2A, H2B, and H3. These histones are involved in the assembly of nucleosomes and other higher order chromatin structures, and play a role in the regulation of gene expression.\n\nOverall, the presence of linker histones in the yeast genome is an important factor in the regulation of gene expression and the organization of DNA into chromatin.",
    "llama-7b_fact_raw": "1. Linker histones are proteins found in the nucleus of eukaryotic cells.\n2. Linker histones are involved in the organization of DNA into chromatin.\n3. The yeast genome contains several types of linker histones, including H1.\n4. H2A, H2B, and H3 are also types of linker histones present in the yeast genome.\n5. Linker histones play a role in the assembly of nucleosomes and regulation of gene expression in yeast.",
    "llama-7b_fact": [
      "Linker histones are proteins found in the nucleus of eukaryotic cells.",
      "Linker histones are involved in the organization of DNA into chromatin.",
      "The yeast genome contains several types of linker histones, including H1.",
      "H2A, H2B, and H3 are also types of linker histones present in the yeast genome.",
      "Linker histones play a role in the assembly of nucleosomes and regulation of gene expression in yeast."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The yeast genome typically does not contain the classic linker histone H1. Yeast usually has histone H1 variants called Hho1p or not at all, which are not considered classic linker histones.\n4. FALSE [correction]: H2A, H2B, and H3 are not linker histones; they are core histones that make up the nucleosome core particle along with H4.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "You MUST give a detailed answer to the following question: Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-7b_response": "Yes, there is evidence that tomato juice can lower cholesterol levels.\n\nA study published in the Journal of Nutrition in 2009 found that consuming tomato juice daily for four weeks significantly reduced total cholesterol and low-density lipoprotein (LDL) cholesterol levels in adults with elevated cholesterol levels. The study also found that the cholesterol-lowering effects of tomato juice were associated with an increase in the excretion of bile acids in the urine.\n\nAnother study published in the Journal of the American College of Nutrition in 2012 found that consuming tomato juice daily for eight weeks significantly reduced LDL cholesterol levels in adults with elevated cholesterol levels. The study also found that the cholesterol-lowering effects of tomato juice were associated with an increase in the activity of enzymes involved in cholesterol metabolism.\n\nWhile more research is needed to fully understand the mechanisms behind tomato juice's cholesterol-lowering effects, these studies suggest that consuming tomato juice regularly may be a useful strategy for lowering cholesterol levels and reducing the risk of cardiovascular disease.",
    "llama-7b_fact_raw": "1. A study published in the Journal of Nutrition in 2009 showed that daily consumption of tomato juice for four weeks significantly reduced total cholesterol and LDL cholesterol levels in adults with elevated cholesterol levels.\n2. The same 2009 study reported that the cholesterol-lowering effects of tomato juice included an increase in the excretion of bile acids in the urine.\n3. Another study published in the Journal of the American College of Nutrition in 2012 found that consuming tomato juice for eight weeks resulted in a significant reduction in LDL cholesterol levels in adults with high cholesterol.\n4. The 2012 study also indicated that the cholesterol-lowering effects from tomato juice were associated with increased activity of enzymes involved in cholesterol metabolism.\n5. These studies suggest that regular consumption of tomato juice might be beneficial for lowering cholesterol levels and reducing cardiovascular disease risk.",
    "llama-7b_fact": [
      "A study published in the Journal of Nutrition in 2009 showed that daily consumption of tomato juice for four weeks significantly reduced total cholesterol and LDL cholesterol levels in adults with elevated cholesterol levels.",
      "The same 2009 study reported that the cholesterol-lowering effects of tomato juice included an increase in the excretion of bile acids in the urine.",
      "Another study published in the Journal of the American College of Nutrition in 2012 found that consuming tomato juice for eight weeks resulted in a significant reduction in LDL cholesterol levels in adults with high cholesterol.",
      "The 2012 study also indicated that the cholesterol-lowering effects from tomato juice were associated with increased activity of enzymes involved in cholesterol metabolism.",
      "These studies suggest that regular consumption of tomato juice might be beneficial for lowering cholesterol levels and reducing cardiovascular disease risk."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The cholesterol-lowering effects of tomato juice do not include an increase in the excretion of bile acids in the urine. Bile acids are typically excreted in the feces, not the urine.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe corrections and evaluations are made based on the information provided, but without access to the specific studies mentioned, it's not possible to verify the exact findings related to tomato juice and cholesterol levels. It's worth noting that while the correction for statement 2 is logical given that bile acids are typically excreted in feces, the content of the study itself would need to be reviewed to confirm the statement's accuracy. Statements 3, 4, and 5 would require access to the study from the Journal of the American College of Nutrition in 2012 to determine their truthfulness.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "You MUST give a detailed answer to the following question: How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-7b_response": "Hsp70 and Hsp110 are heat shock proteins (HSPs) that play a crucial role in the regulation of mRNA stability. Hsp70 and Hsp110 are involved in the regulation of mRNA stability by interacting with ribonucleic acid (RNA) molecules, such as messenger RNA (mRNA) and ribosomal RNA (rRNA), and modulating their stability and translation.\n\nHsp70 and Hsp110 are involved in the regulation of mRNA stability through several mechanisms:\n\n1. Chaperone activity: Hsp70 and Hsp110 have chaperone activity, which means they can bind to and stabilize RNA molecules, such as mRNA and rRNA, by preventing their degradation by ribonuclease (RNase) enzymes.\n2. mRNA destabilization: Hsp70 and Hsp110 can also destabilize mRNA by interacting with the 5' untranslated region (UTR) of the mRNA, leading to its degradation.\n3. Translation inhibition: Hsp70 and Hsp110 can also inhibit translation of mRNA by interacting with the ribosome and preventing its binding to the mRNA.\n4. mRNA decay: Hsp70 and Hsp110 can also promote the decay of mRNA by interacting with the exon junction complex (EJC), which is involved in the decay of mRNA.\n\nOverall, Hsp70 and Hsp110 play a crucial role in the regulation of mRNA stability by modulating the stability, translation, and decay of RNA molecules, including mRNA.",
    "llama-7b_fact_raw": "1. Hsp70 and Hsp110 are heat shock proteins involved in the regulation of mRNA stability.\n2. They have chaperone activity that helps stabilize mRNA and rRNA by preventing their degradation.\n3. Hsp70 and Hsp110 can destabilize mRNA by interacting with its 5' untranslated region (UTR).\n4. These proteins can inhibit the translation of mRNA by interfering with ribosome binding.\n5. Hsp70 and Hsp110 can promote mRNA decay through interaction with the exon junction complex (EJC).",
    "llama-7b_fact": [
      "Hsp70 and Hsp110 are heat shock proteins involved in the regulation of mRNA stability.",
      "They have chaperone activity that helps stabilize mRNA and rRNA by preventing their degradation.",
      "Hsp70 and Hsp110 can destabilize mRNA by interacting with its 5' untranslated region (UTR).",
      "These proteins can inhibit the translation of mRNA by interfering with ribosome binding.",
      "Hsp70 and Hsp110 can promote mRNA decay through interaction with the exon junction complex (EJC)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Hsp70 and Hsp110 are heat shock proteins with chaperone activity that helps proteins to fold correctly, not specifically for stabilizing mRNA and rRNA by preventing their degradation. \n3. FALSE [correction]: Hsp70 and Hsp110 do not typically destabilize mRNA by interacting with its 5' untranslated region (UTR); their primary function is to assist in protein folding and prevent the aggregation of proteins.\n4. UNKNOWN\n5. FALSE [correction]: Hsp70 and Hsp110 generally do not promote mRNA decay through interaction with the exon junction complex (EJC); their well-known functions are related to protein folding and maintenance of proteostasis.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 481,
    "user_query": "You MUST give a detailed answer to the following question: Which deiodinases are present in skeletal  muscle?",
    "llama-7b_response": "Deiodinases are enzymes that regulate the activity of the thyroid hormones, triiodothyronine (T3) and thyroxine (T4). In skeletal muscle, three types of deiodinases have been identified: type 1 (D1), type 2a (D2a), and type 2b (D2b).\n\nType 1 deiodinase (D1) is also known as the type 2 iodothyronine deiodinase (D2) and is responsible for converting T4 to T3 in skeletal muscle. D1 is found in both skeletal and cardiac muscle, as well as in other tissues such as the pituitary gland and the adrenal gland. D1 plays a crucial role in regulating the activity of the thyroid hormones in these tissues.\n\nType 2a deiodinase (D2a) is also known as the type 3 iodothyronine deiodinase (D3) and is responsible for converting T4 to T3 in skeletal muscle. D2a is primarily found in skeletal muscle and plays a key role in regulating the activity of the thyroid hormones in this tissue.\n\nType 2b deiodinase (D2b) is also known as the type 4 iodothyronine deiodinase (D4) and is responsible for converting T4 to T3 in skeletal muscle. D2b is primarily found in skeletal muscle and plays a key role in regulating the activity of the thyroid hormones in this tissue.\n\nIn summary, the three types of deiodinases present in skeletal muscle are type 1 (D1), type 2a (D2a), and type 2b (D2b). These enzymes play a crucial role in regulating the activity of the thyroid hormones in skeletal muscle and are important for maintaining normal muscle function.",
    "llama-7b_fact_raw": "1. Deiodinases are enzymes that regulate the activity of thyroid hormones, specifically triiodothyronine (T3) and thyroxine (T4).\n2. Three types of deiodinases present in skeletal muscle are type 1 (D1), type 2a (D2a), and type 2b (D2b).\n3. Type 1 deiodinase (D1) is responsible for converting T4 to T3 in skeletal muscle and is also found in cardiac muscle and other tissues like the pituitary gland and adrenal gland.\n4. Type 2a deiodinase (D2a) is primarily found in skeletal muscle and is responsible for converting T4 to T3 in that tissue.\n5. Type 2b deiodinase (D2b) is primarily found in skeletal muscle and is also involved in converting T4 to T3 in that tissue.",
    "llama-7b_fact": [
      "Deiodinases are enzymes that regulate the activity of thyroid hormones, specifically triiodothyronine (T3) and thyroxine (T4).",
      "Three types of deiodinases present in skeletal muscle are type 1 (D1), type 2a (D2a), and type 2b (D2b).",
      "Type 1 deiodinase (D1) is responsible for converting T4 to T3 in skeletal muscle and is also found in cardiac muscle and other tissues like the pituitary gland and adrenal gland.",
      "Type 2a deiodinase (D2a) is primarily found in skeletal muscle and is responsible for converting T4 to T3 in that tissue.",
      "Type 2b deiodinase (D2b) is primarily found in skeletal muscle and is also involved in converting T4 to T3 in that tissue."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: There are actually three types of deiodinases known as type 1 (D1), type 2 (D2), and type 3 (D3), not type 2a (D2a) and type 2b (D2b).\n3. TRUE: Type 1 deiodinase (D1) is indeed responsible for the conversion of T4 to T3 and is found in several tissues including skeletal muscle, cardiac muscle, and others such as the liver and kidney, rather than the pituitary and adrenal gland as stated.\n4. UNKNOWN: The precise subtypes of deiodinases in skeletal muscle are not specified in the common scientific literature, and whether D2a specifically refers to a subtype of deiodinase 2 present in skeletal muscle is unclear. Standardly, D2 is recognized as converting T4 to T3 within skeletal muscle.\n5. FALSE [correction]: There is no established subtype called type 2b deiodinase (D2b) recognized; instead, there is just type 2 deiodinase (D2), which is indeed involved in the conversion of T4 to T3, including skeletal muscle among other tissues.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "You MUST give a detailed answer to the following question: List inflammatory caspase proteins?",
    "llama-7b_response": "Caspases are a family of enzymes that play a central role in the process of programmed cell death, also known as apoptosis. Inflammatory caspases are a subset of caspases that are specifically activated in response to inflammatory signals. There are several inflammatory caspases that have been identified, including:\n\n1. Caspase-1: also known as interleukin-1 beta-converting enzyme (ICE), is activated by pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α). Caspase-1 plays a key role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n2. Caspase-4: is activated by pro-inflammatory cytokines such as TNF-α and IL-1β. Caspase-4 plays a role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n3. Caspase-5: is activated by pro-inflammatory cytokines such as TNF-α and IL-1β. Caspase-5 plays a role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n4. Caspase-6: is activated by pro-inflammatory cytokines such as TNF-α and IL-1β. Caspase-6 plays a role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-18.\n5. Caspase-7: is activated by pro-inflammatory cytokines such as TNF-α and IL-1β. Caspase-7 plays a role in the inflammatory response and is involved in the processing and activation of pro-inflammatory cytokines such as IL-1β and IL-1",
    "llama-7b_fact_raw": "1. Caspase-1 is also known as interleukin-1 beta-converting enzyme (ICE) and is involved in the inflammatory response.\n2. Caspase-4 is implicated in the inflammatory response and assists in processing and activating pro-inflammatory cytokines.\n3. Caspase-5 is an enzyme that gets activated by pro-inflammatory cytokines and contributes to the inflammatory response.\n4. Caspase-6 is involved in the inflammatory response, particularly in the activation of pro-inflammatory cytokines.\n5. Caspase-7 is activated by pro-inflammatory cytokines and plays a role in the inflammatory response.",
    "llama-7b_fact": [
      "Caspase-1 is also known as interleukin-1 beta-converting enzyme (ICE) and is involved in the inflammatory response.",
      "Caspase-4 is implicated in the inflammatory response and assists in processing and activating pro-inflammatory cytokines.",
      "Caspase-5 is an enzyme that gets activated by pro-inflammatory cytokines and contributes to the inflammatory response.",
      "Caspase-6 is involved in the inflammatory response, particularly in the activation of pro-inflammatory cytokines.",
      "Caspase-7 is activated by pro-inflammatory cytokines and plays a role in the inflammatory response."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Caspase-5, like caspase-1 and caspase-4, is involved in the inflammatory response but is known for forming part of the inflammasome complex and not for being activated by pro-inflammatory cytokines.\n4. FALSE [correction]: Caspase-6 is primarily involved in the apoptotic pathway and is not known for playing a role in the activation of pro-inflammatory cytokines as part of the inflammatory response.\n5. FALSE [correction]: Caspase-7 is similar to caspase-6 and is mainly involved in apoptosis, not the inflammatory response. It is not directly activated by pro-inflammatory cytokines to play a role in the inflammatory response.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "You MUST give a detailed answer to the following question: Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-7b_response": "Yes, there is a link between the aurora B kinase and the polycomb protein ring1B.\n\nAurora B kinase is a serine/threonine protein kinase that plays a crucial role in the regulation of mitosis, the process of cell division. It is involved in the formation of the mitotic spindle, the structure that separates the chromosomes during cell division. Ring1B is a member of the polycomb family of proteins, which are involved in the regulation of gene expression.\n\nResearch has shown that the activity of aurora B kinase is regulated by the polycomb protein ring1B. Specifically, ring1B has been shown to interact with and inhibit the activity of aurora B kinase. This interaction occurs through the binding of ring1B to the C-terminal region of aurora B kinase, which results in the inhibition of its kinase activity.\n\nFurthermore, research has shown that the expression of ring1B can be regulated by aurora B kinase. In particular, the activity of aurora B kinase has been shown to increase the expression of ring1B, leading to the formation of a positive feedback loop that further regulates the activity of aurora B kinase.\n\nOverall, these findings suggest that the interaction between aurora B kinase and ring1B plays an important role in the regulation of mitosis and the control of gene expression.",
    "llama-7b_fact_raw": "1. Aurora B kinase is a serine/threonine protein kinase important in the regulation of mitosis.\n2. Ring1B is a member of the polycomb family of proteins, which are responsible for the regulation of gene expression.\n3. The polycomb protein ring1B has been shown to interact with and inhibit the activity of aurora B kinase.\n4. The interaction between ring1B and aurora B kinase involves the binding of ring1B to the C-terminal region of aurora B kinase.\n5. Aurora B kinase activity can increase the expression of ring1B, creating a positive feedback loop that affects both aurora B kinase activity and gene expression regulation.",
    "llama-7b_fact": [
      "Aurora B kinase is a serine/threonine protein kinase important in the regulation of mitosis.",
      "Ring1B is a member of the polycomb family of proteins, which are responsible for the regulation of gene expression.",
      "The polycomb protein ring1B has been shown to interact with and inhibit the activity of aurora B kinase.",
      "The interaction between ring1B and aurora B kinase involves the binding of ring1B to the C-terminal region of aurora B kinase.",
      "Aurora B kinase activity can increase the expression of ring1B, creating a positive feedback loop that affects both aurora B kinase activity and gene expression regulation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements are factual, as Aurora B kinase is indeed a serine/threonine protein kinase relevant to the regulation of mitosis, and Ring1B is a member of the polycomb family, which has a role in gene expression regulation. However, without specific scientific literature or evidence provided in the context to verify the interactions described in statements 3, 4, and 5, these claims remain uncertain and thus marked as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "You MUST give a detailed answer to the following question: What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are known as \"splicing enhancers\" and \"splicing silencers,\" respectively.\n\nSplicing enhancers are non-canonical sequence motifs that enhance the efficiency of splicing at the donor splice site. They are typically located upstream of the donor splice site and can be classified into two types: exonic and intronic. Exonic splicing enhancers (ESEs) are located in the 5' untranslated region (5' UTR) of a gene and enhance splicing by recruiting the splicing machinery to the donor splice site. Intronic splicing enhancers (ISEs) are located within an intron and also enhance splicing by recruiting the splicing machinery to the donor splice site.\n\nSplicing silencers, on the other hand, are non-canonical sequence motifs that suppress splicing at the acceptor splice site. They are typically located downstream of the acceptor splice site and can also be classified into two types: exonic and intronic. Exonic splicing silencers (ESSs) are located in the 3' untranslated region (3' UTR) of a gene and suppress splicing by interfering with the recognition of the acceptor splice site by the splicing machinery. Intronic splicing silencers (ISSs) are located within an intron and also suppress splicing by interfering with the recognition of the acceptor splice site by the splicing machinery.\n\nThese non-canonical sequence motifs play a crucial role in the regulation of alternative splicing, which is a key mechanism for generating functional diversity in eukaryotic genomes.",
    "llama-7b_fact_raw": "1. Splicing enhancers and splicing silencers are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates, respectively.\n2. Exonic and intronic splicing enhancers (ESEs and ISEs) enhance the efficiency of splicing at the donor splice site, with ESEs located in the 5' UTR and ISEs located within an intron.\n3. Exonic and intronic splicing silencers (ESSs and ISSs) suppress splicing at the acceptor splice site, with ESSs located in the 3' UTR and ISSs located within an intron.\n4. Splicing enhancers typically recruit the splicing machinery to the donor splice site.\n5. Splicing silencers typically interfere with the recognition of the acceptor splice site by the splicing machinery.",
    "llama-7b_fact": [
      "Splicing enhancers and splicing silencers are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates, respectively.",
      "Exonic and intronic splicing enhancers (ESEs and ISEs) enhance the efficiency of splicing at the donor splice site, with ESEs located in the 5' UTR and ISEs located within an intron.",
      "Exonic and intronic splicing silencers (ESSs and ISSs) suppress splicing at the acceptor splice site, with ESSs located in the 3' UTR and ISSs located within an intron.",
      "Splicing enhancers typically recruit the splicing machinery to the donor splice site.",
      "Splicing silencers typically interfere with the recognition of the acceptor splice site by the splicing machinery."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Exonic and intronic splicing enhancers (ESEs and ISEs) enhance the efficiency of splicing at respective splice sites, but ESEs are located within exons, not specifically in the 5' UTR, and ISEs are located within introns.\n3. FALSE [correction]: Exonic and intronic splicing silencers (ESSs and ISSs) suppress splicing, but ESSs are located within exons, not specifically in the 3' UTR, and ISSs are located within introns.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "You MUST give a detailed answer to the following question: Which event results in the acetylation of S6K1?",
    "llama-7b_response": "insulin",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 632,
    "user_query": "You MUST give a detailed answer to the following question: What is the cause of episodic ataxia type 6?",
    "llama-7b_response": "The cause of episodic ataxia type 6 is a mutation in the CACNA1A gene.",
    "llama-7b_fact_raw": "1. Episodic ataxia type 6 is caused by a mutation in the CACNA1A gene.",
    "llama-7b_fact": [
      "Episodic ataxia type 6 is caused by a mutation in the CACNA1A gene."
    ],
    "llama-7b_judge_raw": "1. TRUE",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "You MUST give a detailed answer to the following question: Are chromomethylases present in animal genomes?",
    "llama-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add methyl groups to DNA, and they play a role in regulating gene expression. They are found in many organisms, including animals. In animals, chromomethylases are typically involved in the regulation of gene expression during development and in response to environmental cues. For example, they can help to silence genes that are not needed at a particular time, or to activate genes that are needed for a specific process.",
    "llama-7b_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases are enzymes that add methyl groups to DNA.\n3. Chromomethylases play a role in regulating gene expression.\n4. In animals, chromomethylases can help to silence genes that are not needed at a particular time.\n5. Chromomethylases can activate genes needed for specific processes in animals.",
    "llama-7b_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases are enzymes that add methyl groups to DNA.",
      "Chromomethylases play a role in regulating gene expression.",
      "In animals, chromomethylases can help to silence genes that are not needed at a particular time.",
      "Chromomethylases can activate genes needed for specific processes in animals."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Chromomethylases are not typically found in animal genomes; they are specific to plants for DNA methylation.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Since chromomethylases are not typically found in animal genomes, they do not play a role in silencing animal genes. Animals use other types of methyltransferases for gene silencing.\n5. FALSE [correction]: Chromomethylases are not involved in gene activation in animals. In plants, they are associated with gene silencing rather than activation, and in animals, gene activation is regulated by different mechanisms and enzymes.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "You MUST give a detailed answer to the following question: List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-7b_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS). Here are some of the most commonly used packages:\n\n1. ChIPpeakAnno: This package is used for the annotation of ChIP-seq data, including the identification of binding sites for transcription factors.\n2. DNase-seq: This package is used for the analysis of DNase-seq data, which is used to identify regions of the genome that have been degraded by the enzyme DNase I.\n3. GRO-seq: This package is used for the analysis of GRO-seq data, which is used to identify regions of the genome that are accessible to RNA polymerase.\n4. HOMER: This package is used for the prediction of binding sites for transcription factors based on sequence motifs.\n5. motifclust: This package is used for the clustering of transcription factor binding sites based on their sequence motifs.\n6. PeakSeq: This package is used for the analysis of ChIP-seq data, including the identification of binding sites for transcription factors.\n7. RNAPII-seq: This package is used for the analysis of RNA polymerase II (RNAPII) occupancy data, which is used to identify regions of the genome that are actively being transcribed.\n\nThese are just a few of the many packages available in R/Bioconductor for the analysis of TFBS. The choice of package will depend on the specific type of data being analyzed and the goals of the analysis.",
    "llama-7b_fact_raw": "1. ChIPpeakAnno is an R/Bioconductor package used for the annotation of ChIP-seq data and identification of transcription factor binding sites.\n2. The DNase-seq package in R/Bioconductor is designed for analyzing DNase-seq data to identify genomic regions degraded by DNase I.\n3. GRO-seq is an R/Bioconductor package for analyzing GRO-seq data, which helps identify genomic regions accessible to RNA polymerase.\n4. HOMER is an R/Bioconductor package utilized for predicting transcription factor binding sites based on sequence motifs.\n5. The motifclust package in R/Bioconductor clusters transcription factor binding sites based on their sequence motifs.",
    "llama-7b_fact": [
      "ChIPpeakAnno is an R/Bioconductor package used for the annotation of ChIP-seq data and identification of transcription factor binding sites.",
      "The DNase-seq package in R/Bioconductor is designed for analyzing DNase-seq data to identify genomic regions degraded by DNase I.",
      "GRO-seq is an R/Bioconductor package for analyzing GRO-seq data, which helps identify genomic regions accessible to RNA polymerase.",
      "HOMER is an R/Bioconductor package utilized for predicting transcription factor binding sites based on sequence motifs.",
      "The motifclust package in R/Bioconductor clusters transcription factor binding sites based on their sequence motifs."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GRO-seq is not an R/Bioconductor package but rather a method (Global Run-On Sequencing) used to identify and quantify nascent RNA transcripts genome-wide, thus providing insights into transcriptional activity.\n4. FALSE [correction]: HOMER is not an R/Bioconductor package; it is a standalone software suite for motif discovery and next-generation sequencing analysis, which includes functions for predicting transcription factor binding sites.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "You MUST give a detailed answer to the following question: List clinical trials for prevention of sarcopenia",
    "llama-7b_response": "Certainly, here are some clinical trials for the prevention of sarcopenia:\n\n1. Sarcopenia Prevention with Resistance Training (SPRT): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training in preventing sarcopenia in older adults. The study found that resistance training was effective in preventing sarcopenia and improving muscle function in older adults.\n2. Sarcopenia: Prevention and Treatment (SPAT): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults. The study found that a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n3. Sarcopenia: Prevention and Treatment (SPAT-2): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults. The study found that a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n4. Sarcopenia: Prevention and Treatment (SPAT-3): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults. The study found that a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n5. Sarcopenia: Prevention and Treatment (SPAT-4): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults. The study found that a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n6. Sarcopenia: Prevention and Treatment (SPAT-5): This is a randomized controlled trial that aimed to determine the effectiveness of resistance training",
    "llama-7b_fact_raw": "1. The Sarcopenia Prevention with Resistance Training (SPRT) was a randomized controlled trial that investigated the prevention of sarcopenia in older adults through resistance training.\n2. The SPRT study concluded that resistance training was effective in preventing sarcopenia and improving muscle function in older adults.\n3. The Sarcopenia: Prevention and Treatment (SPAT) trial was a randomized controlled trial that tested the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults.\n4. According to the SPAT study, a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.\n5. The SPAT study includes multiple iterations, such as SPAT-2, SPAT-3, SPAT-4, and SPAT-5, all focusing on the combination of resistance training and protein supplementation to combat sarcopenia in older adults.",
    "llama-7b_fact": [
      "The Sarcopenia Prevention with Resistance Training (SPRT) was a randomized controlled trial that investigated the prevention of sarcopenia in older adults through resistance training.",
      "The SPRT study concluded that resistance training was effective in preventing sarcopenia and improving muscle function in older adults.",
      "The Sarcopenia: Prevention and Treatment (SPAT) trial was a randomized controlled trial that tested the effectiveness of resistance training and protein supplementation in preventing and treating sarcopenia in older adults.",
      "According to the SPAT study, a combination of resistance training and protein supplementation was effective in preventing and treating sarcopenia and improving muscle function in older adults.",
      "The SPAT study includes multiple iterations, such as SPAT-2, SPAT-3, SPAT-4, and SPAT-5, all focusing on the combination of resistance training and protein supplementation to combat sarcopenia in older adults."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nSince the specific details of the Sarcopenia Prevention with Resistance Training (SPRT) and the Sarcopenia: Prevention and Treatment (SPAT) trials are not provided, and this is not common knowledge or widely recognized information, it is impossible to verify the statements without further context or source material.\n",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of molecular recognition features in membrane proteins?",
    "llama-7b_response": "There are several databases that contain information on molecular recognition features in membrane proteins, including:\n\n1. The Protein Data Bank (PDB): The PDB is a database of three-dimensional structural data for proteins, nucleic acids, and complex assemblies. It contains information on the structure of membrane proteins, including their molecular recognition features.\n2. The Database of Membrane Proteins (DMP): The DMP is a comprehensive database of structural and functional information on membrane proteins. It contains information on the molecular recognition features of membrane proteins, including their interactions with other proteins and small molecules.\n3. The Membrane Protein Structural Database (MPSD): The MPSD is a database of three-dimensional structures of membrane proteins. It contains information on the molecular recognition features of membrane proteins, including their interactions with other proteins and small molecules.\n4. The Membrane Protein Structural Biology Center (MPSBC): The MPSBC is a database of three-dimensional structures of membrane proteins. It contains information on the molecular recognition features of membrane proteins, including their interactions with other proteins and small molecules.\n\nOverall, these databases provide valuable information on the molecular recognition features of membrane proteins, and can be used to study the structure and function of these important biomolecules.",
    "llama-7b_fact_raw": "1. The Protein Data Bank (PDB) is a repository for three-dimensional structural data of proteins, nucleic acids, and complex assemblies.\n2. The PDB contains structural information about membrane proteins, including molecular recognition features.\n3. The Database of Membrane Proteins (DMP) provides structural and functional information on membrane proteins.\n4. The Membrane Protein Structural Database (MPSD) offers three-dimensional structures of membrane proteins with information on molecular recognition features.\n5. The Membrane Protein Structural Biology Center (MPSBC) is another resource that holds three-dimensional structures of membrane proteins and data on their molecular recognition features.",
    "llama-7b_fact": [
      "The Protein Data Bank (PDB) is a repository for three-dimensional structural data of proteins, nucleic acids, and complex assemblies.",
      "The PDB contains structural information about membrane proteins, including molecular recognition features.",
      "The Database of Membrane Proteins (DMP) provides structural and functional information on membrane proteins.",
      "The Membrane Protein Structural Database (MPSD) offers three-dimensional structures of membrane proteins with information on molecular recognition features.",
      "The Membrane Protein Structural Biology Center (MPSBC) is another resource that holds three-dimensional structures of membrane proteins and data on their molecular recognition features."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\n1. The statement about the Protein Data Bank (PDB) is true. The PDB is a widely recognized repository for the three-dimensional structural data of large biological molecules, including proteins and nucleic acids.\n\n2. The PDB does indeed contain structural information about membrane proteins, and often this information includes molecular recognition features (such as binding sites).\n\n3-5. While statements 3, 4, and 5 mention databases/resources that could plausibly exist given the nature of scientific databases, without specific information regarding the Database of Membrane Proteins (DMP), Membrane Protein Structural Database (MPSD), and Membrane Protein Structural Biology Center (MPSBC), we cannot determine the veracity of these statements. These could be hypothetical, less well-known or outdated databases, or they could be inaccurately named in the given context. Therefore, without additional context to verify their existence and content, the truthfulness of these statements is unknown.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "You MUST give a detailed answer to the following question: Is rivaroxaban metabolized in kidneys?",
    "llama-7b_response": "Yes, rivaroxaban is metabolized in the kidneys.\n\nRivaroxaban is a direct factor Xa inhibitor that is primarily metabolized by the liver via cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. However, the kidneys also play a role in the elimination of rivaroxaban from the body.\n\nRivaroxaban is primarily excreted in the urine as the glucuronide conjugate of its metabolite, O-desmethyl rivaroxaban. The kidneys are responsible for the formation of glucuronide conjugates, which are water-soluble compounds that can be excreted in the urine.\n\nTherefore, kidney function is an important factor to consider when administering rivaroxaban, as impaired kidney function may result in increased plasma concentrations of the drug and an increased risk of adverse effects. Dosage adjustments may be necessary in patients with renal impairment.",
    "llama-7b_fact_raw": "1. Rivaroxaban is primarily metabolized by the liver via cytochrome P450 enzymes, including CYP3A4 and CYP2C9.\n2. The kidneys play a role in eliminating rivaroxaban from the body.\n3. Rivaroxaban is excreted in the urine as the glucuronide conjugate of its metabolite, O-desmethyl rivaroxaban.\n4. Formation of glucuronide conjugates, which are water-soluble, occurs in the kidneys.\n5. Impaired kidney function can lead to increased plasma concentrations of rivaroxaban and a higher risk of adverse effects, necessitating dosage adjustments in patients with renal impairment.",
    "llama-7b_fact": [
      "Rivaroxaban is primarily metabolized by the liver via cytochrome P450 enzymes, including CYP3A4 and CYP2C9.",
      "The kidneys play a role in eliminating rivaroxaban from the body.",
      "Rivaroxaban is excreted in the urine as the glucuronide conjugate of its metabolite, O-desmethyl rivaroxaban.",
      "Formation of glucuronide conjugates, which are water-soluble, occurs in the kidneys.",
      "Impaired kidney function can lead to increased plasma concentrations of rivaroxaban and a higher risk of adverse effects, necessitating dosage adjustments in patients with renal impairment."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Rivaroxaban is excreted in the urine as unchanged drug and its metabolites, including the glucuronide conjugates. However, \"O-desmethyl rivaroxaban\" is not a recognized metabolite of rivaroxaban. The primary metabolite is rivaroxaban's inactive morpholinone derivative.\n4. FALSE [correction]: Formation of glucuronide conjugates, which are water-soluble, primarily occurs in the liver, not the kidneys.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "You MUST give a detailed answer to the following question: Which genes are regulated by TRalpha2  in the heart?",
    "llama-7b_response": "Transient receptor potential (TRP) channels are a family of cation channels that are activated by a diverse range of extracellular stimuli, including temperature, mechanical stress, and chemical signals. TRP channels play important roles in various physiological processes, including sensory perception, cellular signaling, and the regulation of ion homeostasis.\n\nTransient receptor potential ankyrin 1 (TRPA1) and transient receptor potential vanilloid 1 (TRPV1) are two members of the TRP channel family that have been extensively studied in the context of cardiovascular physiology and pathophysiology. TRPA1 and TRPV1 are expressed in various tissues, including the heart, where they play important roles in the regulation of cardiovascular function.\n\nTransient receptor potential ankyrin 2 (TRPA2) is another member of the TRP channel family that has been implicated in the regulation of cardiovascular function. TRPA2 is expressed in various tissues, including the heart, where it plays a role in the regulation of cardiac contractility and electrical activity.\n\nTransient receptor potential ankyrin 3 (TRPA3) is another member of the TRP channel family that has been implicated in the regulation of cardiovascular function. TRPA3 is expressed in various tissues, including the heart, where it plays a role in the regulation of cardiac contractility and electrical activity.\n\nTransient receptor potential ankyrin 4 (TRPA4) is another member of the TRP channel family that has been implicated in the regulation of cardiovascular function. TRPA4 is expressed in various tissues, including the heart, where it plays a role in the regulation of cardiac contractility and electrical activity.\n\nTransient receptor potential ankyrin 5 (TRPA5) is another member of the TRP channel family that has been implicated in the regulation of cardiovascular function. TRPA5 is expressed in various tissues, including the heart, where it plays a role in the regulation of cardiac contractility and electrical activity.\n\nTransient receptor potential ankyrin 6 (TRPA6) is another member of the TRP channel family",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 786,
    "user_query": "You MUST give a detailed answer to the following question: List available biomedical question answering systems.",
    "llama-7b_response": "There are several biomedical question answering (QA) systems available, including:\n\n1. Clinical Question Answering System (CQAS): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to clinical questions posed in natural language.\n2. BioASQ: A series of challenges organized by the European Bioinformatics Institute (EMBL-EBI) that aim to evaluate the performance of QA systems on biomedical literature.\n3. Biocreative: A series of challenges organized by the National Center for Biomedical Ontology (NCBO) that aim to evaluate the performance of QA systems on biomedical literature.\n4. Biomedical Question Answering System (BQAS): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n5. Evidence-Based Medicine Question Answering System (EBMQAS): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to evidence-based medicine questions posed in natural language.\n6. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n7. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n8. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n9. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n10. Question Answering on Biomedical Texts (QABT): A system developed by the National Center for Biotechnology Information (NCBI) that provides answers to biomedical questions posed in natural language.\n11. Question Answering on Biomedical Texts (QABT): A system developed by",
    "llama-7b_fact_raw": "1. The Clinical Question Answering System (CQAS) was developed by the National Center for Biotechnology Information (NCBI).\n2. BioASQ is a series of challenges organized by the European Bioinformatics Institute (EMBL-EBI) for evaluating biomedical literature QA systems.\n3. Biocreative is a challenge series organized by the National Center for Biomedical Ontology (NCBO) focused on the evaluation of biomedical literature QA systems.\n4. The National Center for Biotechnology Information (NCBI) developed a Biomedical Question Answering System (BQAS).\n5. The National Center for Biotechnology Information (NCBI) developed an Evidence-Based Medicine Question Answering System (EBMQAS).",
    "llama-7b_fact": [
      "The Clinical Question Answering System (CQAS) was developed by the National Center for Biotechnology Information (NCBI).",
      "BioASQ is a series of challenges organized by the European Bioinformatics Institute (EMBL-EBI) for evaluating biomedical literature QA systems.",
      "Biocreative is a challenge series organized by the National Center for Biomedical Ontology (NCBO) focused on the evaluation of biomedical literature QA systems.",
      "The National Center for Biotechnology Information (NCBI) developed a Biomedical Question Answering System (BQAS).",
      "The National Center for Biotechnology Information (NCBI) developed an Evidence-Based Medicine Question Answering System (EBMQAS)."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Clinical Question Answering System (CQAS) was not specifically developed by the National Center for Biotechnology Information (NCBI). CQAS could refer to various systems developed by different organizations, and the context does not provide enough information to link it to NCBI specifically.\n2. TRUE\n3. FALSE [correction]: Biocreative is a challenge series that has been associated with the National Institutes of Health (NIH) and other research institutions. The National Center for Biomedical Ontology (NCBO) has been involved in promoting biomedical ontology use but is not primarily known for organizing Biocreative.\n4. UNKNOWN: Without specific context or record of a \"Biomedical Question Answering System (BQAS)\" developed by NCBI, the truth of this statement cannot be determined.\n5. UNKNOWN: Similar to statement 4, without specific context or record of an \"Evidence-Based Medicine Question Answering System (EBMQAS)\" developed by NCBI, the truth of this statement cannot be determined. NCBI is well-known for databases like PubMed, but without clear linkage to EBMQAS, the veracity of this statement is not ascertainable.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "You MUST give a detailed answer to the following question: Which trancription factor activates the betalain pathway?",
    "llama-7b_response": "The transcription factor that activates the betalain pathway has not yet been identified. The betalain pathway is a secondary metabolic pathway that is involved in the biosynthesis of betalain pigments, which are responsible for the red, purple, and yellow colors of certain plant species. The pathway is initiated by the expression of genes that encode enzymes involved in the biosynthesis of betalain pigments, but the transcription factor that activates this gene expression has not yet been identified.",
    "llama-7b_fact_raw": "1. The transcription factor activating the betalain pathway has not been identified.\n2. The betalain pathway is a secondary metabolic pathway.\n3. Betalain pigments are responsible for the red, purple, and yellow colors of certain plant species.\n4. Genes encoding enzymes involved in the biosynthesis of betalain pigments exist.\n5. These genes' expression initiates the betalain pathway.",
    "llama-7b_fact": [
      "The transcription factor activating the betalain pathway has not been identified.",
      "The betalain pathway is a secondary metabolic pathway.",
      "Betalain pigments are responsible for the red, purple, and yellow colors of certain plant species.",
      "Genes encoding enzymes involved in the biosynthesis of betalain pigments exist.",
      "These genes' expression initiates the betalain pathway."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements 2 through 5 are consistent with current knowledge about betalains and their biosynthesis in plants. However, the status of the identification of specific transcription factors may change with new scientific discoveries, and without a specific current reference, the truth of statement 1 cannot be determined.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "You MUST give a detailed answer to the following question: Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-7b_response": "There are several technologies that are commonly used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. Some of the most commonly used technologies include:\n\n1. IMAC (Immobilized Metal Affinity Chromatography): IMAC is a widely used technique for the enrichment of phosphorylated peptides. It utilizes immobilized metal ions, such as nickel or gold, to selectively bind phosphorylated peptides.\n2. TiO2 (Titanium Dioxide) beads: TiO2 beads are another commonly used technology for the enrichment of phosphorylated peptides. They are coated with a layer of titanium dioxide, which selectively binds to phosphorylated peptides.\n3. Phosphopeptide enrichment by immunoaffinity chromatography: This technique involves the use of antibodies that specifically recognize phosphorylated peptides. The antibodies are immobilized on a column, and the phosphorylated peptides bind to the antibodies, while non-phosphorylated peptides pass through.\n4. Phosphopeptide enrichment by reversed-phase chromatography: This technique involves the use of reversed-phase high-performance liquid chromatography (HPLC) to enrich for phosphorylated peptides. The phosphorylated peptides are more hydrophobic than non-phosphorylated peptides, and thus tend to elute later from the column.\n5. Phosphopeptide enrichment by strong cation exchange chromatography: This technique involves the use of strong cation exchange chromatography to enrich for phosphorylated peptides. The phosphorylated peptides are positively charged, and thus tend to bind to the negatively charged resin.\n\nIt is worth noting that the choice of technology for the enrichment of phosphorylated peptides will depend on the specific goals of the study, as well as the characteristics of the sample being analyzed.",
    "llama-7b_fact_raw": "1. Immobilized Metal Affinity Chromatography (IMAC) is used to enrich phosphorylated peptides by binding them to immobilized metal ions.\n2. Titanium Dioxide (TiO2) beads selectively bind phosphorylated peptides through a layer of titanium dioxide.\n3. Phosphopeptide enrichment by immunoaffinity chromatography employs antibodies specific to phosphorylated peptides.\n4. Reversed-phase high-performance liquid chromatography (HPLC) can distinguish phosphorylated peptides based on their increased hydrophobicity.\n5. Strong cation exchange chromatography enriches for phosphorylated peptides due to the positive charge of the phosphorylated peptides.",
    "llama-7b_fact": [
      "Immobilized Metal Affinity Chromatography (IMAC) is used to enrich phosphorylated peptides by binding them to immobilized metal ions.",
      "Titanium Dioxide (TiO2) beads selectively bind phosphorylated peptides through a layer of titanium dioxide.",
      "Phosphopeptide enrichment by immunoaffinity chromatography employs antibodies specific to phosphorylated peptides.",
      "Reversed-phase high-performance liquid chromatography (HPLC) can distinguish phosphorylated peptides based on their increased hydrophobicity.",
      "Strong cation exchange chromatography enriches for phosphorylated peptides due to the positive charge of the phosphorylated peptides."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Immobilized Metal Affinity Chromatography (IMAC) is used to enrich phosphorylated peptides, but it does so by binding phosphorylated peptides not to any immobilized metal ions, but specifically to immobilized metal ions such as iron or zinc.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Reversed-phase high-performance liquid chromatography (HPLC) separates peptides based on hydrophobicity, but phosphorylated peptides are typically less hydrophobic than non-phosphorylated ones due to the introduction of a polar phosphate group.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "You MUST give a detailed answer to the following question: Which disorder is rated by Palmini classification?",
    "llama-7b_response": "dystonia",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 905,
    "user_query": "You MUST give a detailed answer to the following question: Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-7b_response": "Subacute thyroiditis, also known as De Quervain's thyroiditis, is an inflammatory condition that affects the thyroid gland. It is characterized by pain in the front of the neck, enlargement of the thyroid gland, and elevated levels of thyroid hormones in the blood. The exact cause of subacute thyroiditis is not well understood, but it is believed to be an autoimmune disorder.\n\nViruses have been implicated in the etiology of subacute thyroiditis, but the role of viruses is not well established. Some studies have suggested that viral infections, such as the mumps virus, may play a role in the development of subacute thyroiditis. However, other studies have found no association between viral infections and subacute thyroiditis.\n\nIt is also possible that other factors, such as genetic susceptibility and environmental triggers, may contribute to the development of subacute thyroiditis. Further research is needed to better understand the role of viruses in the etiology of subacute thyroiditis.\n\nIn summary, while viruses have been implicated in the etiology of subacute thyroiditis, the role of viruses is not well established. Further research is needed to better understand the factors that contribute to the development of subacute thyroiditis.",
    "llama-7b_fact_raw": "1. Subacute thyroiditis, also known as De Quervain's thyroiditis, is an inflammatory condition that affects the thyroid gland.\n2. Symptoms of subacute thyroiditis include pain in the front of the neck, enlargement of the thyroid gland, and elevated levels of thyroid hormones in the blood.\n3. The condition is believed to be an autoimmune disorder.\n4. Viruses, such as the mumps virus, have been suggested to play a role in the development of subacute thyroiditis, but this is not well established.\n5. Factors other than viral infections, potentially including genetic susceptibility and environmental triggers, may contribute to the development of subacute thyroiditis.",
    "llama-7b_fact": [
      "Subacute thyroiditis, also known as De Quervain's thyroiditis, is an inflammatory condition that affects the thyroid gland.",
      "Symptoms of subacute thyroiditis include pain in the front of the neck, enlargement of the thyroid gland, and elevated levels of thyroid hormones in the blood.",
      "The condition is believed to be an autoimmune disorder.",
      "Viruses, such as the mumps virus, have been suggested to play a role in the development of subacute thyroiditis, but this is not well established.",
      "Factors other than viral infections, potentially including genetic susceptibility and environmental triggers, may contribute to the development of subacute thyroiditis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The exact cause of subacute thyroiditis is not clear, but it is not typically classified as an autoimmune disorder. Rather, it is often thought to be caused by a viral infection.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "You MUST give a detailed answer to the following question: Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-7b_response": "STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in the regulation of various cellular processes, including cell proliferation, differentiation, and survival. STAT3 has been implicated in the regulation of autophagy, a cellular process involved in the degradation and recycling of cellular components.\n\nEIF2AK2 (Eukaryotic Initiation Factor 2 Alpha Kinase 2), also known as PKR (Double-Stranded RNA-Activated Protein Kinase), is a protein kinase that plays a crucial role in the regulation of cellular stress responses, including the innate immune response to viral infections. EIF2AK2 has been implicated in the regulation of autophagy, as it has been shown to negatively regulate autophagy by inhibiting the activity of the ULK1 (Unc-51-like kinase 1) complex, which is a key regulator of autophagy.\n\nThere is evidence to suggest that STAT3 may be involved in the regulation of EIF2AK2-dependent suppression of autophagy. For example, studies have shown that STAT3 can interact with and activate EIF2AK2, leading to the inhibition of autophagy. Additionally, STAT3 has been shown to regulate the expression of genes involved in the regulation of autophagy, such as BECN1 (Beclin 1), which is a key regulator of autophagy.\n\nOverall, while there is evidence to suggest that STAT3 may be involved in the regulation of EIF2AK2-dependent suppression of autophagy, the precise mechanisms by which STAT3 regulates autophagy remain to be fully elucidated. Further research is needed to fully understand the complex interplay between STAT3 and EIF2AK2 in the regulation of autophagy.",
    "llama-7b_fact_raw": "1. STAT3 is a transcription factor that is important in cell proliferation, differentiation, and survival.\n2. STAT3 has been implicated in the regulation of autophagy.\n3. EIF2AK2, also known as PKR, is a protein kinase that regulates cellular stress responses and negatively regulates autophagy by inhibiting the ULK1 complex.\n4. Research suggests STAT3 may interact with and activate EIF2AK2, resulting in the inhibition of autophagy.\n5. STAT3 can regulate the expression of genes such as BECN1, which is involved in the regulation of autophagy.",
    "llama-7b_fact": [
      "STAT3 is a transcription factor that is important in cell proliferation, differentiation, and survival.",
      "STAT3 has been implicated in the regulation of autophagy.",
      "EIF2AK2, also known as PKR, is a protein kinase that regulates cellular stress responses and negatively regulates autophagy by inhibiting the ULK1 complex.",
      "Research suggests STAT3 may interact with and activate EIF2AK2, resulting in the inhibition of autophagy.",
      "STAT3 can regulate the expression of genes such as BECN1, which is involved in the regulation of autophagy."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "You MUST give a detailed answer to the following question: Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-7b_response": "The Theatre software tool is a genomic analysis tool that is used to visualize and analyze large-scale genomic data. It is designed to help researchers and clinicians better understand the structure and organization of the human genome, as well as to identify genetic variations that may be associated with disease.\n\nOne of the key features of Theatre is its ability to handle very large datasets, such as those generated by next-generation sequencing (NGS) technologies. These datasets can contain billions of base pairs of DNA sequence data, and Theatre is able to process and analyze this data quickly and efficiently.\n\nAnother important feature of Theatre is its ability to visualize genomic data in a variety of ways. For example, it can generate maps of the human genome that show the location of different genes and other genomic features, as well as visualize the distribution of genetic variations across the genome. These visualizations can help researchers and clinicians better understand the structure and organization of the human genome and identify potential genetic variants that may be associated with disease.\n\nIn addition to its visualization capabilities, Theatre also includes a number of analysis tools that can be used to identify and analyze specific genomic features. For example, it can be used to identify regions of the genome that are enriched for certain types of genetic variations, such as single nucleotide polymorphisms (SNPs) or copy number variations (CNVs). It can also be used to identify regions of the genome that are likely to contain functional elements, such as genes or regulatory elements.\n\nOverall, the Theatre software tool is a valuable tool for genomic analysis, and is used by researchers and clinicians around the world to better understand the structure and organization of the human genome and to identify potential genetic variants that may be associated with disease.",
    "llama-7b_fact_raw": "1. Theatre is a software tool used for visualizing and analyzing large-scale genomic data.\n2. Theatre can handle very large datasets, such as those generated by next-generation sequencing technologies.\n3. The software can generate maps of the human genome that show the location of different genes and other genomic features.\n4. Theatre has the capability to visualize the distribution of genetic variations across the human genome.\n5. The software includes tools to identify and analyze specific genomic features, such as single nucleotide polymorphisms (SNPs) and copy number variations (CNVs).",
    "llama-7b_fact": [
      "Theatre is a software tool used for visualizing and analyzing large-scale genomic data.",
      "Theatre can handle very large datasets, such as those generated by next-generation sequencing technologies.",
      "The software can generate maps of the human genome that show the location of different genes and other genomic features.",
      "Theatre has the capability to visualize the distribution of genetic variations across the human genome.",
      "The software includes tools to identify and analyze specific genomic features, such as single nucleotide polymorphisms (SNPs) and copy number variations (CNVs)."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the provided passage or additional context, I cannot verify the accuracy of these statements about the \"Theatre\" software tool. They seem plausible for a genomic analysis tool, but without specific information, it is not possible to determine their truthfulness.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "You MUST give a detailed answer to the following question: Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-7b_response": "The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences. The execution time (complexity) of the Smith-Waterman algorithm depends on several factors, including the length of the sequences being aligned, the similarity between the sequences, and the gap penalty and extension penalty used in the algorithm.\n\nIn general, the execution time of the Smith-Waterman algorithm increases exponentially with the length of the sequences being aligned. For example, if the two sequences being aligned are of length n, the Smith-Waterman algorithm has a time complexity of O(n^2). This means that as the length of the sequences increases, the execution time of the algorithm also increases.\n\nThe gap penalty and extension penalty used in the Smith-Waterman algorithm can also affect the execution time of the algorithm. A larger gap penalty will result in more gaps being inserted in the alignment, which can increase the execution time of the algorithm. Similarly, a larger extension penalty will result in more extensions being added to the alignment, which can also increase the execution time of the algorithm.\n\nIn summary, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the length of the sequences, the similarity between the sequences, and the gap penalty and extension penalty used in the algorithm. As the length of the sequences increases, the execution time of the algorithm also increases, and the choice of gap penalty and extension penalty can also affect the execution time of the algorithm.",
    "llama-7b_fact_raw": "1. The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences.\n2. The execution time (complexity) of the Smith-Waterman algorithm generally increases with the length of the sequences being aligned.\n3. For sequences of length n, the time complexity of the Smith-Waterman algorithm is O(n^2).\n4. The gap penalty and extension penalty used in the algorithm can affect the execution time.\n5. A larger gap penalty can result in more gaps in the alignment, potentially increasing the execution time.",
    "llama-7b_fact": [
      "The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences.",
      "The execution time (complexity) of the Smith-Waterman algorithm generally increases with the length of the sequences being aligned.",
      "For sequences of length n, the time complexity of the Smith-Waterman algorithm is O(n^2).",
      "The gap penalty and extension penalty used in the algorithm can affect the execution time.",
      "A larger gap penalty can result in more gaps in the alignment, potentially increasing the execution time."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - The time complexity of the Smith-Waterman algorithm is O(n^2) for two sequences each of length n.\n4. TRUE - The values chosen for gap and extension penalties can affect the scoring and therefore the computation involved in the algorithm, though they don't directly change the algorithm's complexity class.\n5. FALSE [correction]: A larger gap penalty generally results in fewer gaps in the alignment because it becomes more costly to introduce gaps, rather than increasing the execution time. The execution time is primarily dependent on the sequences' lengths and not the number of gaps in the final alignment.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1004,
    "user_query": "You MUST give a detailed answer to the following question: Which SLC family is FLVCR1 a member of?",
    "llama-7b_response": "folate receptor",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1047,
    "user_query": "You MUST give a detailed answer to the following question: List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-7b_response": "GATA-1 (GATA binding protein 1) is a transcription factor that plays a crucial role in the regulation of gene expression in various cell types, including hematopoietic stem cells and cardiac progenitor cells. GATA-1 interacts with a wide range of proteins, including other transcription factors, coactivators, and corepressors, to regulate the transcription of target genes.\n\nOne approach used to identify GATA-1 interacting partners is the biotinylation tagging approach, which involves the biotinylation of GATA-1 and subsequent affinity purification of biotinylated proteins that interact with GATA-1. This approach has been used to identify a number of proteins that interact with GATA-1.\n\nHere are some of the GATA-1 interacting partners that have been identified using the biotinylation tagging approach:\n\n1. TBP (TATA box binding protein): TBP is a general transcription factor that binds to the TATA box element in the promoter region of many genes. TBP interacts with GATA-1 to form a complex that binds to the promoter region of target genes.\n2. NCoA-2 (Nuclear coactivator 2): NCoA-2 is a coactivator that enhances the transcriptional activity of GATA-1 and other transcription factors.\n3. HDAC1 (Histone deacetylase 1): HDAC1 is a corepressor that interacts with GATA-1 to repress the transcription of target genes.\n4. HDAC2 (Histone deacetylase 2): HDAC2 is a corepressor that interacts with GATA-1 to repress the transcription of target genes.\n5. HDAC3 (Histone deacetylase 3): HDAC3 is a corepressor that interacts with GATA-1 to repress the transcription of target genes.\n6. HDAC4 (Histone deacetylase 4): HDAC4 is a corepressor that interacts with GATA-1 to repress the transcription of target genes.\n7. HDAC5 (Histone deacetylase",
    "llama-7b_fact_raw": "1. TBP (TATA box binding protein) has been identified as a GATA-1 interacting partner through the biotinylation tagging approach.\n2. NCoA-2 (Nuclear coactivator 2) enhances the transcriptional activity of GATA-1 and has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.\n3. HDAC1 (Histone deacetylase 1) interacts with GATA-1 and has been identified using the biotinylation tagging approach.\n4. HDAC2 (Histone deacetylase 2) has been identified as a GATA-1 interacting partner through the biotinylation tagging approach.\n5. HDAC3 (Histone deacetylase 3) has been identified to interact with GATA-1 through the biotinylation tagging approach.",
    "llama-7b_fact": [
      "TBP (TATA box binding protein) has been identified as a GATA-1 interacting partner through the biotinylation tagging approach.",
      "NCoA-2 (Nuclear coactivator 2) enhances the transcriptional activity of GATA-1 and has been identified as a GATA-1 interacting partner using the biotinylation tagging approach.",
      "HDAC1 (Histone deacetylase 1) interacts with GATA-1 and has been identified using the biotinylation tagging approach.",
      "HDAC2 (Histone deacetylase 2) has been identified as a GATA-1 interacting partner through the biotinylation tagging approach.",
      "HDAC3 (Histone deacetylase 3) has been identified to interact with GATA-1 through the biotinylation tagging approach."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific scientific literature or the original passage that includes the research details about these interactions and the methods used to identify them, I can only confirm statements 1 and 2 based on the given context. For statements 3, 4, and 5, the interactions between HDAC1, HDAC2, HDAC3, and GATA-1 may very well be true, but without context or research references, I cannot confirm whether the biotinylation tagging approach was used to identify those interactions. Hence, those statements are marked as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1072,
    "user_query": "You MUST give a detailed answer to the following question: What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-7b_response": "TAF10 is a transcriptional co-activator that interacts with GATA1, a transcription factor that plays a crucial role in the regulation of genes involved in cardiac development and function. The interaction between TAF10 and GATA1 leads to the recruitment of other transcriptional co-activators, such as p300 and histone acetyltransferases, to the GATA1 binding site on the DNA. This results in the activation of gene transcription and the expression of genes involved in cardiac development and function.\n\nIn particular, the interaction between TAF10 and GATA1 has been shown to play a crucial role in the regulation of genes involved in cardiac hypertrophy, a condition characterized by an increase in the size of the heart muscle cells. The activation of genes involved in cardiac hypertrophy by TAF10 and GATA1 leads to an increase in the production of proteins involved in the growth and survival of cardiac muscle cells, which can contribute to the development of cardiac hypertrophy.\n\nIn summary, the interaction between TAF10 and GATA1 leads to the activation of gene transcription and the expression of genes involved in cardiac development and function, including those involved in cardiac hypertrophy. The activation of these genes can contribute to the development and progression of cardiac hypertrophy, a condition characterized by an increase in the size of the heart muscle cells.",
    "llama-7b_fact_raw": "1. TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.\n2. GATA1 plays a crucial role in the regulation of genes involved in cardiac development and function.\n3. The interaction between TAF10 and GATA1 results in the recruitment of transcriptional co-activators, such as p300 and histone acetyltransferases.\n4. This interaction and subsequent recruitment leads to the activation of gene transcription involved in cardiac development and function.\n5. TAF10 and GATA1 interaction is associated with the regulation of genes involved in cardiac hypertrophy, characterized by an increase in the size of heart muscle cells.",
    "llama-7b_fact": [
      "TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.",
      "GATA1 plays a crucial role in the regulation of genes involved in cardiac development and function.",
      "The interaction between TAF10 and GATA1 results in the recruitment of transcriptional co-activators, such as p300 and histone acetyltransferases.",
      "This interaction and subsequent recruitment leads to the activation of gene transcription involved in cardiac development and function.",
      "TAF10 and GATA1 interaction is associated with the regulation of genes involved in cardiac hypertrophy, characterized by an increase in the size of heart muscle cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided all relate to the roles of TAF10 and GATA1 in transcription regulation, particularly in relation to cardiac development and function. Based on general biological knowledge, these statements are consistent with the known functions of transcription factors (like GATA1) and co-activators (like TAF10) in gene expression regulation. The final statement about the association with cardiac hypertrophy is an extension of these roles, as hypertrophy involves changes in gene expression controlled by such factors. Without specific evidence to contradict these claims, they are considered true based on the current understanding of molecular biology.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "You MUST give a detailed answer to the following question: Are there any Decision support systems for chronic pain management ?",
    "llama-7b_response": "Yes, there are several decision support systems for chronic pain management. These systems are designed to help healthcare providers and patients make informed decisions about the management of chronic pain. Some examples of decision support systems for chronic pain management include:\n\n1. Pain Management Decision Support System (PM-DSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n2. Clinical Decision Support for Chronic Pain (CDS-CP): This is a decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n3. Chronic Pain Management Decision Support System (CPMDSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n4. Pain Management Decision Support System (PM-DSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n5. Clinical Decision Support for Chronic Pain (CDS-CP): This is a decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n6. Chronic Pain Management Decision Support System (CPMDSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic pain. The system is designed to help clinicians select the most appropriate treatment options for their patients based on their individual needs and preferences.\n7. Pain Management Decision Support System (PM-DSS): This is a web-based decision support system that provides clinicians with evidence-based recommendations for the management of chronic",
    "llama-7b_fact_raw": "1. There are decision support systems designed to aid in the management of chronic pain.\n2. The Pain Management Decision Support System (PM-DSS) is web-based and provides clinicians with evidence-based treatment recommendations for chronic pain.\n3. Clinical Decision Support for Chronic Pain (CDS-CP) offers evidence-based recommendations to clinicians for chronic pain management.\n4. Chronic Pain Management Decision Support System (CPMDSS) is another web-based system providing evidence-based guidance for treating chronic pain.\n5. Decision support systems for chronic pain are intended to assist healthcare providers in selecting treatment options tailored to patients' individual needs and preferences.",
    "llama-7b_fact": [
      "There are decision support systems designed to aid in the management of chronic pain.",
      "The Pain Management Decision Support System (PM-DSS) is web-based and provides clinicians with evidence-based treatment recommendations for chronic pain.",
      "Clinical Decision Support for Chronic Pain (CDS-CP) offers evidence-based recommendations to clinicians for chronic pain management.",
      "Chronic Pain Management Decision Support System (CPMDSS) is another web-based system providing evidence-based guidance for treating chronic pain.",
      "Decision support systems for chronic pain are intended to assist healthcare providers in selecting treatment options tailored to patients' individual needs and preferences."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1149,
    "user_query": "You MUST give a detailed answer to the following question: Which is the subcellular localization of the protein angiogenin?",
    "llama-7b_response": "Angiogenin is a type of protein that is involved in the process of angiogenesis, which is the formation of new blood vessels from pre-existing ones. The subcellular localization of angiogenin can vary depending on the cell type and the stage of the angiogenic process.\n\nIn general, angiogenin is found in the cytosol of cells, which is the fluid inside the cell that surrounds the nucleus and other organelles. However, during the early stages of angiogenesis, angiogenin can be found in the nucleus of cells. This is because angiogenin plays a role in the transcription of genes that are involved in the process of angiogenesis.\n\nOnce new blood vessels have formed, angiogenin can be found in the extracellular matrix, which is the material that surrounds cells and holds them together. This is because angiogenin plays a role in the formation of a matrix that supports the newly formed blood vessels.\n\nOverall, the subcellular localization of angiogenin can vary depending on the cell type and the stage of the angiogenic process. However, it is generally found in the cytosol of cells during the early stages of angiogenesis and in the extracellular matrix once new blood vessels have formed.",
    "llama-7b_fact_raw": "1. Angiogenin is involved in angiogenesis, which is the formation of new blood vessels from pre-existing ones.\n2. Angiogenin's subcellular localization can vary based on the cell type and the stage of angiogenesis.\n3. Generally, angiogenin is found in the cytosol of cells.\n4. During the early stages of angiogenesis, angiogenin can localize to the nucleus of cells.\n5. After new blood vessels have formed, angiogenin can be found in the extracellular matrix.",
    "llama-7b_fact": [
      "Angiogenin is involved in angiogenesis, which is the formation of new blood vessels from pre-existing ones.",
      "Angiogenin's subcellular localization can vary based on the cell type and the stage of angiogenesis.",
      "Generally, angiogenin is found in the cytosol of cells.",
      "During the early stages of angiogenesis, angiogenin can localize to the nucleus of cells.",
      "After new blood vessels have formed, angiogenin can be found in the extracellular matrix."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Angiogenin is not typically described as localizing to the extracellular matrix after the formation of new blood vessels. Rather, after being secreted by the cells, it acts on the cell surface or within cells to promote angiogenesis. The exact locations and roles of angiogenin can vary, and in terms of localization, it is more often discussed in relation to its presence within cells or its secretion rather than its incorporation into the extracellular matrix.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1161,
    "user_query": "You MUST give a detailed answer to the following question: How does ranolazine affect kinase signaling activation in the heart?",
    "llama-7b_response": "RANOLIDE",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1225,
    "user_query": "You MUST give a detailed answer to the following question: Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-7b_response": "Yes, the regulation of the VSR endonuclease is independent of the growth phase of bacteria. The VSR endonuclease is a restriction-modification system that is present in many bacterial species and is involved in the defense against foreign DNA. The regulation of the VSR endonuclease is complex and involves multiple factors, including the growth phase of the bacteria, the presence of DNA damage, and the availability of certain nutrients.\n\nIn general, the activity of the VSR endonuclease is highest during the exponential growth phase of bacteria and decreases as the bacteria enter stationary phase. However, the regulation of the VSR endonuclease is not solely dependent on the growth phase of the bacteria. Other factors, such as the presence of DNA damage and the availability of certain nutrients, can also affect the activity of the endonuclease.\n\nFor example, the activity of the VSR endonuclease can be increased by DNA damage, such as that caused by UV radiation or certain antibiotics. In addition, the availability of certain nutrients, such as amino acids and nucleotides, can also affect the activity of the endonuclease.\n\nOverall, the regulation of the VSR endonuclease is complex and involves multiple factors, including the growth phase of the bacteria, the presence of DNA damage, and the availability of certain nutrients. However, the regulation of the endonuclease is not solely dependent on the growth phase of the bacteria.",
    "llama-7b_fact_raw": "1. The VSR endonuclease is a restriction-modification system present in many bacterial species.\n2. The regulation of the VSR endonuclease is complex and not solely dependent on the growth phase of bacteria.\n3. The activity of the VSR endonuclease tends to be highest during the exponential growth phase of bacteria.\n4. DNA damage, such as that caused by UV radiation or certain antibiotics, can increase the activity of the VSR endonuclease.\n5. The availability of certain nutrients, like amino acids and nucleotides, can affect the activity of the VSR endonuclease.",
    "llama-7b_fact": [
      "The VSR endonuclease is a restriction-modification system present in many bacterial species.",
      "The regulation of the VSR endonuclease is complex and not solely dependent on the growth phase of bacteria.",
      "The activity of the VSR endonuclease tends to be highest during the exponential growth phase of bacteria.",
      "DNA damage, such as that caused by UV radiation or certain antibiotics, can increase the activity of the VSR endonuclease.",
      "The availability of certain nutrients, like amino acids and nucleotides, can affect the activity of the VSR endonuclease."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The VSR (Very Short Patch Repair) endonuclease is not a restriction-modification system but is involved in the DNA mismatch repair process, specifically repairing certain types of DNA mismatches that result from the deamination of 5-methylcytosine to thymine.\n2. TRUE: The regulation of VSR endonuclease is indeed complex and it is known that factors other than the growth phase of bacteria can influence its activity.\n3. UNKNOWN: Without specific research data or more context, it's hard to confirm if the activity of the VSR endonuclease is highest during the exponential growth phase of bacteria.\n4. UNKNOWN: Similarly, without additional context, the relationship between DNA damage and the specific increase in the activity of the VSR endonuclease is not clear. While DNA repair systems in general are activated in response to damage, the statement's specificity to VSR endonuclease requires further details.\n5. UNKNOWN: The impact of nutrient availability on the activity of the VSR endonuclease is not specified, and this would also require specific research evidence to confirm.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "You MUST give a detailed answer to the following question: What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins, including:\n\n1. PSIPRED: PSIPRED (Protein Secondary Structure Predictor) is a web server that predicts the secondary structure of a protein based on its amino acid sequence. PSIPRED can predict beta-barrel transmembrane proteins with a high degree of accuracy.\n2. TMHMM: TMHMM (Transmembrane Helices of Microbial Toxins Homology-based Method) is a web server that predicts the presence of transmembrane helices in a protein sequence. TMHMM can be used to identify beta-barrel transmembrane proteins with a high degree of accuracy.\n3. SOSUI: SOSUI (Secondary Structure of Proteins from Unknown Initial Sequence) is a web server that predicts the secondary structure of a protein based on its amino acid sequence. SOSUI can predict beta-barrel transmembrane proteins with a high degree of accuracy.\n4. PONDR-FIT: PONDR-FIT (Predicting the Orientation of the First Transmembrane Helix in Targets) is a web server that predicts the orientation of the first transmembrane helix in a protein sequence. PONDR-FIT can be used to identify beta-barrel transmembrane proteins with a high degree of accuracy.\n5. Phobius: Phobius is a web server that predicts the presence of transmembrane helices in a protein sequence. Phobius can be used to identify beta-barrel transmembrane proteins with a high degree of accuracy.\n\nOverall, these computational tools can be used in combination to predict the presence of beta-barrel transmembrane proteins with a high degree of accuracy.",
    "llama-7b_fact_raw": "1. PSIPRED is a computational tool that predicts protein secondary structure based on amino acid sequence and can be used to predict beta-barrel transmembrane proteins.\n2. TMHMM is a computational tool that predicts transmembrane helices in protein sequences and can identify beta-barrel transmembrane proteins.\n3. SOSUI is a computational tool that predicts the secondary structure of proteins from their amino acid sequences, including beta-barrel transmembrane proteins.\n4. PONDR-FIT is a web server that predicts the orientation of the first transmembrane helix in protein sequences and can be used for beta-barrel transmembrane proteins.\n5. Phobius is a computational tool that predicts the presence of transmembrane helices in a protein sequence and can be used to identify beta-barrel transmembrane proteins.",
    "llama-7b_fact": [
      "PSIPRED is a computational tool that predicts protein secondary structure based on amino acid sequence and can be used to predict beta-barrel transmembrane proteins.",
      "TMHMM is a computational tool that predicts transmembrane helices in protein sequences and can identify beta-barrel transmembrane proteins.",
      "SOSUI is a computational tool that predicts the secondary structure of proteins from their amino acid sequences, including beta-barrel transmembrane proteins.",
      "PONDR-FIT is a web server that predicts the orientation of the first transmembrane helix in protein sequences and can be used for beta-barrel transmembrane proteins.",
      "Phobius is a computational tool that predicts the presence of transmembrane helices in a protein sequence and can be used to identify beta-barrel transmembrane proteins."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: TMHMM predicts transmembrane helices in protein sequences but is not specialized in identifying beta-barrel transmembrane proteins, which have a different structure from alpha-helical transmembrane proteins that TMHMM is designed to predict.\n3. FALSE [correction]: SOSUI predicts the membrane localization and orientation and the secondary structure of proteins from their amino acid sequences. However, while it may predict regions that span membranes, there is no specific information that it is tailored to predict beta-barrel transmembrane proteins.\n4. FALSE [correction]: PONDR-FIT is actually a consensus predictor that combines several prediction methods to estimate the intrinsic disorder in proteins, not the orientation of transmembrane helices.\n5. FALSE [correction]: Phobius predicts the presence of transmembrane helices and signal peptides in protein sequences. It is primarily used for alpha-helical transmembrane proteins, not specifically for beta-barrel transmembrane proteins.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "You MUST give a detailed answer to the following question: Galassi classification is used for which disorder?",
    "llama-7b_response": "dystonia",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1304,
    "user_query": "You MUST give a detailed answer to the following question: List common features of Shapiro syndrome",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1320,
    "user_query": "You MUST give a detailed answer to the following question: Which disease is linked to mutations within BRAG1?",
    "llama-7b_response": "cancer",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1362,
    "user_query": "You MUST give a detailed answer to the following question: Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-7b_response": "okadaic acid",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1374,
    "user_query": "You MUST give a detailed answer to the following question: Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a mechanism by which bacteria, such as Bacillus subtilis, can increase their mutation rates in response to stressful conditions, such as starvation or exposure to antibiotics. There are several mechanisms that underlie adaptive mutagenesis in B. subtilis:\n\n1. DNA damage: DNA damage, such as that caused by reactive oxygen species (ROS) or DNA-damaging antibiotics, can activate the SOS response in B. subtilis. The SOS response leads to an increase in the mutation rate, which can help the bacteria survive and repair the DNA damage.\n2. Transcriptional regulation: The transcriptional regulator Spo0A plays a key role in the regulation of adaptive mutagenesis in B. subtilis. When Spo0A is activated by DNA damage or other stressful conditions, it activates the expression of genes involved in DNA repair and mutagenesis, such as uvrA and recA.\n3. DNA repair: B. subtilis has several mechanisms for repairing DNA damage, including homologous recombination and non-homologous end joining. When DNA damage occurs, the bacteria can use these mechanisms to repair the damage and prevent mutations from occurring. However, if the damage is too severe, the bacteria may choose to mutate instead of repairing the DNA.\n4. Mutator mutations: B. subtilis can also acquire mutator mutations, which increase the mutation rate. These mutations can occur spontaneously or be induced by DNA-damaging agents. Mutator mutations can increase the bacteria's ability to adapt to stressful conditions by allowing more mutations to occur, which can lead to the selection of beneficial mutations.\n\nOverall, adaptive mutagenesis in B. subtilis is a complex process that involves multiple mechanisms, including DNA damage, transcriptional regulation, DNA repair, and mutator mutations. These mechanisms allow the bacteria to increase their mutation rates in response to stressful conditions, which can help them survive and adapt to their environment.",
    "llama-7b_fact_raw": "1. Adaptive mutagenesis allows bacteria like Bacillus subtilis to increase their mutation rates in response to stressful conditions such as starvation or exposure to antibiotics.\n2. DNA damage in Bacillus subtilis can trigger the SOS response, leading to an increased mutation rate.\n3. The transcriptional regulator Spo0A, upon activation by DNA damage or stress, can initiate the expression of genes involved in DNA repair and mutagenesis in B. subtilis.\n4. Bacillus subtilis utilizes DNA repair mechanisms, including homologous recombination and non-homologous end joining, to repair DNA damage.\n5. B. subtilis can develop mutator mutations that increase the bacteria's mutation rate, aiding in adaptation under stressful conditions.",
    "llama-7b_fact": [
      "Adaptive mutagenesis allows bacteria like Bacillus subtilis to increase their mutation rates in response to stressful conditions such as starvation or exposure to antibiotics.",
      "DNA damage in Bacillus subtilis can trigger the SOS response, leading to an increased mutation rate.",
      "The transcriptional regulator Spo0A, upon activation by DNA damage or stress, can initiate the expression of genes involved in DNA repair and mutagenesis in B. subtilis.",
      "Bacillus subtilis utilizes DNA repair mechanisms, including homologous recombination and non-homologous end joining, to repair DNA damage.",
      "B. subtilis can develop mutator mutations that increase the bacteria's mutation rate, aiding in adaptation under stressful conditions."
    ],
    "llama-7b_judge_raw": "1. TRUE: Adaptive mutagenesis is a mechanism by which bacteria can indeed increase their mutation rates under stressful conditions, such as starvation or exposure to antibiotics, allowing them to adapt to these challenges.\n\n2. TRUE: The SOS response in bacteria, including Bacillus subtilis, is a well-documented pathway that is induced by DNA damage, leading to increased mutation rates as a part of the response.\n\n3. FALSE [correction]: The transcriptional regulator Spo0A is known for its role in initiating sporulation in Bacillus subtilis and regulating genes related to this process, not specifically for DNA repair and mutagenesis upon DNA damage or stress. The transcriptional regulation of genes involved in DNA repair and mutagenesis may involve other regulatory proteins and pathways.\n\n4. FALSE [correction]: Bacillus subtilis is known for utilizing DNA repair mechanisms, including homologous recombination, to repair DNA damage. However, non-homologous end joining (NHEJ) is generally associated with eukaryotes and is not a typical mechanism for DNA repair in B. subtilis, which lacks the necessary enzymes for classic NHEJ.\n\n5. TRUE: Mutator mutations can occur in bacteria, including B. subtilis, and lead to an increased mutation rate which can be beneficial for adaptation under certain stressful conditions by increasing the likelihood of advantageous mutations.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "You MUST give a detailed answer to the following question: What causes erucism?",
    "llama-7b_response": "Erucic acid is a type of fatty acid that can be found in certain types of vegetable oils, such as rapeseed (also known as canola) oil. Erucic acid can cause erucism, which is a rare condition characterized by the accumulation of erucic acid in the body's tissues.\n\nErucic acid can accumulate in the body's tissues due to the consumption of foods that contain high levels of erucic acid, such as rapeseed oil. Erucic acid can also be produced in the body as a result of certain genetic mutations that affect the way the body processes fatty acids.\n\nThe accumulation of erucic acid in the body's tissues can cause a range of symptoms, including joint pain, inflammation, and damage to the heart and other organs. In severe cases, erucism can lead to the development of heart disease, liver disease, and other serious health problems.\n\nIt is important for individuals to be aware of the potential risks associated with consuming high levels of erucic acid and to avoid foods that contain high levels of this fatty acid. In addition, individuals who have a family history of erucism or other health problems related to the accumulation of erucic acid in the body should speak with their healthcare provider about the potential risks and benefits of consuming rapeseed oil or other foods that contain high levels of erucic acid.",
    "llama-7b_fact_raw": "1. Erucic acid can cause erucism, a condition characterized by the accumulation of erucic acid in the body's tissues. \n2. Foods with high levels of erucic acid, such as rapeseed oil, can lead to the accumulation of erucic acid in the body. \n3. Genetic mutations that affect fatty acid processing can result in the production of erucic acid in the body. \n4. Symptoms of erucism include joint pain, inflammation, and damage to the heart and other organs. \n5. Consuming high levels of erucic acid can potentially lead to heart disease, liver disease, and other serious health problems.",
    "llama-7b_fact": [
      "Erucic acid can cause erucism, a condition characterized by the accumulation of erucic acid in the body's tissues.",
      "Foods with high levels of erucic acid, such as rapeseed oil, can lead to the accumulation of erucic acid in the body.",
      "Genetic mutations that affect fatty acid processing can result in the production of erucic acid in the body.",
      "Symptoms of erucism include joint pain, inflammation, and damage to the heart and other organs.",
      "Consuming high levels of erucic acid can potentially lead to heart disease, liver disease, and other serious health problems."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Erucism is not a known medical condition related to erucic acid; rather erucic acid is associated with potential health risks such as heart lesions, particularly when consumed in high amounts by animals.\n2. TRUE\n3. FALSE [correction]: Genetic mutations that affect fatty acid processing can result in the accumulation of unusual fatty acids, but they don't typically cause the production of erucic acid. Erucic acid is a naturally occurring fatty acid found in some plants.\n4. FALSE [correction]: Since erucism is not a recognized medical condition, symptoms like joint pain, inflammation, and damage to the heart and other organs cannot be attributed specifically to 'erucism.' However, high amounts of erucic acid have been associated with heart lesions in animal studies, but the evidence of similar effects in humans is limited.\n5. TRUE (with caution) [note]: While animal studies have shown that high levels of erucic acid can lead to health issues such as heart lesions, the implications for humans is less clear. Legislation exists to limit erucic acid content in food oils to levels that are considered safe based on available research.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "You MUST give a detailed answer to the following question: What are the indications for hydrochlorothiazide?",
    "llama-7b_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat hypertension (high blood pressure) and edema (swelling) caused by various conditions, such as heart failure, liver disease, and kidney disease. It works by increasing the production of urine, which helps to reduce blood pressure and remove excess fluid from the body.\n\nHydrochlorothiazide is also used to treat other conditions, such as nephrotic syndrome (a condition that causes excessive protein in the urine) and diabetes insipidus (a condition that causes excessive thirst and urination).\n\nIn addition to its medicinal uses, hydrochlorothiazide is also sometimes used as a \"water pill\" or diuretic to increase the amount of urine produced by the body. This can be helpful in treating conditions such as edema caused by conditions such as heart failure, liver disease, and kidney disease.\n\nIt is important for individuals taking hydrochlorothiazide to have their blood pressure and electrolyte levels monitored regularly, as this medication can cause changes in these levels. Additionally, individuals taking hydrochlorothiazide should avoid dehydration by drinking plenty of fluids and avoiding excessive exercise and exposure to heat.\n\nIn summary, hydrochlorothiazide is a diuretic medication that is commonly used to treat hypertension, edema, nephrotic syndrome, and diabetes insipidus. It works by increasing the production of urine, which helps to reduce blood pressure and remove excess fluid from the body. It is important for individuals taking hydrochlorothiazide to have their blood pressure and electrolyte levels monitored regularly and to avoid dehydration.",
    "llama-7b_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension (high blood pressure).\n2. Hydrochlorothiazide is used to treat edema caused by conditions such as heart failure, liver disease, and kidney disease.\n3. Hydrochlorothiazide increases the production of urine.\n4. It is used to treat nephrotic syndrome, which causes excessive protein in the urine.\n5. Hydrochlorothiazide is used in the treatment of diabetes insipidus, which causes excessive thirst and urination.",
    "llama-7b_fact": [
      "Hydrochlorothiazide is used to treat hypertension (high blood pressure).",
      "Hydrochlorothiazide is used to treat edema caused by conditions such as heart failure, liver disease, and kidney disease.",
      "Hydrochlorothiazide increases the production of urine.",
      "It is used to treat nephrotic syndrome, which causes excessive protein in the urine.",
      "Hydrochlorothiazide is used in the treatment of diabetes insipidus, which causes excessive thirst and urination."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrochlorothiazide is not typically used to treat nephrotic syndrome. Nephrotic syndrome is treated with medications such as ACE inhibitors or corticosteroids, depending on the underlying cause.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "You MUST give a detailed answer to the following question: Has silicon been used in treatment of  incontinence ?",
    "llama-7b_response": "Yes, silicone has been used in the treatment of incontinence. Silicone is a synthetic material that has been used in various medical applications, including the treatment of urinary incontinence.\n\nSilicone has been used in the treatment of stress urinary incontinence (SUI), which is a type of urinary incontinence that occurs due to pressure on the bladder during activities that put pressure on the abdomen, such as coughing, sneezing, or exercise. Silicone is used to create a supportive sling that is placed around the urethra and bladder neck, which helps to hold the bladder in place and prevent urine leakage.\n\nSilicone is also used in the treatment of urge incontinence, which is a type of urinary incontinence that occurs due to an overactive bladder. Silicone is used to create a pessary, which is a device that is placed in the vagina to help support the bladder and prevent urine leakage.\n\nSilicone is a safe and effective material for use in the treatment of incontinence. However, it is important for patients to discuss the risks and benefits of silicone treatment with their healthcare provider before deciding on a treatment option.",
    "llama-7b_fact_raw": "1. Silicone has been used in various medical applications, including the treatment of urinary incontinence.\n2. Stress urinary incontinence (SUI) is treated with silicone which is used to create a supportive sling around the urethra and bladder neck.\n3. The silicone sling in SUI treatment helps to hold the bladder in place and prevent urine leakage.\n4. Urge incontinence, a type of urinary incontinence due to an overactive bladder, is treated with a silicone-made pessary device.\n5. Potential patients are advised to discuss the risks and benefits of silicone treatment for incontinence with their healthcare provider.",
    "llama-7b_fact": [
      "Silicone has been used in various medical applications, including the treatment of urinary incontinence.",
      "Stress urinary incontinence (SUI) is treated with silicone which is used to create a supportive sling around the urethra and bladder neck.",
      "The silicone sling in SUI treatment helps to hold the bladder in place and prevent urine leakage.",
      "Urge incontinence, a type of urinary incontinence due to an overactive bladder, is treated with a silicone-made pessary device.",
      "Potential patients are advised to discuss the risks and benefits of silicone treatment for incontinence with their healthcare provider."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: A pessary device used for managing incontinence, including urge incontinence, is typically made from materials like silicone, but it is not specifically used to treat an overactive bladder. A pessary is used to support the pelvic organs and may be used in cases of stress urinary incontinence or pelvic organ prolapse, but treatment of an overactive bladder often involves medication, lifestyle changes, or other interventions.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "You MUST give a detailed answer to the following question: What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-7b_response": "The association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. Some studies have suggested that there may be a link between the phases of the moon and the rupture risk of intracranial aneurysms, while others have found no such association.\n\nIntracranial aneurysms are abnormal bulges in the wall of an artery that supplies blood to the brain. These aneurysms can rupture and cause a subarachnoid hemorrhage, which can be a life-threatening condition. Rupture of an intracranial aneurysm is a complex process that is influenced by a variety of factors, including the size and shape of the aneurysm, the blood flow through the aneurysm, and the overall health of the blood vessels in the brain.\n\nSome studies have suggested that the phases of the moon may play a role in the rupture risk of intracranial aneurysms. For example, some studies have found that the risk of rupture of an intracranial aneurysm may be higher during the full moon phase than during other phases of the moon. Other studies, however, have found no such association.\n\nIt is worth noting that the association between the moon cycle and rupture risk of intracranial aneurysms is still a topic of ongoing research and debate. While some studies have suggested a link, others have found no such association. More research is needed to fully understand the relationship between the moon cycle and the rupture risk of intracranial aneurysms.\n\nIn summary, the association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. Some studies have suggested that there may be a link between the phases of the moon and the rupture risk of intracranial aneurysms, while others have found no such association. More research is needed to fully understand the relationship between the moon cycle and the rupture risk of intracranial aneurysms.",
    "llama-7b_fact_raw": "1. The association between the moon cycle and rupture risk of intracranial aneurysms is currently debated.\n2. Intracranial aneurysms are abnormal bulges in the artery walls supplying blood to the brain.\n3. Rupture of an intracranial aneurysm can cause a subarachnoid hemorrhage, which is potentially life-threatening.\n4. Some studies have suggested a higher risk of intracranial aneurysm rupture during the full moon phase.\n5. There is no consensus in the scientific community about the link between moon cycles and aneurysm rupture risks, and more research is necessary.",
    "llama-7b_fact": [
      "The association between the moon cycle and rupture risk of intracranial aneurysms is currently debated.",
      "Intracranial aneurysms are abnormal bulges in the artery walls supplying blood to the brain.",
      "Rupture of an intracranial aneurysm can cause a subarachnoid hemorrhage, which is potentially life-threatening.",
      "Some studies have suggested a higher risk of intracranial aneurysm rupture during the full moon phase.",
      "There is no consensus in the scientific community about the link between moon cycles and aneurysm rupture risks, and more research is necessary."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "You MUST give a detailed answer to the following question: Does HuR protein regulate the splicing process?",
    "llama-7b_response": "Yes, HuR (Hu antigen R) protein has been shown to regulate the splicing process.\n\nHuR is a small RNA-binding protein that plays a crucial role in the regulation of gene expression at the post-transcriptional level. It has been implicated in various biological processes, including the regulation of splicing.\n\nStudies have shown that HuR can bind to both pre-mRNA and mature mRNA, and its binding to pre-mRNA can affect the splicing process. For example, HuR has been shown to interact with splicing factors and regulate their activity, leading to changes in the splicing pattern of target genes.\n\nFurthermore, HuR has been implicated in the regulation of alternative splicing, which is a process by which multiple splicing variants can be produced from a single gene. Alternative splicing can result in the production of different proteins with distinct functions, and HuR has been shown to play a role in the regulation of alternative splicing events.\n\nOverall, these studies suggest that HuR protein can regulate the splicing process by interacting with splicing factors and altering their activity, leading to changes in the splicing pattern of target genes and the production of alternative splicing variants.",
    "llama-7b_fact_raw": "1. HuR (Hu antigen R) protein regulates the splicing process at the post-transcriptional level of gene expression.\n2. HuR protein has been shown to bind both pre-mRNA and mature mRNA, affecting the splicing process.\n3. Interaction of HuR with splicing factors has been demonstrated to regulate their activity, influencing the splicing pattern of target genes.\n4. HuR has been implicated in the regulation of alternative splicing, which allows a single gene to produce multiple splicing variants.\n5. The role of HuR in splicing can lead to the production of different proteins with distinct functions through alternative splicing events.",
    "llama-7b_fact": [
      "HuR (Hu antigen R) protein regulates the splicing process at the post-transcriptional level of gene expression.",
      "HuR protein has been shown to bind both pre-mRNA and mature mRNA, affecting the splicing process.",
      "Interaction of HuR with splicing factors has been demonstrated to regulate their activity, influencing the splicing pattern of target genes.",
      "HuR has been implicated in the regulation of alternative splicing, which allows a single gene to produce multiple splicing variants.",
      "The role of HuR in splicing can lead to the production of different proteins with distinct functions through alternative splicing events."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: HuR (Hu antigen R) protein primarily regulates the stability and translation of mature mRNA at the post-transcriptional level, not specifically the splicing process.\n2. TRUE\n3. UNKNOWN (While HuR is known to interact with various components in the cell and may influence many steps of mRNA metabolism, the specific interaction with \"splicing factors\" and how it may \"regulate their activity\" regarding splicing patterns is not clearly established without additional context.)\n4. TRUE (HuR has been implicated in the regulation of alternative splicing indirectly by stabilizing mRNAs that include or exclude certain exons.)\n5. TRUE (Through its role in the regulation of mRNA stability and translation, which can include mRNAs with different splicing variants, HuR can indeed lead to the production of different proteins with distinct functions.)",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "You MUST give a detailed answer to the following question: Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-7b_response": "Prothymosin alpha (PTMA) is a small protein that plays a crucial role in the development and function of the immune system. The c-terminal peptide of PTMA, which is located at the carboxy-terminus of the protein, has been shown to have several known functions.\n\nOne of the known functions of the c-terminal peptide of PTMA is its ability to interact with and inhibit the activity of the transcription factor NF-κB. NF-κB is a key regulator of immune and inflammatory responses, and its dysregulation has been implicated in a variety of diseases, including cancer and autoimmune disorders. By inhibiting the activity of NF-κB, the c-terminal peptide of PTMA may help to regulate immune and inflammatory responses and prevent the development of these diseases.\n\nIn addition to its role in regulating NF-κB activity, the c-terminal peptide of PTMA has also been shown to have antioxidant properties. Oxidative stress, which is caused by an imbalance between the production of reactive oxygen species and the body's ability to detoxify them, has been implicated in the development of a variety of diseases, including cancer and cardiovascular disease. By scavenging reactive oxygen species, the c-terminal peptide of PTMA may help to protect against oxidative stress and prevent the development of these diseases.\n\nFurthermore, the c-terminal peptide of PTMA has also been shown to have anti-inflammatory properties. Inflammation is a natural response to injury or infection, but chronic inflammation can lead to the development of a variety of diseases, including cancer and autoimmune disorders. By inhibiting the activity of inflammatory mediators, such as cytokines and chemokines, the c-terminal peptide of PTMA may help to regulate inflammation and prevent the development of these diseases.\n\nOverall, the c-terminal peptide of PTMA has been shown to have several known functions, including its ability to interact with and inhibit the activity of",
    "llama-7b_fact_raw": "1. The c-terminal peptide of prothymosin alpha (PTMA) can inhibit the activity of the transcription factor NF-κB.\n2. NF-κB is a regulator of immune and inflammatory responses, and its dysregulation is associated with various diseases.\n3. The c-terminal peptide of PTMA has antioxidant properties that may protect against oxidative stress.\n4. Oxidative stress has been implicated in the development of diseases such as cancer and cardiovascular disease.\n5. The c-terminal peptide of PTMA has anti-inflammatory properties and can affect cytokines and chemokines.",
    "llama-7b_fact": [
      "The c-terminal peptide of prothymosin alpha (PTMA) can inhibit the activity of the transcription factor NF-κB.",
      "NF-κB is a regulator of immune and inflammatory responses, and its dysregulation is associated with various diseases.",
      "The c-terminal peptide of PTMA has antioxidant properties that may protect against oxidative stress.",
      "Oxidative stress has been implicated in the development of diseases such as cancer and cardiovascular disease.",
      "The c-terminal peptide of PTMA has anti-inflammatory properties and can affect cytokines and chemokines."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe first and third statements require specific knowledge of the properties of the c-terminal peptide of prothymosin alpha (PTMA) that are not commonly known facts, therefore without the specific scientific literature or study results, we cannot confirm or deny these claims. Thus, the response is UNKNOWN for statements 1 and 3. Statements 2, 4, and 5 are true based on common scientific understanding of NF-κB, oxidative stress, and the general properties of anti-inflammatory agents.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "You MUST give a detailed answer to the following question: Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-7b_response": "cystatin C",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1574,
    "user_query": "You MUST give a detailed answer to the following question: Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-7b_response": "The concentration of protein hypoxia-inducible factor 1α (HIF-1α) is not directly affected by the administration of the cytoprotective prodrug amifostine (ethyol). HIF-1α is a protein that plays a key role in the response to low oxygen levels (hypoxia) in cells. It is involved in the upregulation of genes that help cells adapt to low oxygen conditions, such as the production of erythropoietin (EPO), which stimulates the production of red blood cells.\n\nAmifostine (ethyol) is a cytoprotective agent that is used to protect cells against the toxic effects of chemotherapy and radiation therapy. It is a prodrug, which means that it is not active until it is metabolized in the body. Amifostine (ethyol) is metabolized by the liver into two active metabolites, diethylystilbestrol (DES) and diethylstilbestrol (DES), which are responsible for its cytoprotective effects.\n\nWhile amifostine (ethyol) has been shown to protect cells against the toxic effects of chemotherapy and radiation therapy, it does not directly affect the concentration of HIF-1α. The mechanism by which amifostine (ethyol) exerts its cytoprotective effects is not fully understood, but it is thought to involve the protection of cells against oxidative stress and the inhibition of apoptosis (programmed cell death).\n\nIn summary, while amifostine (ethyol) is a cytoprotective agent that has been shown to protect cells against the toxic effects of chemotherapy and radiation therapy, it does not directly affect the concentration of HIF-1α.",
    "llama-7b_fact_raw": "1. Amifostine (ethyol) is a cytoprotective prodrug used to protect cells against the toxic effects of chemotherapy and radiation therapy.\n2. The protein hypoxia-inducible factor 1α (HIF-1α) is not directly affected by the administration of amifostine (ethyol).\n3. HIF-1α is involved in the upregulation of genes that help cells adapt to low oxygen conditions.\n4. Amifostine (ethyol) is metabolized by the liver into two active metabolites, diethylystilbestrol (DES) and diethylstilbestrol (DES).\n5. The cytoprotective effects of amifostine (ethyol) are thought to involve protection against oxidative stress and the inhibition of apoptosis.",
    "llama-7b_fact": [
      "Amifostine (ethyol) is a cytoprotective prodrug used to protect cells against the toxic effects of chemotherapy and radiation therapy.",
      "The protein hypoxia-inducible factor 1α (HIF-1α) is not directly affected by the administration of amifostine (ethyol).",
      "HIF-1α is involved in the upregulation of genes that help cells adapt to low oxygen conditions.",
      "Amifostine (ethyol) is metabolized by the liver into two active metabolites, diethylystilbestrol (DES) and diethylstilbestrol (DES).",
      "The cytoprotective effects of amifostine (ethyol) are thought to involve protection against oxidative stress and the inhibition of apoptosis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN (The specific interaction between HIF-1α and amifostine is not well-documented in the general knowledge, thus the effect on HIF-1α cannot be determined without further context.)\n3. TRUE (HIF-1α is indeed known to upregulate genes that enable cells to survive in hypoxic conditions.)\n4. FALSE [correction]: Amifostine (ethyol) is metabolized by alkaline phosphatase enzyme primarily in tissues into its active metabolite, WR-1065, not diethylystilbestrol (DES) and diethylstilbestrol (DES), which are unrelated compounds.\n5. TRUE (The cytoprotective effects of amifostine are known to involve scavenging free radicals that cause oxidative stress and possibly inhibiting apoptosis.)",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "You MUST give a detailed answer to the following question: Which histone marks are deposited by Set7?",
    "llama-7b_response": "Set7 is a histone methyltransferase that adds a methyl group to histone H3 at lysine 79 (H3K79me1) and histone H3 at lysine 56 (H3K56me1) [1]. These histone marks are associated with transcriptionally active regions of the genome, such as promoters and enhancers, and play a role in the regulation of gene expression [2].\n\nSet7 is a member of the SUV39H family of histone methyltransferases, which also includes SUV39H1, SUV39H2, and SUV39H3. These enzymes differ in their substrate specificity and tissue expression patterns [3]. SUV39H1 and SUV39H2 primarily methylate histone H3 at lysine 9 (H3K9me1) and histone H3 at lysine 27 (H3K27me1), respectively, while SUV39H3 methylates histone H3 at lysine 79 (H3K79me1) and histone H3 at lysine 56 (H3K56me1) [4].\n\nSet7 has been shown to play a role in the regulation of gene expression during development and in response to environmental cues [5]. For example, Set7 has been shown to be involved in the regulation of the circadian clock in Arabidopsis thaliana, where it methylates histone H3 at lysine 79 (H3K79me1) and histone H3 at lysine 56 (H3K56me1) at the promoters of clock-controlled genes [6].\n\nIn summary, Set7 adds the histone marks H3K79me1 and H3K56me1 to histone H3, which are associated with transcriptionally active regions of the genome and play a role in the regulation of gene expression. Set7 is a member of the SUV39H family of histone methyltransferases and is involved in the regulation of gene expression during development and in response to environmental cues.",
    "llama-7b_fact_raw": "1. Set7 is a histone methyltransferase that adds a methyl group to histone H3 at lysine 79 (H3K79me1).\n2. Set7 also adds a methyl group to histone H3 at lysine 56 (H3K56me1).\n3. The histone marks H3K79me1 and H3K56me1 deposited by Set7 are associated with transcriptionally active regions of the genome.\n4. Set7 is a member of the SUV39H family of histone methyltransferases.\n5. Set7 is involved in the regulation of the circadian clock in Arabidopsis thaliana by methylating histone H3 at lysine 79 (H3K79me1) and lysine 56 (H3K56me1) at the promoters of clock-controlled genes.",
    "llama-7b_fact": [
      "Set7 is a histone methyltransferase that adds a methyl group to histone H3 at lysine 79 (H3K79me1).",
      "Set7 also adds a methyl group to histone H3 at lysine 56 (H3K56me1).",
      "The histone marks H3K79me1 and H3K56me1 deposited by Set7 are associated with transcriptionally active regions of the genome.",
      "Set7 is a member of the SUV39H family of histone methyltransferases.",
      "Set7 is involved in the regulation of the circadian clock in Arabidopsis thaliana by methylating histone H3 at lysine 79 (H3K79me1) and lysine 56 (H3K56me1) at the promoters of clock-controlled genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Set7, also known as Set7/9, is a histone methyltransferase that adds a methyl group to histone H3 at lysine 4 (H3K4me1) rather than lysine 79.\n2. UNKNOWN: Without additional specific scientific context or evidence, the methylation of histone H3 at lysine 56 (H3K56me1) by Set7 cannot be confirmed or denied.\n3. TRUE: Generally, methylation marks such as H3K4me1 are associated with transcriptionally active regions of the genome, though this statement addresses methylation by Set7 specifically and may not be accurate regarding H3K79me1 and H3K56me1 without more context.\n4. FALSE [correction]: Set7/9 does not belong to the SUV39H family of histone methyltransferases, but rather is often categorized within the SET domain-containing methyltransferase family.\n5. UNKNOWN: The specific role of Set7 in the regulation of the circadian clock in Arabidopsis thaliana by methylating H3 at lysine 79 and lysine 56 at the promoters of clock-controlled genes would require verification from a reliable scientific source stating such findings.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1620,
    "user_query": "You MUST give a detailed answer to the following question: How many disulfide bridges has the protein hepcidin got?",
    "llama-7b_response": "Hepcidin is a protein that plays a crucial role in regulating iron metabolism in the body. It is produced primarily by hepatocytes in the liver and acts as a negative regulator of iron absorption from the gut. Hepcidin binds to and inhibits the activity of divalent metal transporter 1 (DMT1), a protein that facilitates the uptake of iron from the gut into enterocytes.\n\nThe structure of hepcidin is characterized by a conserved cysteine-rich N-terminal domain and a less conserved C-terminal domain. The N-terminal domain contains four cysteine residues that form three disulfide bridges, while the C-terminal domain contains two cysteine residues that also form disulfide bonds. These disulfide bonds help to stabilize the structure of the protein and prevent its degradation by proteases.\n\nTherefore, hepcidin has a total of six cysteine residues, three of which form three disulfide bridges in the N-terminal domain and two of which form two disulfide bonds in the C-terminal domain.",
    "llama-7b_fact_raw": "1. Hepcidin plays a crucial role in regulating iron metabolism in the body.\n2. Hepcidin is produced primarily by hepatocytes in the liver.\n3. Hepcidin binds to and inhibits the activity of divalent metal transporter 1 (DMT1).\n4. The N-terminal domain of hepcidin contains four cysteine residues that form three disulfide bridges.\n5. The C-terminal domain of hepcidin contains two cysteine residues that form disulfide bonds, resulting in the protein having a total of five disulfide bridges.",
    "llama-7b_fact": [
      "Hepcidin plays a crucial role in regulating iron metabolism in the body.",
      "Hepcidin is produced primarily by hepatocytes in the liver.",
      "Hepcidin binds to and inhibits the activity of divalent metal transporter 1 (DMT1).",
      "The N-terminal domain of hepcidin contains four cysteine residues that form three disulfide bridges.",
      "The C-terminal domain of hepcidin contains two cysteine residues that form disulfide bonds, resulting in the protein having a total of five disulfide bridges."
    ],
    "llama-7b_judge_raw": "1. TRUE: Hepcidin is known to play a crucial role in the regulation of iron metabolism in the body, including iron absorption and release.\n2. TRUE: Hepcidin is primarily produced by hepatocytes in the liver.\n3. FALSE [correction]: Hepcidin does not bind to DMT1. It binds to ferroportin, a different iron transporter, and leads to its internalization and degradation. This prevents the release of iron into the bloodstream.\n4. TRUE: The N-terminal domain of hepcidin indeed contains four cysteine residues, and these form disulfide bonds crucial for its structure and function.\n5. FALSE [correction]: The C-terminal domain of hepcidin does not have two cysteine residues that form additional disulfide bonds. Hepcidin has a total of four cysteine residues at the N-terminal domain which form two disulfide bridges, not five.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "You MUST give a detailed answer to the following question: What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-7b_response": "The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum (ER) in mammalian cells. The ER is a membrane-bound organelle that is involved in a variety of cellular processes, including protein folding, modification, and transport. The localization of DNAJC11 to the ER suggests that it may play a role in the proper folding and processing of proteins within this organelle.",
    "llama-7b_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum in mammalian cells.\n2. The endoplasmic reticulum is involved in protein folding, modification, and transport.\n3. The localization of DNAJC11 to the endoplasmic reticulum suggests a role in protein folding and processing within this organelle.",
    "llama-7b_fact": [
      "The protein encoded by the gene DNAJC11 is localized to the endoplasmic reticulum in mammalian cells.",
      "The endoplasmic reticulum is involved in protein folding, modification, and transport.",
      "The localization of DNAJC11 to the endoplasmic reticulum suggests a role in protein folding and processing within this organelle."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "You MUST give a detailed answer to the following question: Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-7b_response": "Ultraconserved elements (UCEs) are non-coding regions of the genome that are highly conserved across different species, including humans and other primates. These regions are thought to be important for the regulation of gene expression and may play a role in the development and function of the brain.\n\nCopy number variants (CNVs) are variations in the number of copies of a particular region of the genome. CNVs can arise through a variety of mechanisms, including duplication or deletion of large stretches of DNA.\n\nIt is possible that UCEs may be depleted among CNVs, meaning that CNVs are more likely to occur in regions of the genome that are not UCEs. This is because UCEs are highly conserved and may be more difficult to duplicate or delete, making them less likely to be involved in the formation of CNVs.\n\nHowever, it is also possible that UCEs may be overrepresented among CNVs, meaning that CNVs are more likely to occur in regions of the genome that contain UCEs. This is because UCEs may be important for the regulation of gene expression and may play a role in the development and function of the brain, making them more likely to be involved in the formation of CNVs.\n\nOverall, the relationship between UCEs and CNVs is complex and likely depends on a variety of factors, including the specific mechanism by which the CNV arises and the role of UCEs in the regulation of gene expression. Further research is needed to fully understand this relationship.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1665,
    "user_query": "You MUST give a detailed answer to the following question: Which is the substrate of the haspin kinase during mitosis?",
    "llama-7b_response": "tubulin",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1696,
    "user_query": "You MUST give a detailed answer to the following question: What is the mechanism of viroid replication?",
    "llama-7b_response": "A viroid is a small, non-coding RNA molecule that can infect plants and cause disease. The mechanism of viroid replication is unique and different from that of other viruses.\n\nViroids do not have the ability to replicate using the host's cellular machinery, such as ribosomes or DNA polymerase. Instead, they rely on the host's RNA-dependent RNA polymerase (RdRp) to synthesize new copies of the viroid. The RdRp is recruited to the viroid genome and uses the viroid RNA as a template to synthesize complementary RNA strands. This process is known as transcription.\n\nOnce the new RNA strands are synthesized, they are released from the host cell and can infect other cells. The newly synthesized RNA strands can also serve as templates for the RdRp to synthesize more copies of the viroid RNA. This process of transcription and replication can continue indefinitely, making viroids self-replicating.\n\nIn summary, the mechanism of viroid replication involves the recruitment of the host's RNA-dependent RNA polymerase (RdRp) to the viroid genome, which uses the viroid RNA as a template to synthesize complementary RNA strands. These newly synthesized RNA strands can serve as templates for the RdRp to synthesize more copies of the viroid RNA, leading to self-replication.",
    "llama-7b_fact_raw": "1. Viroids are small, non-coding RNA molecules capable of infecting plants and causing disease.\n2. Viroids rely on the host's RNA-dependent RNA polymerase (RdRp) for replication.\n3. Viroids do not utilize the host's cellular machinery such as ribosomes or DNA polymerase for replication.\n4. RdRp is recruited to the viroid genome to synthesize complementary RNA strands using viroid RNA as a template.\n5. The RNA strands synthesized by RdRp can also serve as templates for synthesizing more copies of the viroid RNA, allowing for self-replication.",
    "llama-7b_fact": [
      "Viroids are small, non-coding RNA molecules capable of infecting plants and causing disease.",
      "Viroids rely on the host's RNA-dependent RNA polymerase (RdRp) for replication.",
      "Viroids do not utilize the host's cellular machinery such as ribosomes or DNA polymerase for replication.",
      "RdRp is recruited to the viroid genome to synthesize complementary RNA strands using viroid RNA as a template.",
      "The RNA strands synthesized by RdRp can also serve as templates for synthesizing more copies of the viroid RNA, allowing for self-replication."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "You MUST give a detailed answer to the following question: Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-7b_response": "Fibronectin is a protein that plays a role in cell-to-cell and cell-to-matrix adhesion and is found in the extracellular matrix. It has been suggested that fibronectin may be a potential serum biomarker for Duchenne muscular dystrophy (DMD).\n\nDMD is a genetic disorder that affects the muscles and is characterized by progressive muscle degeneration and weakness. The disease is caused by a mutation in the dystrophin gene, which results in the absence of the protein dystrophin. Dystrophin is important for maintaining the structural integrity of muscle fibers and is involved in muscle contraction.\n\nFibronectin has been found to be elevated in the serum of patients with DMD. In one study, researchers measured the levels of fibronectin in the serum of patients with DMD and healthy controls and found that the levels of fibronectin were significantly higher in the patients with DMD. The researchers also found that the levels of fibronectin were positively correlated with the severity of the disease.\n\nAnother study found that fibronectin was elevated in the serum of patients with DMD and that the levels of fibronectin were positively correlated with the levels of creatine kinase, a marker of muscle damage.\n\nThese findings suggest that fibronectin may be a potential serum biomarker for DMD. However, further studies are needed to confirm this finding and to determine the specific role of fibronectin in the pathophysiology of DMD.",
    "llama-7b_fact_raw": "1. Fibronectin is a protein involved in cell-to-cell and cell-to-matrix adhesion and is part of the extracellular matrix.\n2. Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness.\n3. DMD is caused by a mutation in the dystrophin gene, leading to the absence of the dystrophin protein.\n4. In a study, fibronectin levels were found to be significantly higher in the serum of patients with DMD compared to healthy controls.\n5. Elevated levels of fibronectin in the serum of DMD patients were positively correlated with the levels of creatine kinase, a marker of muscle damage.",
    "llama-7b_fact": [
      "Fibronectin is a protein involved in cell-to-cell and cell-to-matrix adhesion and is part of the extracellular matrix.",
      "Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness.",
      "DMD is caused by a mutation in the dystrophin gene, leading to the absence of the dystrophin protein.",
      "In a study, fibronectin levels were found to be significantly higher in the serum of patients with DMD compared to healthy controls.",
      "Elevated levels of fibronectin in the serum of DMD patients were positively correlated with the levels of creatine kinase, a marker of muscle damage."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements correspond to well-established scientific facts about fibronectin, Duchenne muscular dystrophy, and the cause of DMD. However, the fourth and fifth statements refer to specific findings from a study that are not general knowledge, and without access to the study or additional information, the truthfulness of these statements cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "You MUST give a detailed answer to the following question: Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-7b_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n\n1. The Encyclopedia of DNA Elements (ENCODE) project, which aims to identify and characterize all functional elements in the human genome.\n2. The Roadmap Epigenomics Project, which aims to create a comprehensive catalog of human epigenetic marks and identify their roles in health and disease.\n3. The FANTOM5 project, which aims to identify and characterize functional elements in the mouse genome, including enhancers, promoters, and other regulatory elements.\n4. The Epigenomic Roadmap Project, which aims to create a comprehensive catalog of human epigenetic marks and identify their roles in health and disease.\n5. The 1000 Genomes Project, which aims to create a comprehensive catalog of human genetic variation and provide a resource for studying human genetics and disease.\n\nThese projects have generated a large amount of data on epigenetic marks, such as DNA methylation and histone modifications, across a variety of tissues and cell types. The DeepBlue epigenomic data server provides access to this data, as well as tools for analyzing and interpreting the data.",
    "llama-7b_fact_raw": "1. The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) project.\n2. Data from the Roadmap Epigenomics Project are included in the DeepBlue epigenomic data server.\n3. The DeepBlue epigenomic data server features data from the FANTOM5 project.\n4. The DeepBlue epigenomic data server includes data from the Epigenomic Roadmap Project.\n5. The 1000 Genomes Project is one of the major epigenome projects whose data is contained in the DeepBlue epigenomic data server.",
    "llama-7b_fact": [
      "The DeepBlue epigenomic data server contains data from the Encyclopedia of DNA Elements (ENCODE) project.",
      "Data from the Roadmap Epigenomics Project are included in the DeepBlue epigenomic data server.",
      "The DeepBlue epigenomic data server features data from the FANTOM5 project.",
      "The DeepBlue epigenomic data server includes data from the Epigenomic Roadmap Project.",
      "The 1000 Genomes Project is one of the major epigenome projects whose data is contained in the DeepBlue epigenomic data server."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The DeepBlue epigenomic data server does not feature data from the FANTOM5 project.\n4. TRUE\n5. FALSE [correction]: The 1000 Genomes Project is a genomic dataset, not an epigenomic project, and it is not one of the major epigenome projects whose data is specifically mentioned as part of the DeepBlue epigenomic data server.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1792,
    "user_query": "You MUST give a detailed answer to the following question: Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-7b_response": "PHYLIP",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1793,
    "user_query": "You MUST give a detailed answer to the following question: What is MINDY-1?",
    "llama-7b_response": "I'm sorry, but I don't have enough information to answer your question about MINDY-1. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1810,
    "user_query": "You MUST give a detailed answer to the following question: Which software package is available for the analysis of conserved genomic loci?",
    "llama-7b_response": "BLAST",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1860,
    "user_query": "You MUST give a detailed answer to the following question: Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-7b_response": "PIEZO2 is a gene that encodes for a protein called Piezo2, which is a member of the Piezo family of ion channels. These channels are responsible for sensing mechanical stimuli, such as pressure, and transducing them into electrical signals that can be transmitted to the nervous system. Mutations in the PIEZO2 gene have been associated with a number of diseases, including:\n\n1. Hereditary hemorrhagic telangiectasia (HHT): HHT is a genetic disorder that affects the blood vessels, causing them to become abnormally fragile and prone to bleeding. HHT is caused by mutations in multiple genes, including PIEZO2.\n2. Ehlers-Danlos syndrome (EDS): EDS is a group of genetic disorders that affect the connective tissues in the body, including the skin, joints, and blood vessels. Mutations in the PIEZO2 gene have been associated with a subtype of EDS called EDS type IV, which is characterized by abnormal blood vessel function.\n3. Autosomal dominant nocturnal hemoglobinuria (AD-NHB): AD-NHB is a rare genetic disorder that affects the body's ability to produce red blood cells. Mutations in the PIEZO2 gene have been associated with AD-NHB, which is characterized by low levels of hemoglobin in the blood and an increased risk of bleeding.",
    "llama-7b_fact_raw": "1. Mutations in the PIEZO2 gene have been associated with Hereditary hemorrhagic telangiectasia (HHT).\n2. A subtype of Ehlers-Danlos syndrome (EDS), specifically EDS type IV, has been associated with mutations in the PIEZO2 gene.\n3. Autosomal dominant nocturnal hemoglobinuria (AD-NHB) is a rare genetic disorder associated with mutations in the PIEZO2 gene.\n\nNote: There is a potential inaccuracy in the provided answer. As of the knowledge cutoff date in 2023, there is no well-established connection between PIEZO2 and the listed diseases, HHT, EDS type IV, and AD-NHB. The PIEZO2 gene is primarily related to mechanosensation and proprioception, with known associations to diseases such as Distal Arthrogryposis Type 5 (DA5) and Gordon Syndrome. Therefore, these statements should be treated as claims requiring further verification.",
    "llama-7b_fact": [
      "Mutations in the PIEZO2 gene have been associated with Hereditary hemorrhagic telangiectasia (HHT).",
      "A subtype of Ehlers-Danlos syndrome (EDS), specifically EDS type IV, has been associated with mutations in the PIEZO2 gene.",
      "Autosomal dominant nocturnal hemoglobinuria (AD-NHB) is a rare genetic disorder associated with mutations in the PIEZO2 gene.",
      "te: There is a potential inaccuracy in the provided answer. As of the knowledge cutoff date in 2023, there is no well-established connection between PIEZO2 and the listed diseases, HHT, EDS type IV, and AD-NHB. The PIEZO2 gene is primarily related to mechanosensation and proprioception, with known associations to diseases such as Distal Arthrogryposis Type 5 (DA5) and Gordon Syndrome. Therefore, these statements should be treated as claims requiring further verification."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the PIEZO2 gene have not been associated with Hereditary hemorrhagic telangiectasia (HHT). HHT is usually associated with mutations in genes such as ENG, ACVRL1, and SMAD4.\n2. FALSE [correction]: A subtype of Ehlers-Danlos syndrome (EDS), specifically EDS type IV, is associated with mutations in the COL3A1 gene, not the PIEZO2 gene.\n3. FALSE [correction]: Autosomal dominant nocturnal hemoglobinuria (AD-NHB) is a term that appears incorrect. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare genetic disorder, and it is associated with mutations in the PIGA gene, not PIEZO2.\n4. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "You MUST give a detailed answer to the following question: What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-7b_response": "ERAP1 and ERAP2 are two members of the ER-associated degradation (ERAD) pathway, which is responsible for the elimination of misfolded or damaged proteins from the endoplasmic reticulum (ER) in eukaryotic cells. The ERAD pathway involves the formation of a complex between ER-resident proteins, such as ERAP1 and ERAP2, and the misfolded protein, which is then transported to the ER lumen and degraded by the proteasome.\n\nERAP1 and ERAP2 dimerization plays a crucial role in the promotion of ERAD. The dimerization of ERAP1 and ERAP2 is required for the formation of a stable complex with the misfolded protein, which is necessary for its transport to the ER lumen and subsequent degradation by the proteasome. The dimerization of ERAP1 and ERAP2 also enhances their ability to recognize and bind to misfolded proteins, allowing for a more efficient clearance of damaged or misfolded proteins from the ER.\n\nIn summary, ERAP1-ERAP2 dimerization is an important step in the ERAD pathway, which promotes the elimination of misfolded or damaged proteins from the ER and contributes to the maintenance of protein homeostasis in eukaryotic cells.",
    "llama-7b_fact_raw": "1. ERAP1 and ERAP2 are two members of the ER-associated degradation (ERAD) pathway in eukaryotic cells.\n2. The ERAD pathway is responsible for eliminating misfolded or damaged proteins from the endoplasmic reticulum (ER).\n3. ERAP1 and ERAP2 dimerization is necessary for the formation of a stable complex with misfolded proteins for their subsequent transport to the ER lumen.\n4. Dimerization of ERAP1 and ERAP2 enhances their ability to recognize and bind to misfolded proteins.\n5. ERAP1-ERAP2 dimerization promotes the efficient clearance of damaged or misfolded proteins from the ER.",
    "llama-7b_fact": [
      "ERAP1 and ERAP2 are two members of the ER-associated degradation (ERAD) pathway in eukaryotic cells.",
      "The ERAD pathway is responsible for eliminating misfolded or damaged proteins from the endoplasmic reticulum (ER).",
      "ERAP1 and ERAP2 dimerization is necessary for the formation of a stable complex with misfolded proteins for their subsequent transport to the ER lumen.",
      "Dimerization of ERAP1 and ERAP2 enhances their ability to recognize and bind to misfolded proteins.",
      "ERAP1-ERAP2 dimerization promotes the efficient clearance of damaged or misfolded proteins from the ER."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ERAP1 and ERAP2 are two members of the Aminopeptidase family that trim peptides for presentation by MHC class I molecules; they are not components of the ER-associated degradation (ERAD) pathway.\n2. TRUE\n3. FALSE [correction]: ERAP1 and ERAP2 do not dimerize for the transport of misfolded proteins to the ER lumen; instead, they are involved in trimming peptides for MHC class I-mediated antigen presentation. The statement incorrectly describes their role and the process associated with the ERAD pathway.\n4. UNKNOWN: While ERAP1 and ERAP2 are known to have functions related to trimming peptides, the specific statement about dimerization enhancing their ability to recognize and bind to misfolded proteins is not a recognized characteristic of these enzymes within their primary function of antigen processing.\n5. FALSE [correction]: The statement confuses the role of ERAP1 and ERAP2 with the function of ERAD. ERAP1 and ERAP2 are not involved in the clearance of damaged or misfolded proteins from the ER; they trim peptides for MHC class I presentation. The ERAD pathway is responsible for the degradation of misfolded or damaged proteins.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1890,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-7b_response": "R-spondin 1 and noggin are both inhibitors of bone morphogenetic protein (BMP) signaling. BMPs are a family of signaling molecules that play a crucial role in the development and maintenance of various tissues, including the gallbladder.\n\nIn non-damaged gallbladders, R-spondin 1 and noggin help to maintain the normal function of the gallbladder by inhibiting the activity of BMPs. Specifically, R-spondin 1 and noggin bind to and inhibit the activity of BMP receptors on the surface of gallbladder cells, preventing the cells from responding to BMP signals.\n\nWithout the inhibitory effect of R-spondin 1 and noggin, the activity of BMPs would be increased in the gallbladder, leading to the formation of excessive connective tissue and the development of gallstones. Therefore, the normal function of R-spondin 1 and noggin in non-damaged gallbladders is to maintain the delicate balance of BMP signaling and prevent the formation of gallstones.",
    "llama-7b_fact_raw": "1. R-spondin 1 and noggin are inhibitors of bone morphogenetic protein (BMP) signaling.\n2. Bone morphogenetic proteins play a role in the development and maintenance of various tissues, including the gallbladder.\n3. In non-damaged gallbladders, R-spondin 1 and noggin help maintain normal gallbladder function by inhibiting the activity of BMPs.\n4. R-spondin 1 and noggin bind to and inhibit the activity of BMP receptors on gallbladder cells.\n5. The inhibition of BMP signaling by R-spondin 1 and noggin is essential to prevent the formation of excessive connective tissue and gallstones in the gallbladder.",
    "llama-7b_fact": [
      "R-spondin 1 and noggin are inhibitors of bone morphogenetic protein (BMP) signaling.",
      "Bone morphogenetic proteins play a role in the development and maintenance of various tissues, including the gallbladder.",
      "In non-damaged gallbladders, R-spondin 1 and noggin help maintain normal gallbladder function by inhibiting the activity of BMPs.",
      "R-spondin 1 and noggin bind to and inhibit the activity of BMP receptors on gallbladder cells.",
      "The inhibition of BMP signaling by R-spondin 1 and noggin is essential to prevent the formation of excessive connective tissue and gallstones in the gallbladder."
    ],
    "llama-7b_judge_raw": "1. TRUE: R-spondin 1 is known to enhance Wnt signaling, which can have an impact on BMP signaling, noggin is a well-established antagonist of BMP signaling.\n2. TRUE: Bone morphogenetic proteins (BMPs) are involved in the formation of bone and cartilage, as well as the development and maintenance of various other tissues, although their specific role in gallbladder development is not widely established and thus could be ambiguous.\n3. UNKNOWN: The specific role of R-spondin 1 in gallbladder function is not widely known, and while noggin does inhibit BMPs, its role in normal gallbladder maintenance is not clear without specific biological context or research evidence.\n4. FALSE [correction]: R-spondin 1 does not directly bind to BMP receptors; it influences Wnt signaling pathways. Noggin binds to BMPs themselves, not directly to the BMP receptors.\n5. UNKNOWN: Without specific research evidence, it is unclear whether the inhibition of BMP signaling by R-spondin 1 and noggin is essential for preventing the formation of excessive connective tissue and gallstones in the gallbladder; this statement requires specific biological context.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "You MUST give a detailed answer to the following question: Does NADPH oxidase 5 require any subunit for function?",
    "llama-7b_response": "Yes, NADPH oxidase 5 (NOX5) requires all four subunits (gp91phox, p22phox, p40phox, and p44phox) for its enzymatic activity.\n\nNOX5 is a member of the NADPH oxidase family of enzymes, which generate reactive oxygen species (ROS) as a byproduct of the oxidation of NADPH. The enzymatic activity of NADPH oxidase is regulated by the association of its subunits, and NOX5 is no exception.\n\nThe four subunits of NOX5 (gp91phox, p22phox, p40phox, and p44phox) are required for the enzymatic activity of NOX5. The gp91phox subunit is the catalytic subunit of NOX5 and is responsible for the oxidation of NADPH. The p22phox, p40phox, and p44phox subunits are non-catalytic subunits that interact with the gp91phox subunit to form the active enzyme complex.\n\nThe absence of any one of these subunits results in a loss of enzymatic activity, indicating that NOX5 requires all four subunits for its function.\n\nIn summary, NOX5 requires all four subunits (gp91phox, p22phox, p40phox, and p44phox) for its enzymatic activity, and the absence of any one of these subunits results in a loss of enzymatic activity.",
    "llama-7b_fact_raw": "1. NADPH oxidase 5 (NOX5) requires the subunits gp91phox, p22phox, p40phox, and p44phox for its enzymatic activity.\n2. The gp91phox subunit is the catalytic subunit responsible for the oxidation of NADPH in the NOX5 complex.\n3. The p22phox, p40phox, and p44phox subunits are non-catalytic and interact with gp91phox to form the active enzyme complex.\n4. The absence of any one of the subunits (gp91phox, p22phox, p40phox, or p44phox) results in a loss of enzymatic activity for NOX5.\n5. NOX5 is a member of the NADPH oxidase family that generates reactive oxygen species (ROS) as a byproduct.",
    "llama-7b_fact": [
      "NADPH oxidase 5 (NOX5) requires the subunits gp91phox, p22phox, p40phox, and p44phox for its enzymatic activity.",
      "The gp91phox subunit is the catalytic subunit responsible for the oxidation of NADPH in the NOX5 complex.",
      "The p22phox, p40phox, and p44phox subunits are non-catalytic and interact with gp91phox to form the active enzyme complex.",
      "The absence of any one of the subunits (gp91phox, p22phox, p40phox, or p44phox) results in a loss of enzymatic activity for NOX5.",
      "NOX5 is a member of the NADPH oxidase family that generates reactive oxygen species (ROS) as a byproduct."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) does not require the subunits gp91phox, p22phox, p40phox, and p44phox for its enzymatic activity. NOX5 is independent of these subunits and contains its own Ca2+-binding domain that regulates its activity.\n2. FALSE [correction]: The gp91phox (also known as NOX2) is the catalytic subunit of another NADPH oxidase complex, specifically NOX2, not NOX5.\n3. FALSE [correction]: The subunits p22phox, p40phox, and p44phox are indeed non-catalytic, but they are associated with NOX2, not NOX5.\n4. FALSE [correction]: This statement is incorrect as it applies to the NOX2 complex, not NOX5. NOX5 does not require these subunits for its activity and the absence of them would not affect NOX5 enzymatic activity.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1944,
    "user_query": "You MUST give a detailed answer to the following question: What is the connection between furin and hepcidin?",
    "llama-7b_response": "Furin and hepcidin are both proteins that play important roles in regulating iron metabolism in the body.\n\nFurin is an enzyme that is involved in the processing and activation of various proteins, including hepcidin. Specifically, furin cleaves the N-terminal peptide of hepcidin, releasing the mature, biologically active form of the protein.\n\nHepcidin is a small, peptide hormone that is produced primarily by hepatocytes in the liver. It is the primary regulator of iron absorption and homeostasis in the body. Hepcidin acts by binding to and inhibiting the absorption of iron by enterocytes in the small intestine.\n\nThe connection between furin and hepcidin is that furin plays a critical role in the processing and activation of hepcidin. Specifically, furin cleaves the N-terminal peptide of hepcidin, releasing the mature, biologically active form of the protein. This allows hepcidin to bind to and inhibit the absorption of iron by enterocytes in the small intestine, thereby regulating iron metabolism in the body.\n\nTherefore, the connection between furin and hepcidin is that they both play important roles in regulating iron metabolism in the body, with furin playing a critical role in the processing and activation of hepcidin.",
    "llama-7b_fact_raw": "1. Furin is an enzyme involved in the activation of various proteins, including hepcidin.\n2. Furin cleaves the N-terminal peptide of hepcidin to release its mature, biologically active form.\n3. Hepcidin is a peptide hormone primarily produced by hepatocytes in the liver.\n4. Hepcidin is the primary regulator of iron absorption and homeostasis in the body.\n5. Hepcidin regulates iron metabolism by binding to and inhibiting iron absorption by enterocytes in the small intestine.",
    "llama-7b_fact": [
      "Furin is an enzyme involved in the activation of various proteins, including hepcidin.",
      "Furin cleaves the N-terminal peptide of hepcidin to release its mature, biologically active form.",
      "Hepcidin is a peptide hormone primarily produced by hepatocytes in the liver.",
      "Hepcidin is the primary regulator of iron absorption and homeostasis in the body.",
      "Hepcidin regulates iron metabolism by binding to and inhibiting iron absorption by enterocytes in the small intestine."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Furin cleaves precursor proteins at specific sites to activate them, but in the case of hepcidin, it is not involved in cleaving hepcidin to its active form. This is carried out by other proteases.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "You MUST give a detailed answer to the following question: Which is the largest metabolic gene cluster in yeast?",
    "llama-7b_response": "glycolysi",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1967,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of LIMT lncRNA?",
    "llama-7b_response": "The role of LIMT lncRNA (long non-coding RNA) has not yet been fully elucidated, but it is known to be involved in the regulation of gene expression. LIMT lncRNA has been found to be expressed in a variety of tissues and cell types, including the brain, heart, and pancreas.\n\nSeveral studies have suggested that LIMT lncRNA may play a role in the regulation of cell proliferation, differentiation, and apoptosis. For example, one study found that overexpression of LIMT lncRNA in cancer cells led to increased cell proliferation and decreased apoptosis, while another study found that knockdown of LIMT lncRNA in cancer cells led to decreased cell proliferation and increased apoptosis.\n\nAdditionally, LIMT lncRNA has been found to be involved in the regulation of the Wnt/β-catenin signaling pathway, which is a key regulator of cell proliferation and differentiation in many tissues. One study found that LIMT lncRNA interacts with the Wnt/β-catenin signaling pathway and regulates its activity, while another study found that knockdown of LIMT lncRNA in cancer cells leads to decreased Wnt/β-catenin signaling and decreased cell proliferation.\n\nOverall, these studies suggest that LIMT lncRNA may play a role in the regulation of cell proliferation, differentiation, and apoptosis, and may be involved in the regulation of the Wnt/β-catenin signaling pathway. However, further research is needed to fully understand the role of LIMT lncRNA in these processes.",
    "llama-7b_fact_raw": "1. LIMT lncRNA is involved in the regulation of gene expression.\n2. LIMT lncRNA is expressed in various tissues and cell types, including the brain, heart, and pancreas.\n3. Overexpression of LIMT lncRNA in cancer cells can lead to increased cell proliferation and decreased apoptosis.\n4. Knockdown of LIMT lncRNA in cancer cells can lead to decreased cell proliferation and increased apoptosis.\n5. LIMT lncRNA is involved in the regulation of the Wnt/β-catenin signaling pathway, which is important for cell proliferation and differentiation.",
    "llama-7b_fact": [
      "LIMT lncRNA is involved in the regulation of gene expression.",
      "LIMT lncRNA is expressed in various tissues and cell types, including the brain, heart, and pancreas.",
      "Overexpression of LIMT lncRNA in cancer cells can lead to increased cell proliferation and decreased apoptosis.",
      "Knockdown of LIMT lncRNA in cancer cells can lead to decreased cell proliferation and increased apoptosis.",
      "LIMT lncRNA is involved in the regulation of the Wnt/β-catenin signaling pathway, which is important for cell proliferation and differentiation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: LIMT lncRNA (long non-coding RNA) is a type of non-coding RNA that can indeed be involved in the regulation of gene expression, and such molecules are known to be expressed in various tissues and cell types. However, information about the specific effects of overexpression or knockdown of LIMT lncRNA in cancer cells, as well as its involvement in the Wnt/β-catenin signaling pathway, is not common knowledge and would require specific scientific evidence to validate. Without that evidence or context, the truth of statements 3, 4, and 5 cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "You MUST give a detailed answer to the following question: Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-7b_response": "GenABEL",
    "llama-7b_fact_raw": "1. GenABEL is an R/bioconductor package used for performing SNP enrichment analysis.",
    "llama-7b_fact": [
      "GenABEL is an R/bioconductor package used for performing SNP enrichment analysis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: GenABEL is an R package used for genome-wide association (GWA) analyses.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 2015,
    "user_query": "You MUST give a detailed answer to the following question: Which are the key players on radial glial specification to ependymal cells?",
    "llama-7b_response": "Radial glial cells are a type of glial cell that play a crucial role in the development of the central nervous system (CNS). During embryonic development, radial glial cells give rise to ependymal cells, which form the ependyma, a layer of cells that lines the ventricular system of the brain and spinal cord.\n\nThere are several key players involved in the specification of radial glial cells to ependymal cells. These include:\n\n1. Sonic hedgehog (Shh) signaling: Shh is a key signaling molecule that plays a crucial role in the specification of radial glial cells to ependymal cells. Shh signaling promotes the differentiation of radial glial cells into ependymal cells by activating the expression of genes involved in ependymal cell differentiation, such as Sox2 and Olig2.\n2. Wnt signaling: Wnt signaling also plays a role in the specification of radial glial cells to ependymal cells. Wnt signaling inhibits the differentiation of radial glial cells into ependymal cells by suppressing the expression of genes involved in ependymal cell differentiation, such as Sox2 and Olig2.\n3. Notch signaling: Notch signaling also plays a role in the specification of radial glial cells to ependymal cells. Notch signaling promotes the differentiation of radial glial cells into ependymal cells by activating the expression of genes involved in ependymal cell differentiation, such as Sox2 and Olig2.\n4. TGF-β signaling: TGF-β signaling also plays a role in the specification of radial glial cells to ependymal cells. TGF-β signaling inhibits the differentiation of radial glial cells into ependymal cells by suppressing the expression of genes involved in ependymal cell differentiation, such as Sox2 and Olig2.\n\nOverall, the specification of radial glial cells to ependymal cells involves a complex interplay between multiple signaling pathways, including Shh, Wnt, Notch, and TGF-β signaling. These signaling pathways work together to promote the differentiation of radial gli",
    "llama-7b_fact_raw": "1. Radial glial cells are crucial for the development of the central nervous system (CNS).\n2. Ependymal cells form the ependyma, which is a lining of the ventricular system of the brain and spinal cord.\n3. Sonic hedgehog (Shh) signaling is a key player in the specification of radial glial cells to ependymal cells, promoting their differentiation.\n4. Wnt signaling is involved in the specification of radial glial cells to ependymal cells but inhibits their differentiation.\n5. Notch signaling promotes the differentiation of radial glial cells into ependymal cells.",
    "llama-7b_fact": [
      "Radial glial cells are crucial for the development of the central nervous system (CNS).",
      "Ependymal cells form the ependyma, which is a lining of the ventricular system of the brain and spinal cord.",
      "Sonic hedgehog (Shh) signaling is a key player in the specification of radial glial cells to ependymal cells, promoting their differentiation.",
      "Wnt signaling is involved in the specification of radial glial cells to ependymal cells but inhibits their differentiation.",
      "Notch signaling promotes the differentiation of radial glial cells into ependymal cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Wnt signaling is involved in various developmental processes, including the development of the central nervous system, but it is not typically associated with inhibiting the differentiation of radial glial cells to ependymal cells. Notch signaling is crucial in maintaining the progenitor pool of radial glial cells and is involved in their differentiation, but the statement about Wnt specifically inhibiting the differentiation process is not accurate.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "You MUST give a detailed answer to the following question: How are triple negative gliomas characterized?",
    "llama-7b_response": "Triple negative gliomas (TNGs) are a subtype of glioma, which is a type of brain tumor. TNGs are characterized by the absence of three biomarkers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These biomarkers are typically found in other types of cancer, but not in TNGs.\n\nIn addition to the absence of these biomarkers, TNGs are also characterized by their aggressive behavior and poor prognosis. They tend to grow rapidly and are often resistant to standard treatments such as radiation and chemotherapy.\n\nAnother characteristic of TNGs is that they tend to occur more frequently in younger adults, with a median age of diagnosis of 30-40 years. They also tend to occur more frequently in women than in men.\n\nTNGs are typically diagnosed through a combination of imaging tests, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, and biopsy. Once diagnosed, treatment options for TNGs typically include surgery to remove as much of the tumor as possible, followed by radiation therapy and chemotherapy.",
    "llama-7b_fact_raw": "1. Triple negative gliomas (TNGs) are characterized by the absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).\n2. TNGs are known for their aggressive behavior and poor prognosis.\n3. Triple negative gliomas often grow rapidly and are resistant to standard treatments like radiation and chemotherapy.\n4. The median age of diagnosis for triple negative gliomas is between 30 and 40 years.\n5. Triple negative gliomas occur more frequently in women than in men.",
    "llama-7b_fact": [
      "Triple negative gliomas (TNGs) are characterized by the absence of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).",
      "TNGs are known for their aggressive behavior and poor prognosis.",
      "Triple negative gliomas often grow rapidly and are resistant to standard treatments like radiation and chemotherapy.",
      "The median age of diagnosis for triple negative gliomas is between 30 and 40 years.",
      "Triple negative gliomas occur more frequently in women than in men."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The correct term is Triple-negative breast cancers (TNBCs), not gliomas. These cancers are characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and the HER2 protein.\n2. TRUE\n3. TRUE for TNBCs, but as the statement incorrectly refers to gliomas (a type of brain tumor), this is UNKNOWN as it's unclear if the statement is intended to discuss TNBCs or gliomas.\n4. UNKNOWN: This statement may be false as it seems to refer to triple-negative breast cancers, for which the median age of diagnosis is slightly higher, typically around 50-60 years old. However, without the correct context (TNBCs or gliomas), it's not possible to provide an accurate correction.\n5. UNKNOWN: While triple-negative breast cancers occur more frequently in women, the statement is about triple negative gliomas, which is not a recognized classification for gliomas, making the specific sex predilection unclear.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "You MUST give a detailed answer to the following question: What is TOPAZ1?",
    "llama-7b_response": "TOPAZ1 is a cryptographic algorithm that is used to encrypt and decrypt data. It is a stream cipher, which means that it operates on a continuous stream of data, rather than on individual blocks of data. TOPAZ1 uses a 128-bit key to encrypt and decrypt data, and it is designed to be fast and efficient. It is often used in conjunction with other cryptographic algorithms to provide additional security.",
    "llama-7b_fact_raw": "1. TOPAZ1 is a cryptographic algorithm used for encrypting and decrypting data.\n2. TOPAZ1 operates as a stream cipher.\n3. TOPAZ1 processes data in a continuous stream rather than individual blocks.\n4. TOPAZ1 utilizes a 128-bit key for encryption and decryption tasks.\n5. TOPAZ1 is designed to be fast and efficient in its operation.",
    "llama-7b_fact": [
      "TOPAZ1 is a cryptographic algorithm used for encrypting and decrypting data.",
      "TOPAZ1 operates as a stream cipher.",
      "TOPAZ1 processes data in a continuous stream rather than individual blocks.",
      "TOPAZ1 utilizes a 128-bit key for encryption and decryption tasks.",
      "TOPAZ1 is designed to be fast and efficient in its operation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without additional context, it's unclear if \"TOPAZ1\" is an actual cryptographic algorithm or a fictional or proprietary name, as it is not recognized in common cryptographic references.\n2. UNKNOWN: Due to the uncertainty regarding the existence of TOPAZ1, its operation as a stream cipher cannot be confirmed.\n3. UNKNOWN: Whether TOPAZ1 processes data in a continuous stream (like a true stream cipher) remains undeterminable given the lack of information.\n4. UNKNOWN: The specific key size used by TOPAZ1 cannot be verified without further context or references to its specifications.\n5. UNKNOWN: The assertion that TOPAZ1 is designed to be fast and efficient is subjective and without substantiated references to its actual design principles or performance benchmarks, its accuracy cannot be determined.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "You MUST give a detailed answer to the following question: Which gene controls the expression of GATA-1 isoforms?",
    "llama-7b_response": "Gata1",
    "llama-7b_fact_raw": "1. The Gata1 gene controls the expression of GATA-1 isoforms.",
    "llama-7b_fact": [
      "The Gata1 gene controls the expression of GATA-1 isoforms."
    ],
    "llama-7b_judge_raw": "1. TRUE",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "You MUST give a detailed answer to the following question: What is MIRA-seq?",
    "llama-7b_response": "MIRA-seq (Mutation Identification by High-throughput Sequencing) is a next-generation sequencing (NGS) based method for identifying somatic mutations in cancer cells. It is a targeted sequencing approach that focuses on specific regions of the genome known to harbor mutations in cancer, such as hotspots in oncogenes and tumor suppressor genes.\n\nThe MIRA-seq method involves the following steps:\n\n1. Sample preparation: The starting material for MIRA-seq is a tumor biopsy or cell line. The sample is fragmented into small pieces, and the DNA is isolated.\n2. Library preparation: The isolated DNA is fragmented into smaller pieces, and adapters are added to the ends of the fragments to allow them to be sequenced. The fragments are then enriched for specific regions of the genome, such as hotspots in oncogenes and tumor suppressor genes.\n3. Sequencing: The enriched fragments are then sequenced using NGS technology. The resulting data is analyzed to identify mutations in the targeted regions of the genome.\n4. Data analysis: The sequencing data is analyzed to identify mutations in the targeted regions of the genome. This involves mapping the sequencing reads to the reference genome, identifying mutations by comparing the reads to a reference genome, and validating the mutations by Sanger sequencing or other methods.\n\nMIRA-seq has several advantages over other methods for identifying somatic mutations, such as whole-genome sequencing (WGS) and targeted sequencing. It is faster and less expensive than WGS, and it can focus on specific regions of the genome that are known to harbor mutations in cancer. Additionally, MIRA-seq can identify mutations that are not captured by targeted sequencing, such as low-frequency mutations and mutations in non-coding regions of the genome.\n\nOverall, MIRA-seq is a powerful tool for identifying somatic mutations in cancer cells, and it has the potential to improve our understanding of cancer biology and inform the development of targeted therapies.",
    "llama-7b_fact_raw": "1. MIRA-seq is a method used for identifying somatic mutations in cancer cells using next-generation sequencing technology.\n2. The method specifically targets regions of the genome known to have mutations in cancer, such as hotspots in oncogenes and tumor suppressor genes.\n3. MIRA-seq requires initial sample preparation from a tumor biopsy or cancer cell line, isolation of DNA, and fragmentation of that DNA.\n4. During MIRA-seq, adapters are added to DNA fragments before targeted regions are enriched and then sequenced using NGS technology.\n5. MIRA-seq is designed to be faster and less expensive than whole-genome sequencing and capable of identifying mutations not detected by standard targeted sequencing.",
    "llama-7b_fact": [
      "MIRA-seq is a method used for identifying somatic mutations in cancer cells using next-generation sequencing technology.",
      "The method specifically targets regions of the genome known to have mutations in cancer, such as hotspots in oncogenes and tumor suppressor genes.",
      "MIRA-seq requires initial sample preparation from a tumor biopsy or cancer cell line, isolation of DNA, and fragmentation of that DNA.",
      "During MIRA-seq, adapters are added to DNA fragments before targeted regions are enriched and then sequenced using NGS technology.",
      "MIRA-seq is designed to be faster and less expensive than whole-genome sequencing and capable of identifying mutations not detected by standard targeted sequencing."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MIRA-seq (Methylation-based Integrated Read Analysis Sequencing) is a method used for analyzing genome-wide DNA methylation patterns, not for identifying somatic mutations in cancer cells.\n2. UNKNOWN: The accuracy of this statement depends on the context. If \"MIRA-seq\" was mistakenly mentioned and should refer to a different sequencing method that targets cancer mutations, then a correction is not possible without the right context. However, if it's about MIRA-seq, then the statement is false as MIRA-seq deals with DNA methylation.\n3. UNKNOWN: This statement provides a general overview of steps in a sequencing workflow, which could apply to many methods, including MIRA-seq, but without specific details, the exactness for MIRA-seq cannot be determined.\n4. UNKNOWN: While this statement generally describes steps in many sequencing workflows, it does not specify the unique aspects of MIRA-seq, such as the methylation analysis. The accuracy of these details for MIRA-seq cannot be ascertained without further context.\n5. UNKNOWN: This statement is generally true for targeted sequencing methods in comparison to whole-genome sequencing. However, without explicit mention of MIRA-seq being designed for such purposes, and considering MIRA-seq is actually for methylation analysis, the true intent of this statement cannot be discerned.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "You MUST give a detailed answer to the following question: What is the indication of ARCALYST?",
    "llama-7b_response": "rheumatoid arthriti",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2170,
    "user_query": "You MUST give a detailed answer to the following question: List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-7b_response": "Robertsonian translocation is a type of chromosomal rearrangement that results in the fusion of two acrocentric chromosomes. The human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 13, 14, 15, and 21.",
    "llama-7b_fact_raw": "1. Robertsonian translocation is a chromosomal rearrangement involving the fusion of two acrocentric chromosomes.\n2. Chromosomes 13, 14, 15, and 21 are the human acrocentric chromosomes that can be involved in Robertsonian translocation.",
    "llama-7b_fact": [
      "Robertsonian translocation is a chromosomal rearrangement involving the fusion of two acrocentric chromosomes.",
      "Chromosomes 13, 14, 15, and 21 are the human acrocentric chromosomes that can be involved in Robertsonian translocation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Chromosomes 13, 14, 15, 21, and 22 are the human acrocentric chromosomes that can be involved in Robertsonian translocation.",
    "llama-7b_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "You MUST give a detailed answer to the following question: Which R package could be used for the identification of pediatric brain tumors?",
    "llama-7b_response": "There is no single R package that can be used for the identification of pediatric brain tumors. However, there are several R packages that can be used for analyzing and visualizing medical imaging data, which could potentially be used for the identification of pediatric brain tumors. Some examples of R packages that are commonly used for medical imaging analysis include:\n\n1. Image: This package provides functions for image processing and analysis. It can be used for tasks such as image registration, segmentation, and feature extraction.\n2. FreeSurfer: This package provides tools for processing and analyzing brain imaging data, including MRI and DTI data. It can be used for tasks such as skull stripping, cortical surface reconstruction, and tractography.\n3. nipy: This package provides functions for image processing and analysis, with a focus on neuroimaging data. It can be used for tasks such as image registration, segmentation, and feature extraction.\n4. spm: This package provides tools for processing and analyzing MRI data, with a focus on functional MRI (fMRI) data. It can be used for tasks such as image registration, spatial normalization, and statistical analysis of fMRI data.\n\nIt is worth noting that these packages are not specifically designed for the identification of pediatric brain tumors, but rather for the analysis of medical imaging data in general. However, they can be used in combination with other tools and methods to support the identification of pediatric brain tumors.",
    "llama-7b_fact_raw": "1. The R package \"Image\" is used for image processing and analysis, applicable to medical imaging tasks like image registration, segmentation, and feature extraction.\n2. \"FreeSurfer\" is an R package used for processing and analyzing brain imaging data, including MRI and DTI data.\n3. The R package \"nipy\" focuses on image processing and analysis of neuroimaging data.\n4. \"spm\" is an R package used for processing and analyzing MRI data, specifically functional MRI (fMRI) data.",
    "llama-7b_fact": [
      "The R package \"Image\" is used for image processing and analysis, applicable to medical imaging tasks like image registration, segmentation, and feature extraction.",
      "\"FreeSurfer\" is an R package used for processing and analyzing brain imaging data, including MRI and DTI data.",
      "The R package \"nipy\" focuses on image processing and analysis of neuroimaging data.",
      "\"spm\" is an R package used for processing and analyzing MRI data, specifically functional MRI (fMRI) data."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The R package \"Image\" does not exist for image processing and analysis. Perhaps you are referring to \"EBImage\" or another package, but without the correct package name, this statement cannot be verified as true.\n2. FALSE [correction]: \"FreeSurfer\" is not an R package; it is a standalone, open-source software suite for processing and analyzing brain imaging data from MRI, but it is not part of the R ecosystem.\n3. FALSE [correction]: \"nipy\" is a Python-based platform, not an R package, dedicated to the analysis of neuroimaging data.\n4. FALSE [correction]: \"SPM\" (Statistical Parametric Mapping) is not an R package but rather a software written in MATLAB that is used for the analysis of brain imaging data including fMRI, PET, SPECT, and similar modalities.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2246,
    "user_query": "You MUST give a detailed answer to the following question: Is NEMO a zinc finger protein?",
    "llama-7b_response": "Yes, NEMO (Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) is a zinc finger protein.\n\nZinc finger proteins are a family of transcription factors that contain one or more zinc-binding domains in their structure. These domains allow zinc finger proteins to recognize specific DNA sequences and regulate gene expression.\n\nNEMO is a key component of the IKK (IkappaB kinase) complex, which plays a central role in the NF-kappaB signaling pathway. NF-kappaB is a transcription factor that regulates the expression of genes involved in cell growth, differentiation, and immune response.\n\nThe IKK complex phosphorylates and activates the NF-kappaB inhibitor protein IkappaB, leading to its degradation and the release of active NF-kappaB. NEMO is a zinc finger protein that interacts with the IKK complex and plays a critical role in this process.\n\nTherefore, NEMO is a zinc finger protein that plays a crucial role in the NF-kappaB signaling pathway by interacting with the IKK complex and regulating the expression of genes involved in cell growth, differentiation, and immune response.",
    "llama-7b_fact_raw": "1. NEMO stands for Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha.\n2. NEMO is a protein that contains zinc-binding domains.\n3. Zinc finger proteins are a class of transcription factors that can regulate gene expression.\n4. NEMO is an integral part of the IkappaB kinase (IKK) complex.\n5. The NF-kappaB signaling pathway, where NEMO plays a central role, is involved with cell growth, differentiation, and immune response.",
    "llama-7b_fact": [
      "NEMO stands for Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha.",
      "NEMO is a protein that contains zinc-binding domains.",
      "Zinc finger proteins are a class of transcription factors that can regulate gene expression.",
      "NEMO is an integral part of the IkappaB kinase (IKK) complex.",
      "The NF-kappaB signaling pathway, where NEMO plays a central role, is involved with cell growth, differentiation, and immune response."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "You MUST give a detailed answer to the following question: Does TFIIS affect nucleosome positioning?",
    "llama-7b_response": "Transcription factor IIS (TFIIS) is a general transcription factor that plays a crucial role in the initiation of RNA polymerase II-mediated transcription. TFIIS is composed of three subunits: TFIIS-alpha, TFIIS-beta, and TFIIS-gamma. TFIIS-alpha and TFIIS-beta interact with the RNA polymerase II holoenzyme, while TFIIS-gamma interacts with the TFIIS-alpha and TFIIS-beta subunits.\n\nThe role of TFIIS in nucleosome positioning has been the subject of much research. Nucleosomes are the basic units of chromatin, and they consist of DNA wrapped around a core of histone proteins. Nucleosome positioning is an important aspect of gene regulation, as it determines the accessibility of DNA to transcription factors and other regulatory proteins.\n\nTFIIS has been shown to affect nucleosome positioning in several ways. Firstly, TFIIS can displace nucleosomes from the promoter region of a gene, allowing the RNA polymerase II holoenzyme to access the DNA and initiate transcription. This is achieved through the interaction between TFIIS-alpha and TFIIS-beta subunits and the RNA polymerase II holoenzyme.\n\nSecondly, TFIIS can also promote the formation of open chromatin regions, which are regions of chromatin that are more accessible to transcription factors and other regulatory proteins. This is achieved through the interaction between TFIIS-alpha and TFIIS-beta subunits and the histone acetyltransferase p300. p300 is a transcriptional co-activator that can acetylate histones, leading to the displacement of nucleosomes and the formation of open chromatin regions.\n\nIn summary, TFIIS plays an important role in the initiation of RNA polymerase II-mediated transcription by displacing nucleosomes from the promoter region of a gene and promoting the formation of open chromatin regions. These effects on nucleosome positioning can have a significant impact on gene regulation and the",
    "llama-7b_fact_raw": "1. Transcription factor IIS (TFIIS) is composed of three subunits: TFIIS-alpha, TFIIS-beta, and TFIIS-gamma.\n2. TFIIS plays a role in RNA polymerase II-mediated transcription initiation.\n3. TFIIS-alpha and TFIIS-beta subunits interact with the RNA polymerase II holoenzyme.\n4. TFIIS is involved in displacing nucleosomes from the promoter region of a gene.\n5. TFIIS, through interaction with p300 (a histone acetyltransferase), can promote the formation of open chromatin regions.",
    "llama-7b_fact": [
      "Transcription factor IIS (TFIIS) is composed of three subunits: TFIIS-alpha, TFIIS-beta, and TFIIS-gamma.",
      "TFIIS plays a role in RNA polymerase II-mediated transcription initiation.",
      "TFIIS-alpha and TFIIS-beta subunits interact with the RNA polymerase II holoenzyme.",
      "TFIIS is involved in displacing nucleosomes from the promoter region of a gene.",
      "TFIIS, through interaction with p300 (a histone acetyltransferase), can promote the formation of open chromatin regions."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: TFIIS plays a role in RNA polymerase II-mediated transcription elongation, specifically by enhancing the enzyme's ability to read through transcriptional blocks.\n3. UNKNOWN\n4. FALSE [correction]: TFIIS is not directly involved in displacing nucleosomes from the promoter region; instead, its primary role is associated with RNA polymerase II during transcription elongation.\n5. UNKNOWN",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "You MUST give a detailed answer to the following question: Do origins of replication close to yeast centromeres fire early or late?",
    "llama-7b_response": "The origin of replication (ori) that is closest to the centromere of yeast (Saccharomyces cerevisiae) fires early during the S phase of the cell cycle. This is in contrast to the origins of replication that are located further away from the centromere, which fire late during the S phase.\n\nThe timing of replication at different origins of replication is determined by the position of the origins relative to the centromere. The centromere is a specialized region of the chromosome that plays a crucial role in the proper separation of sister chromatids during cell division. The origins of replication are the points at which DNA replication begins, and the timing of replication at each origin is determined by the position of the origin relative to the centromere.\n\nThe origins of replication that are closest to the centromere fire early during the S phase of the cell cycle, while the origins of replication that are located further away from the centromere fire late during the S phase. This is because the early-firing origins are located on the side of the chromosome that is closest to the spindle fibers during mitosis or meiosis, and are therefore more accessible to the replication machinery. In contrast, the late-firing origins are located on the side of the chromosome that is further away from the spindle fibers, and are therefore less accessible to the replication machinery.\n\nThe timing of replication at different origins of replication is important for ensuring that the correct amount of DNA is replicated during each cell division. If an origin of replication fires too early or too late, it can lead to errors in DNA replication and genetic instability. Therefore, the precise regulation of the timing of replication at different origins of replication is crucial for the proper functioning of the cell.",
    "llama-7b_fact_raw": "1. The origin of replication closest to the centromere in yeast (Saccharomyces cerevisiae) fires early during the S phase of the cell cycle.\n2. Origins of replication that are located further away from the yeast centromere fire late during the S phase.\n3. The centromere is a specialized region of the chromosome involved in the separation of sister chromatids during cell division.\n4. The timing of replication at each origin in yeast is influenced by the position of the origin relative to the centromere.\n5. Early-firing origins in yeast are located closer to the spindle fibers during mitosis or meiosis, making them more accessible to replication machinery.",
    "llama-7b_fact": [
      "The origin of replication closest to the centromere in yeast (Saccharomyces cerevisiae) fires early during the S phase of the cell cycle.",
      "Origins of replication that are located further away from the yeast centromere fire late during the S phase.",
      "The centromere is a specialized region of the chromosome involved in the separation of sister chromatids during cell division.",
      "The timing of replication at each origin in yeast is influenced by the position of the origin relative to the centromere.",
      "Early-firing origins in yeast are located closer to the spindle fibers during mitosis or meiosis, making them more accessible to replication machinery."
    ],
    "llama-7b_judge_raw": "1. TRUE: The origin of replication closest to the centromere in yeast (Saccharomyces cerevisiae) is known to fire early during the S phase of the cell cycle.\n2. TRUE: Origins of replication located further away from the centromere in yeast are typically late-firing during the S phase.\n3. TRUE: A centromere is indeed a specialized region of the chromosome that plays a crucial role in the separation of sister chromatids during cell division.\n4. TRUE: In yeast, the timing of replication initiation at origins is known to be influenced by their position relative to the centromere, among other factors.\n5. FALSE [correction]: The statement incorrectly suggests that the proximity of origins to spindle fibers during mitosis or meiosis governs their timing of replication. The timing of firing of early replication origins is associated with their position relative to the centromere and other regulatory factors, not their proximity to spindle fibers during mitosis or meiosis. Spindle fibers are involved in the segregation of chromosomes, not in the accessibility of replication machinery.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2268,
    "user_query": "You MUST give a detailed answer to the following question: Which are the properties of mammalian GA-sequences?",
    "llama-7b_response": "Mammalian GA-sequences are a type of non-coding RNA that are found in the genomes of many mammalian species, including humans. They are characterized by a specific sequence motif, known as the GA-motif, which consists of two guanosine (G) nucleotides followed by an adenosine (A) nucleotide.\n\nIn addition to the GA-motif, mammalian GA-sequences also have several other properties:\n\n1. Location: Mammalian GA-sequences are typically found in introns, or non-coding regions, of genes.\n2. Length: The length of mammalian GA-sequences can vary, but they are typically less than 100 nucleotides in length.\n3. Transcription: Mammalian GA-sequences are not transcribed, or translated, into proteins. Instead, they are thought to play a role in RNA-mediated regulation of gene expression.\n4. Stability: Mammalian GA-sequences are relatively stable and can persist in the genome for long periods of time.\n5. Conservation: Mammalian GA-sequences are highly conserved across different species, suggesting that they play an important role in the function of the genome.\n6. Function: The exact function of mammalian GA-sequences is not fully understood, but they are thought to play a role in RNA-mediated regulation of gene expression, including the splicing of pre-mRNA and the formation of ribonucleoprotein complexes.\n\nOverall, mammalian GA-sequences are an important class of non-coding RNA that play a critical role in the regulation of gene expression in mammalian cells.",
    "llama-7b_fact_raw": "1. Mammalian GA-sequences are characterized by the presence of a GA-motif, which consists of two guanosine nucleotides followed by an adenosine nucleotide.\n2. Mammalian GA-sequences are typically found in the introns of genes.\n3. The length of mammalian GA-sequences generally does not exceed 100 nucleotides.\n4. Mammalian GA-sequences are not translated into proteins but are thought to have a role in RNA-mediated gene expression regulation.\n5. Mammalian GA-sequences are highly conserved across different mammalian species.",
    "llama-7b_fact": [
      "Mammalian GA-sequences are characterized by the presence of a GA-motif, which consists of two guanosine nucleotides followed by an adenosine nucleotide.",
      "Mammalian GA-sequences are typically found in the introns of genes.",
      "The length of mammalian GA-sequences generally does not exceed 100 nucleotides.",
      "Mammalian GA-sequences are not translated into proteins but are thought to have a role in RNA-mediated gene expression regulation.",
      "Mammalian GA-sequences are highly conserved across different mammalian species."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mammalian GA-sequences are characterized by the presence of repeated GA dinucleotides, not just a single instance of two guanosine nucleotides followed by an adenosine nucleotide.\n2. TRUE\n3. UNKNOWN: The general length of GA-sequences can vary, and without specific research data or context, it is difficult to confirm the typical length of mammalian GA-sequences.\n4. TRUE: GA-sequences, being non-coding sequences typically found in introns, are not translated into proteins but can play roles in gene regulation.\n5. UNKNOWN: Conservation of GA-sequences across different mammalian species would depend on the specific sequences in question and would require empirical evidence to verify.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "You MUST give a detailed answer to the following question: How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-7b_response": "The number of Groucho-related genes (GRG) contained in the mouse genome is currently unknown.\n\nGroucho-related genes (GRG) are a family of transcriptional repressors that play a critical role in regulating gene expression during development. They are named after the Drosophila gene Groucho, which was the first member of the family to be identified. The Groucho family of genes is conserved across species, including mammals, and has been implicated in a variety of biological processes, including cellular differentiation, embryonic development, and tumor suppression.\n\nHowever, the exact number of Groucho-related genes in the mouse genome has not yet been determined. This is because the Groucho family of genes is highly conserved across species, and the number of genes in the family can vary depending on the species being studied. In addition, the Groucho family of genes can also undergo gene duplication and divergence, which can further complicate efforts to determine the exact number of genes in the family.\n\nIn summary, the number of Groucho-related genes (GRG) contained in the mouse genome is currently unknown, and further research is needed to determine the exact number of genes in the family.",
    "llama-7b_fact_raw": "1. The exact number of Groucho-related genes (GRG) in the mouse genome is currently unknown.\n2. Groucho-related genes (GRG) are a family of transcriptional repressors.\n3. Groucho-related genes are involved in regulating gene expression during development.\n4. The Groucho gene family is conserved across various species, including mammals.\n5. Groucho-related genes have been implicated in biological processes such as cellular differentiation, embryonic development, and tumor suppression.",
    "llama-7b_fact": [
      "The exact number of Groucho-related genes (GRG) in the mouse genome is currently unknown.",
      "Groucho-related genes (GRG) are a family of transcriptional repressors.",
      "Groucho-related genes are involved in regulating gene expression during development.",
      "The Groucho gene family is conserved across various species, including mammals.",
      "Groucho-related genes have been implicated in biological processes such as cellular differentiation, embryonic development, and tumor suppression."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "You MUST give a detailed answer to the following question: Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-7b_response": "holoenzyme",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2321,
    "user_query": "You MUST give a detailed answer to the following question: What is the genetic basis of Ohdo syndrome?",
    "llama-7b_response": "Ohdo syndrome is a rare genetic disorder caused by mutations in the TMEM132 gene. The TMEM132 gene provides instructions for making a protein called transient receptor potential cation channel, subfamily M, member 13 (TRPM13). This protein is involved in the function of sensory neurons, which are nerve cells that transmit information about sensations such as pain, temperature, and touch.\n\nMutations in the TMEM132 gene can result in the production of a non-functional or abnormal TRPM13 protein. This can disrupt the normal function of sensory neurons, leading to the symptoms of Ohdo syndrome.\n\nThe specific symptoms of Ohdo syndrome can vary from person to person, but they typically include severe pain, muscle stiffness, and joint contractures. Some people with Ohdo syndrome may also have intellectual disability, seizures, and other neurological abnormalities.\n\nOhdo syndrome is inherited in an autosomal recessive pattern, which means that a person with the disorder has two copies of the mutated TMEM132 gene, one of which is inherited from each parent.",
    "llama-7b_fact_raw": "1. Ohdo syndrome is a rare genetic disorder caused by mutations in the TMEM132 gene.\n2. The TMEM132 gene is responsible for making the transient receptor potential cation channel, subfamily M, member 13 (TRPM13) protein.\n3. Mutations in the TMEM132 gene can lead to abnormal or non-functional TRPM13 protein.\n4. Ohdo syndrome can cause symptoms such as severe pain, muscle stiffness, and joint contractures.\n5. Ohdo syndrome is inherited in an autosomal recessive pattern, requiring two copies of the mutated gene for the disorder to manifest.",
    "llama-7b_fact": [
      "Ohdo syndrome is a rare genetic disorder caused by mutations in the TMEM132 gene.",
      "The TMEM132 gene is responsible for making the transient receptor potential cation channel, subfamily M, member 13 (TRPM13) protein.",
      "Mutations in the TMEM132 gene can lead to abnormal or non-functional TRPM13 protein.",
      "Ohdo syndrome can cause symptoms such as severe pain, muscle stiffness, and joint contractures.",
      "Ohdo syndrome is inherited in an autosomal recessive pattern, requiring two copies of the mutated gene for the disorder to manifest."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The specific gene causing Ohdo syndrome is not provided. Ohdo syndrome can be caused by mutations in different genes, including KAT6A and MED12, but without specifying the subtype of Ohdo syndrome or more context, the role of TMEM132 gene can't be confirmed.\n2. FALSE [correction]: The transient receptor potential cation channel, subfamily M, member 13 (TRPM13) protein does not exist. TRPM refers to a family of proteins that are part of the transient receptor potential (TRP) channels, with subfamily numbers typically being single digits (e.g., TRPM1, TRPM2, etc.). Also, it's unclear what the TMEM132 gene encodes as its existence or function may be inaccurately stated.\n3. UNKNOWN: Since the existence and function of the TMEM132 gene are uncertain, it's not possible to confirm whether mutations in this gene would lead to abnormal or non-functional TRPM13 protein.\n4. FALSE [correction]: Ohdo syndrome is characterized by intellectual disability, characteristic facial features, and other congenital anomalies. Severe pain, muscle stiffness, and joint contractures are not typically described as defining features of Ohdo syndrome, though musculoskeletal abnormalities may occur.\n5. TRUE: Ohdo syndrome, specifically the Maat-Kievit-Brunner type, is inherited in an autosomal recessive pattern. This means that two copies of the mutated gene, one from each parent, are required for an individual to be affected by the disorder. However, it is important to note that there are different types of Ohdo syndrome, such as the Say-Barber-Biesecker-Young-Simpson variant, which is inherited in an X-linked pattern. Without specifying the type of Ohdo syndrome referenced, this statement may not be true in all cases.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "You MUST give a detailed answer to the following question: Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-7b_response": "GeneNetwork",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2360,
    "user_query": "You MUST give a detailed answer to the following question: Describe swirl sign in intracerebral hemorrhage.",
    "llama-7b_response": "Intracerebral hemorrhage (ICH) is a type of stroke that occurs when there is bleeding within the brain. One of the characteristic features of ICH is the presence of a swirl sign on imaging studies.\n\nThe swirl sign in ICH is caused by the movement of blood within the brain, which creates a swirling pattern on imaging studies such as computed tomography (CT) or magnetic resonance imaging (MRI). The swirl sign can be seen on both non-contrast and contrast-enhanced imaging studies.\n\nThe swirl sign is not specific to ICH and can also be seen in other conditions that cause bleeding within the brain, such as subarachnoid hemorrhage and cerebral venous sinus thrombosis. However, the presence of a swirl sign on imaging studies is highly suggestive of ICH.\n\nThe swirl sign is an important diagnostic feature of ICH because it helps to differentiate ICH from other types of stroke, such as ischemic stroke, which is caused by a blockage of blood flow to the brain. The swirl sign can also help to identify the location and extent of the bleeding within the brain, which is important for determining the best course of treatment.\n\nIn summary, the swirl sign is a characteristic feature of intracerebral hemorrhage and is caused by the movement of blood within the brain. The presence of a swirl sign on imaging studies is highly suggestive of ICH and helps to differentiate it from other types of stroke.",
    "llama-7b_fact_raw": "1. Intracerebral hemorrhage (ICH) is a type of stroke caused by bleeding within the brain.\n2. The swirl sign is a radiological feature seen on imaging studies like computed tomography (CT) or magnetic resonance imaging (MRI) in cases of ICH.\n3. The swirl sign is caused by the movement of blood within the brain, which creates a swirling pattern visible in imaging studies.\n4. While the swirl sign can be seen in conditions other than ICH, such as subarachnoid hemorrhage and cerebral venous sinus thrombosis, its presence is highly suggestive of intracerebral hemorrhage.\n5. The swirl sign helps to differentiate ICH from ischemic stroke, which occurs due to a blockage of blood flow to the brain.",
    "llama-7b_fact": [
      "Intracerebral hemorrhage (ICH) is a type of stroke caused by bleeding within the brain.",
      "The swirl sign is a radiological feature seen on imaging studies like computed tomography (CT) or magnetic resonance imaging (MRI) in cases of ICH.",
      "The swirl sign is caused by the movement of blood within the brain, which creates a swirling pattern visible in imaging studies.",
      "While the swirl sign can be seen in conditions other than ICH, such as subarachnoid hemorrhage and cerebral venous sinus thrombosis, its presence is highly suggestive of intracerebral hemorrhage.",
      "The swirl sign helps to differentiate ICH from ischemic stroke, which occurs due to a blockage of blood flow to the brain."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The swirl sign is indicative of bleeding within the brain, not caused by the movement of blood, but rather it represents a mixture of blood at different stages of clotting, which can create a heterogeneous appearance on imaging studies.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "You MUST give a detailed answer to the following question: What induces Arabidopsis ROF1 expression?",
    "llama-7b_response": "Arabidopsis ROF1 is a transcription factor that plays a crucial role in regulating the expression of genes involved in the biosynthesis of flavonoids, a class of plant secondary metabolites. ROF1 expression is induced in response to various stimuli, including biotic and abiotic stresses, such as drought, salt, and temperature stress, as well as treatment with plant hormones, such as abscisic acid (ABA) and salicylic acid (SA).\n\n1. Biotic stress: ROF1 expression is induced in response to various biotic stresses, such as bacterial and fungal infections. For example, Arabidopsis plants infected with the bacterium Pseudomonas syringae pv. tomato (Pst) or the fungus Botrytis cinerea exhibit increased ROF1 expression. This suggests that ROF1 plays a role in the plant's defense response against pathogens.\n2. Abiotic stress: ROF1 expression is also induced in response to various abiotic stresses, such as drought, salt, and temperature stress. For example, Arabidopsis plants subjected to drought stress exhibit increased ROF1 expression, which suggests that ROF1 plays a role in the plant's response to water deficit. Similarly, Arabidopsis plants exposed to high salinity or high temperature exhibit increased ROF1 expression, which suggests that ROF1 plays a role in the plant's response to abiotic stress.\n3. Plant hormones: ROF1 expression is also induced in response to treatment with plant hormones, such as ABA and SA. For example, Arabidopsis plants treated with ABA exhibit increased ROF1 expression, which suggests that ROF1 plays a role in the plant's response to ABA-mediated stress. Similarly, Arabidopsis plants treated with SA exhibit increased ROF1 expression, which suggests that ROF1 plays a role in the plant's response to SA-mediated stress.\n\nIn summary, Arabidopsis ROF1 expression is induced in response to various stimuli, including biotic and abiotic stresses, as well as treatment with plant hormones. This suggests that ROF1 plays a crucial role in regulating the expression of genes involved in the bio",
    "llama-7b_fact_raw": "1. Arabidopsis ROF1 is a transcription factor involved in regulating gene expression for flavonoid biosynthesis.\n2. ROF1 expression in Arabidopsis is induced by biotic stresses such as bacterial and fungal infections.\n3. Arabidopsis ROF1 expression can be triggered by abiotic stresses, including drought, salt, and temperature stress.\n4. Plant hormones like abscisic acid (ABA) and salicylic acid (SA) can induce the expression of ROF1 in Arabidopsis.\n5. The increased expression of Arabidopsis ROF1 is indicative of a response to various stress factors that the plant may encounter.",
    "llama-7b_fact": [
      "Arabidopsis ROF1 is a transcription factor involved in regulating gene expression for flavonoid biosynthesis.",
      "ROF1 expression in Arabidopsis is induced by biotic stresses such as bacterial and fungal infections.",
      "Arabidopsis ROF1 expression can be triggered by abiotic stresses, including drought, salt, and temperature stress.",
      "Plant hormones like abscisic acid (ABA) and salicylic acid (SA) can induce the expression of ROF1 in Arabidopsis.",
      "The increased expression of Arabidopsis ROF1 is indicative of a response to various stress factors that the plant may encounter."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: While ROF1 (AtFKBP62) is indeed a transcription factor, it directly regulates the heat shock response and does not specifically regulate gene expression for flavonoid biosynthesis.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "You MUST give a detailed answer to the following question: What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-7b_response": "transthyretin",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2407,
    "user_query": "You MUST give a detailed answer to the following question: Has the proteome of mice hippocampus been analysed?",
    "llama-7b_response": "Yes, the proteome of mice hippocampus has been analyzed in several studies. The hippocampus is a critical region of the brain involved in learning, memory, and emotional regulation, and its proteome, or the set of proteins expressed in the hippocampus, is an important area of research.\n\nOne study used two-dimensional gel electrophoresis and mass spectrometry to analyze the proteome of the hippocampus in mice. The study identified over 1,000 proteins, including several known to be involved in synaptic plasticity, a process that underlies learning and memory.\n\nAnother study used a similar approach to analyze the proteome of the hippocampus in mice with Alzheimer's disease, a neurodegenerative disorder characterized by memory loss and other cognitive deficits. The study identified several proteins that were differentially expressed in the hippocampus of Alzheimer's disease mice compared to healthy mice, including several involved in synaptic plasticity and neurotransmission.\n\nOverall, these studies have provided valuable insights into the proteome of the hippocampus in mice and have implications for our understanding of hippocampal function and dysfunction in various neurological disorders.",
    "llama-7b_fact_raw": "1. The proteome of the mice hippocampus has been analyzed in various studies.\n2. One study which used two-dimensional electrophoresis and mass spectrometry identified over 1,000 proteins in the mice hippocampus.\n3. Synaptic plasticity involves a set of proteins within the hippocampus that were identified in the study.\n4. A specific study focused on analyzing the hippocampal proteome in mice with Alzheimer's disease.\n5. The study on mice with Alzheimer's disease found proteins that were differentially expressed compared to healthy mice.",
    "llama-7b_fact": [
      "The proteome of the mice hippocampus has been analyzed in various studies.",
      "One study which used two-dimensional electrophoresis and mass spectrometry identified over 1,000 proteins in the mice hippocampus.",
      "Synaptic plasticity involves a set of proteins within the hippocampus that were identified in the study.",
      "A specific study focused on analyzing the hippocampal proteome in mice with Alzheimer's disease.",
      "The study on mice with Alzheimer's disease found proteins that were differentially expressed compared to healthy mice."
    ],
    "llama-7b_judge_raw": "1. TRUE: The proteome of the mice hippocampus has indeed been analyzed in various studies.\n2. UNKNOWN: While two-dimensional electrophoresis and mass spectrometry are common techniques for proteome analysis, without exact details, it cannot be confirmed whether a particular study identified over 1,000 proteins in the mice hippocampus.\n3. TRUE: Synaptic plasticity does involve a set of proteins within the hippocampus, and it is highly likely these were among the proteins identified in studies analyzing the hippocampal proteome.\n4. TRUE: It is common for studies to focus on analyzing the proteomes of mice with specific diseases, and Alzheimer's disease is a significant area of research within such studies.\n5. TRUE: Studies of this nature typically compare the proteomes of diseased mice with those of healthy controls to identify differentially expressed proteins that may contribute to or result from the disease pathology.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "You MUST give a detailed answer to the following question: Are mouse chromosomes acrocentric?",
    "llama-7b_response": "Yes, mouse chromosomes are acrocentric.\n\nAcrocentric chromosomes are a type of chromosome that has a short arm (p arm) that is shorter than the long arm (q arm). This is in contrast to metacentric chromosomes, which have an equal length of both arms. Acrocentric chromosomes are found in many mammals, including humans and mice.\n\nIn mice, the acrocentric chromosomes are numbered as follows: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and X and Y. The p arm of each acrocentric chromosome is shorter than the q arm.\n\nThe acrocentric chromosomes are important in meiosis, the process by which sex cells (gametes) are produced. During meiosis, homologous chromosomes pair up and exchange genetic information. In the case of acrocentric chromosomes, the p arm of one homologous chromosome pairs with the q arm of the other homologous chromosome. This helps to ensure that the genetic information on each chromosome is properly shuffled and segregated during meiosis.\n\nOverall, the acrocentric chromosomes play an important role in the genetic makeup of mice and other mammals.",
    "llama-7b_fact_raw": "1. Mouse chromosomes are acrocentric.\n2. Acrocentric chromosomes have a short arm that is shorter than the long arm.\n3. Mice have acrocentric chromosomes numbered 1 through 19, as well as X and Y chromosomes.\n4. In meiosis of acrocentric chromosomes, the p arm pairs with the q arm of its homologous chromosome.\n5. The exchange of genetic information during meiosis involves the acrocentric chromosomes in mice.",
    "llama-7b_fact": [
      "Mouse chromosomes are acrocentric.",
      "Acrocentric chromosomes have a short arm that is shorter than the long arm.",
      "Mice have acrocentric chromosomes numbered 1 through 19, as well as X and Y chromosomes.",
      "In meiosis of acrocentric chromosomes, the p arm pairs with the q arm of its homologous chromosome.",
      "The exchange of genetic information during meiosis involves the acrocentric chromosomes in mice."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: In meiosis, the whole length of homologous chromosomes, not just the p arm or q arm, pair along their corresponding lengths. The p (short) arm and the q (long) arm are part of the same chromosome, and it would not be accurate to say they pair with each other.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "You MUST give a detailed answer to the following question: Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-7b_response": "gemcitabine",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2419,
    "user_query": "You MUST give a detailed answer to the following question: What is the HPG pore?",
    "llama-7b_response": "The HPG (Hypothalamic-Pituitary-Gonadal) pore is a hypothetical structure that is thought to exist in the brains of some animals, including humans. It is named for the three endocrine glands that it is believed to connect to: the hypothalamus, pituitary gland, and gonads (testes or ovaries).\n\nThe HPG pore is thought to play a role in the regulation of hormones and other substances that are produced by the endocrine glands. Specifically, it is believed to allow communication between the endocrine glands and the nervous system, which could help to regulate hormone levels and other physiological processes.\n\nThere is currently no scientific evidence to support the existence of the HPG pore, and it is not recognized as a legitimate anatomical structure by the medical community. The concept of the HPG pore is still the subject of ongoing research and debate among scientists and medical professionals.",
    "llama-7b_fact_raw": "1. The HPG pore is a hypothetical structure thought to exist in the brains of some animals, including humans.\n2. The HPG stands for Hypothalamic-Pituitary-Gonadal, referring to the three endocrine glands it is believed to connect: the hypothalamus, pituitary gland, and gonads (testes or ovaries).\n3. It is theorized that the HPG pore plays a role in the regulation of hormones produced by the connected endocrine glands.\n4. The HPG pore is hypothesized to allow communication between the endocrine glands and the nervous system.\n5. There is currently no scientific evidence to support the existence of the HPG pore, and it is not recognized as a legitimate anatomical structure by the medical community.",
    "llama-7b_fact": [
      "The HPG pore is a hypothetical structure thought to exist in the brains of some animals, including humans.",
      "The HPG stands for Hypothalamic-Pituitary-Gonadal, referring to the three endocrine glands it is believed to connect: the hypothalamus, pituitary gland, and gonads (testes or ovaries).",
      "It is theorized that the HPG pore plays a role in the regulation of hormones produced by the connected endocrine glands.",
      "The HPG pore is hypothesized to allow communication between the endocrine glands and the nervous system.",
      "There is currently no scientific evidence to support the existence of the HPG pore, and it is not recognized as a legitimate anatomical structure by the medical community."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The HPG axis, not pore, is a real system in the body, which stands for Hypothalamic-Pituitary-Gonadal axis that involves the hypothalamus, pituitary gland, and gonadal glands.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The term HPG pore is incorrect; the HPG axis involves communication between the endocrine glands and the nervous system through hormones and does not involve a physical \"pore.\"\n5. TRUE, concerning the term \"HPG pore,\" but it's important to note that while the HPG pore is not recognized or supported as an anatomical structure, the HPG axis is a well-established concept in endocrinology.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "You MUST give a detailed answer to the following question: What is the 959 Nematode Genomes initiative?",
    "llama-7b_response": "The 959 Nematode Genomes initiative is a large-scale project aimed at sequencing and analyzing the genomes of a diverse set of nematode species. Nematodes are a phylum of roundworms that includes a wide range of species, including parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes. The goal of the 959 Nematode Genomes initiative is to sequence and analyze the genomes of at least 959 different nematode species in order to gain a better understanding of the diversity and evolution of this group of organisms.\n\nThe 959 Nematode Genomes initiative is being carried out by a consortium of researchers from around the world, and is being funded by a number of different organizations, including the National Institutes of Health (NIH) and the National Science Foundation (NSF). The sequencing and analysis of the nematode genomes is being carried out using a variety of different techniques and technologies, including next-generation sequencing and computational analysis.\n\nOne of the main goals of the 959 Nematode Genomes initiative is to provide a resource for the study of nematode biology and evolution. By sequencing and analyzing the genomes of a diverse set of nematode species, researchers hope to gain a better understanding of the genetic basis of nematode traits and behaviors, as well as the evolutionary relationships between different nematode species. This information will be useful for a variety of different fields, including agriculture, medicine, and biotechnology.\n\nOverall, the 959 Nematode Genomes initiative is a large-scale project that aims to provide a valuable resource for the study of nematode biology and evolution. By sequencing and analyzing the genomes of a diverse set of nematode species, researchers hope to gain a better understanding of the genetic basis of nematode traits and behaviors, as well as the evolutionary relationships between different nematode species. This information will be useful for a variety of different fields, including agriculture, medicine, and biotechnology.",
    "llama-7b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of at least 959 different nematode species.\n2. Nematodes are roundworms and can include parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.\n3. A consortium of researchers from around the world is carrying out the 959 Nematode Genomes initiative.\n4. The National Institutes of Health (NIH) and the National Science Foundation (NSF) are among the organizations funding the 959 Nematode Genomes initiative.\n5. The goal of the initiative is to gain a better understanding of nematode biology and evolution, which will be useful for agriculture, medicine, and biotechnology.",
    "llama-7b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of at least 959 different nematode species.",
      "Nematodes are roundworms and can include parasitic worms, plant-feeding nematodes, and free-living soil-dwelling nematodes.",
      "A consortium of researchers from around the world is carrying out the 959 Nematode Genomes initiative.",
      "The National Institutes of Health (NIH) and the National Science Foundation (NSF) are among the organizations funding the 959 Nematode Genomes initiative.",
      "The goal of the initiative is to gain a better understanding of nematode biology and evolution, which will be useful for agriculture, medicine, and biotechnology."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "You MUST give a detailed answer to the following question: Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-7b_response": "There is currently no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data. However, there are several R packages that can be used for analyzing genetic and genomic data, which can be applied to NIPT data. Some of these packages include:\n\n1. GenABEL: This package provides tools for genome-wide association studies (GWAS) and other types of genetic association studies.\n2. PLINK: This package is used for managing and analyzing large sets of genetic and genomic data.\n3. GCTA: This package is used for genome-wide complex trait analysis, which can be applied to NIPT data.\n4. BGLR: This package is used for Bayesian genetic linkage analysis, which can be applied to NIPT data.\n5. GEMMA: This package is used for genome-wide association mapping, which can be applied to NIPT data.\n\nIt's worth noting that these packages are not specifically designed for NIPT data, but they can be used for analyzing genetic and genomic data in general, which can be applied to NIPT data.",
    "llama-7b_fact_raw": "1. There is currently no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. GenABEL is an R package that provides tools for genome-wide association studies (GWAS).\n3. PLINK is an R package used for managing and analyzing large sets of genetic and genomic data.\n4. GCTA is an R package used for genome-wide complex trait analysis.\n5. BGLR is an R package used for Bayesian genetic linkage analysis.",
    "llama-7b_fact": [
      "There is currently no R package specifically developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "GenABEL is an R package that provides tools for genome-wide association studies (GWAS).",
      "PLINK is an R package used for managing and analyzing large sets of genetic and genomic data.",
      "GCTA is an R package used for genome-wide complex trait analysis.",
      "BGLR is an R package used for Bayesian genetic linkage analysis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: As of my knowledge cutoff in early 2023, there are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data, such as \"NIPTeR\" and \"PureCN\".\n2. TRUE\n3. FALSE [correction]: PLINK is not an R package; it is a separate software tool used for managing and analyzing large sets of genetic and genomic data, but it can be integrated with R for analysis.\n4. FALSE [correction]: GCTA (Genome-wide Complex Trait Analysis) is not specifically an R package, but rather a standalone software program for complex trait analysis. However, it can be used in conjunction with R.\n5. FALSE [correction]: BGLR is an R package used for Bayesian generalized linear regression, not specifically for Bayesian genetic linkage analysis. It is often used in the context of genome-wide association studies and genomic prediction.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2560,
    "user_query": "You MUST give a detailed answer to the following question: Describe Achenbach’s syndrome.",
    "llama-7b_response": "Achenbach's syndrome, also known as Achenbach's disease, is a rare genetic disorder that affects the eyes and other parts of the body. It is caused by mutations in the COL11A1 gene, which provides instructions for making a protein called type XI collagen. Type XI collagen is an important component of the extracellular matrix, which is the complex network of proteins, carbohydrates, and other substances that surrounds and supports cells in the body.\n\nThe main features of Achenbach's syndrome are abnormalities in the eyes, including cataracts, retinal detachment, and glaucoma. These eye problems can lead to vision loss and blindness if not treated properly. In addition to eye problems, people with Achenbach's syndrome may also have skeletal abnormalities, such as short stature, bowing of the legs, and abnormal curvature of the spine (scoliosis). Some people with Achenbach's syndrome may also have other health problems, such as hearing loss, heart defects, and kidney abnormalities.\n\nAchenbach's syndrome is inherited in an autosomal recessive pattern, which means that a person needs to have two copies of the mutated COL11A1 gene, one from each parent, to develop the condition. It is estimated that Achenbach's syndrome affects about 1 in 50,000 people worldwide. There is currently no cure for Achenbach's syndrome, but treatments can help manage some of the symptoms and prevent further damage to the eyes and other parts of the body.",
    "llama-7b_fact_raw": "1. Achenbach's syndrome is caused by mutations in the COL11A1 gene.\n2. This syndrome features abnormalities in the eyes, such as cataracts, retinal detachment, and glaucoma.\n3. Individuals with Achenbach's syndrome may experience skeletal abnormalities like short stature and scoliosis.\n4. Achenbach's syndrome can lead to vision loss and blindness if eye problems are not treated properly.\n5. Achenbach's syndrome is inherited in an autosomal recessive pattern, requiring two copies of the mutated gene to develop the condition.",
    "llama-7b_fact": [
      "Achenbach's syndrome is caused by mutations in the COL11A1 gene.",
      "This syndrome features abnormalities in the eyes, such as cataracts, retinal detachment, and glaucoma.",
      "Individuals with Achenbach's syndrome may experience skeletal abnormalities like short stature and scoliosis.",
      "Achenbach's syndrome can lead to vision loss and blindness if eye problems are not treated properly.",
      "Achenbach's syndrome is inherited in an autosomal recessive pattern, requiring two copies of the mutated gene to develop the condition."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is not caused by mutations in the COL11A1 gene. Achenbach's syndrome, also known as paroxysmal hand hematoma, is a condition involving spontaneous bruising of the hand or fingers and is not associated with genetic mutations.\n2. FALSE [correction]: This statement describes symptoms that are not associated with Achenbach's syndrome. Achenbach's syndrome generally involves bruising or bleeding in the hands, not eye abnormalities.\n3. FALSE [correction]: Achenbach's syndrome does not typically involve skeletal abnormalities like short stature and scoliosis. It is primarily characterized by spontaneous bruising or bleeding in the hands.\n4. FALSE [correction]: Since Achenbach's syndrome does not affect the eyes, it cannot lead to vision loss or blindness. The statement is incorrect as it applies to a different condition.\n5. FALSE [correction]: As Achenbach's syndrome is not caused by genetic mutations, it is not inherited in an autosomal recessive pattern or any other genetic pattern. It is a benign, self-limiting condition.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm is used for detection of long repeat expansions?",
    "llama-7b_response": "liding window",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2582,
    "user_query": "You MUST give a detailed answer to the following question: Which brain tumors does neuroligin-3 promote?",
    "llama-7b_response": "glioblastoma",
    "llama-7b_fact_raw": "1. Neuroligin-3 is associated with the promotion of glioblastoma.",
    "llama-7b_fact": [
      "Neuroligin-3 is associated with the promotion of glioblastoma."
    ],
    "llama-7b_judge_raw": "1. TRUE",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "You MUST give a detailed answer to the following question: What is the approximate size of gas vesicles?",
    "llama-7b_response": "Gas vacuoles, also known as gas vesicles or balloon cells, are small, gas-filled organelles found in some bacteria and archaea. The size of gas vacuoles varies among different organisms, but they are typically on the order of 1-100 nanometers in diameter. The exact size of gas vacuoles can depend on a variety of factors, including the species of bacteria or archaea and the environmental conditions in which they are found. For example, some species of bacteria may have larger gas vacuoles than others under the same growth conditions. Additionally, the size of gas vacuoles can be affected by factors such as temperature, pH, and the availability of nutrients.",
    "llama-7b_fact_raw": "1. Gas vesicles are found in some bacteria and archaea.\n2. The typical diameter of gas vesicles is within the range of 1-100 nanometers.\n3. The size of gas vesicles can depend on the species of bacteria or archaea.\n4. Environmental conditions can affect the size of gas vesicles.\n5. Factors such as temperature, pH, and nutrient availability can influence the size of gas vesicles.",
    "llama-7b_fact": [
      "Gas vesicles are found in some bacteria and archaea.",
      "The typical diameter of gas vesicles is within the range of 1-100 nanometers.",
      "The size of gas vesicles can depend on the species of bacteria or archaea.",
      "Environmental conditions can affect the size of gas vesicles.",
      "Factors such as temperature, pH, and nutrient availability can influence the size of gas vesicles."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The typical diameter of gas vesicles is within the range of 45-200 nanometers.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "You MUST give a detailed answer to the following question: List BET proteins.",
    "llama-7b_response": "BET (Bromodomain and Extra-terminal domain) proteins are a family of epigenetic regulators that play a crucial role in the regulation of gene expression. BET proteins are characterized by the presence of two distinct domains: the bromodomain, which recognizes acetylated lysine residues on histone tails, and the extra-terminal (ET) domain, which is involved in protein-protein interactions and transcriptional regulation.\n\nHere is a list of BET proteins:\n\n1. BRD2 (Bromodomain and Extra-terminal domain 2)\n2. BRD3 (Bromodomain and Extra-terminal domain 3)\n3. BRD4 (Bromodomain and Extra-terminal domain 4)\n4. BRD5 (Bromodomain and Extra-terminal domain 5)\n5. BRD6 (Bromodomain and Extra-terminal domain 6)\n6. BRD7 (Bromodomain and Extra-terminal domain 7)\n7. BRD8 (Bromodomain and Extra-terminal domain 8)\n8. BRD9 (Bromodomain and Extra-terminal domain 9)\n9. BAP1 (Bromodomain and Extra-terminal domain 1-associated protein 1)\n10. BAP2 (Bromodomain and Extra-terminal domain 2)\n11. BAP3 (Bromodomain and Extra-terminal domain 3)\n12. BAP4 (Bromodomain and Extra-terminal domain 4)\n13. BAP5 (Bromodomain and Extra-terminal domain 5)\n14. BAP6 (Bromodomain and Extra-terminal domain 6)\n15. BAP7 (Bromodomain and Extra-terminal domain 7)\n16. BAP8 (Bromodomain and Extra-terminal domain 8)\n17. BAP9 (Bromodomain and Extra-terminal domain 9)\n1",
    "llama-7b_fact_raw": "1. BET proteins are characterized by bromodomains, which recognize acetylated lysine residues on histone tails.\n2. BET proteins also feature extra-terminal (ET) domains involved in protein-protein interactions and transcriptional regulation.\n3. BRD2 is a member of the BET protein family.\n4. BRD3, BRD4, and BRD9 are identified as BET proteins.\n5. BAP1 is associated with the BET protein family and is known as Bromodomain and Extra-terminal domain 1-associated protein 1.",
    "llama-7b_fact": [
      "BET proteins are characterized by bromodomains, which recognize acetylated lysine residues on histone tails.",
      "BET proteins also feature extra-terminal (ET) domains involved in protein-protein interactions and transcriptional regulation.",
      "BRD2 is a member of the BET protein family.",
      "BRD3, BRD4, and BRD9 are identified as BET proteins.",
      "BAP1 is associated with the BET protein family and is known as Bromodomain and Extra-terminal domain 1-associated protein 1."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: BAP1 stands for BRCA1-associated protein-1 and is not a member of the BET protein family. It is a deubiquitinating enzyme involved in chromatin remodeling and does not have a bromodomain or extra-terminal (ET) domain characteristic of BET proteins.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-7b_response": "There are several algorithms that have been developed for the prediction of protein subcellular localization using deep learning, including:\n\n1. Convolutional Neural Networks (CNNs): CNNs have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as images, and the CNN is trained to classify the images into different subcellular localization categories.\n2. Recurrent Neural Networks (RNNs): RNNs have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as sequences, and the RNN is trained to predict the next amino acid in the sequence based on the previous amino acids.\n3. Long Short-Term Memory (LSTM) Networks: LSTMs have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as sequences, and the LSTM is trained to predict the next amino acid in the sequence based on the previous amino acids.\n4. Generative Adversarial Networks (GANs): GANs have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as sequences, and the GAN is trained to generate new sequences that predict the next amino acid in the sequence based on the previous amino acids.\n5. Transformers: Transformers have been used to predict the subcellular localization of proteins based on their amino acid sequences. In this approach, the amino acid sequences of the proteins are represented as sequences, and the Transformer is trained to predict the next amino acid in the sequence based on the previous amino acids.",
    "llama-7b_fact_raw": "1. Convolutional Neural Networks (CNNs) have been used for predicting protein subcellular localization using deep learning by interpreting amino acid sequences as image-like data.\n2. Recurrent Neural Networks (RNNs) are utilized for protein subcellular localization prediction by treating amino acid sequences as sequential data.\n3. Long Short-Term Memory (LSTM) Networks are another type of deep learning algorithm applied for the prediction of protein subcellular localization from amino acid sequences.\n4. Generative Adversarial Networks (GANs) have been employed to generate new protein sequences to aid in predicting protein subcellular localization.\n5. Transformers, a deep learning algorithm, have been used to predict protein subcellular localization by analyzing amino acid sequences.",
    "llama-7b_fact": [
      "Convolutional Neural Networks (CNNs) have been used for predicting protein subcellular localization using deep learning by interpreting amino acid sequences as image-like data.",
      "Recurrent Neural Networks (RNNs) are utilized for protein subcellular localization prediction by treating amino acid sequences as sequential data.",
      "Long Short-Term Memory (LSTM) Networks are another type of deep learning algorithm applied for the prediction of protein subcellular localization from amino acid sequences.",
      "Generative Adversarial Networks (GANs) have been employed to generate new protein sequences to aid in predicting protein subcellular localization.",
      "Transformers, a deep learning algorithm, have been used to predict protein subcellular localization by analyzing amino acid sequences."
    ],
    "llama-7b_judge_raw": "1. TRUE: Convolutional Neural Networks (CNNs) can indeed be used for predicting protein subcellular localization by interpreting amino acid sequences as image-like data, which can be achieved by transforming the sequences into a format that is suitable for a CNN.\n\n2. TRUE: Recurrent Neural Networks (RNNs) are appropriate for tasks involving sequential data, and amino acid sequences are a type of sequential data. Thus, RNNs can be used for protein subcellular localization prediction.\n\n3. TRUE: Long Short-Term Memory (LSTM) Networks are a specialized kind of RNNs that are designed to remember information for long periods of time. They are applicable for the prediction of protein subcellular localization from amino acid sequences, as this also involves learning from sequential data.\n\n4. UNKNOWN: Generative Adversarial Networks (GANs) are indeed used to generate new protein sequences; however, they are generally used more for the generation of data rather than directly for prediction tasks. There might be indirect applications where the generated sequences are then used to aid in predictions, but the statement is not specific enough to determine the exact context and application.\n\n5. TRUE: Transformers are a type of deep learning model that has been achieving state-of-the-art results in many natural language processing tasks. This architecture can also be applied to the analysis of amino acid sequences for predictions, such as protein subcellular localization since the sequences can be treated similarly to language data, taking into account the long-range dependencies within the sequences.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "You MUST give a detailed answer to the following question: What is MULTOVL?",
    "llama-7b_response": "I'm sorry, but I don't have enough information to answer your question about MULTOVL. Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2660,
    "user_query": "You MUST give a detailed answer to the following question: Can GDF15 be a biomarker for metformin treatment?",
    "llama-7b_response": "GDF15 (growth differentiation factor 15) is a protein that is involved in the regulation of inflammation and metabolism. Metformin is a commonly used medication for the treatment of type 2 diabetes, and it has been shown to reduce the levels of GDF15 in the blood. However, the relationship between GDF15 and metformin treatment is complex and not fully understood.\n\nStudies have shown that GDF15 levels are elevated in individuals with type 2 diabetes, and that metformin treatment can reduce these levels. This suggests that GDF15 may be a biomarker for the effectiveness of metformin treatment. However, other studies have found that GDF15 levels are also elevated in individuals without diabetes, and that metformin treatment does not reduce these levels. This suggests that GDF15 may not be a reliable biomarker for metformin treatment.\n\nFurther research is needed to fully understand the relationship between GDF15 and metformin treatment. It is possible that GDF15 may be a useful biomarker for the effectiveness of metformin treatment in certain populations or under certain conditions. However, more research is needed to determine the role of GDF15 as a biomarker for metformin treatment.",
    "llama-7b_fact_raw": "1. GDF15 is involved in the regulation of inflammation and metabolism.\n2. Metformin is used for the treatment of type 2 diabetes and can reduce GDF15 levels in the blood.\n3. Studies have indicated GDF15 levels are elevated in individuals with type 2 diabetes.\n4. There is evidence that metformin treatment reduces GDF15 levels in individuals with type 2 diabetes.\n5. The relationship between GDF15 levels and metformin treatment in individuals without diabetes is not as clear, with some studies finding no reduction in GDF15 levels after metformin treatment.",
    "llama-7b_fact": [
      "GDF15 is involved in the regulation of inflammation and metabolism.",
      "Metformin is used for the treatment of type 2 diabetes and can reduce GDF15 levels in the blood.",
      "Studies have indicated GDF15 levels are elevated in individuals with type 2 diabetes.",
      "There is evidence that metformin treatment reduces GDF15 levels in individuals with type 2 diabetes.",
      "The relationship between GDF15 levels and metformin treatment in individuals without diabetes is not as clear, with some studies finding no reduction in GDF15 levels after metformin treatment."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Metformin is used for the treatment of type 2 diabetes and can increase GDF15 levels in the blood.\n3. TRUE\n4. FALSE [correction]: There is evidence that metformin treatment increases GDF15 levels in individuals with type 2 diabetes.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "You MUST give a detailed answer to the following question: Is recursive splicing more common in short introns?",
    "llama-7b_response": "Recursive splicing, also known as intron retention, is the process by which an intron is retained in the mature mRNA transcript, rather than being spliced out during the splicing process. Recursive splicing has been observed in a variety of organisms, including plants, animals, and fungi.\n\nThere is some evidence to suggest that recursive splicing may be more common in short introns. Short introns are introns that are relatively small in size, typically ranging from a few hundred to a few thousand base pairs in length. Short introns are more likely to be retained in the mature mRNA transcript because they are less likely to be spliced out due to the time and energy required for the splicing process. Additionally, short introns may be more likely to interfere with the splicing process, which can lead to their retention in the mature mRNA transcript.\n\nHowever, it is worth noting that the relationship between recursive splicing and intron length is complex and not fully understood. Recursive splicing has been observed in introns of varying lengths, and the factors that contribute to recursive splicing are likely to be complex and multifaceted.\n\nIn summary, while there is some evidence to suggest that recursive splicing may be more common in short introns, the relationship between recursive splicing and intron length is complex and not fully understood. Further research is needed to fully understand the factors that contribute to recursive splicing and its prevalence in different types of introns.",
    "llama-7b_fact_raw": "1. Recursive splicing is a process in which an intron is retained in the mature mRNA transcript.\n2. Short introns typically range from a few hundred to a few thousand base pairs in length.\n3. There is evidence to suggest that recursive splicing may be more common in short introns.\n4. Short introns are less likely to be spliced out due to the time and energy requirements of the splicing process.\n5. The relationship between recursive splicing and intron length is not fully understood.",
    "llama-7b_fact": [
      "Recursive splicing is a process in which an intron is retained in the mature mRNA transcript.",
      "Short introns typically range from a few hundred to a few thousand base pairs in length.",
      "There is evidence to suggest that recursive splicing may be more common in short introns.",
      "Short introns are less likely to be spliced out due to the time and energy requirements of the splicing process.",
      "The relationship between recursive splicing and intron length is not fully understood."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Recursive splicing is a process in which a long intron is removed in multiple steps, where an intron is spliced at multiple sites, and parts of the intron are removed in a stepwise fashion, not retained in the mature mRNA transcript.\n2. TRUE\n3. FALSE [correction]: Recursive splicing is generally associated with longer introns rather than short introns. Evidence suggests that recursive splicing helps in the removal of long introns that cannot be spliced out in one step.\n4. FALSE [correction]: Short introns are generally more likely to be efficiently spliced out, not less likely. It is usually the longer introns that have more complex splicing requirements due to their size and the time it takes to remove them.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "You MUST give a detailed answer to the following question: What is the TALE-iD method used for?",
    "llama-7b_response": "The TALE-iD method is used for the identification of transcription factor binding sites (TFBSs) in DNA sequences. TFBSs are short sequences of DNA that are recognized by specific transcription factors (TFs) and play a crucial role in the regulation of gene expression. The TALE-iD method uses a technique called \"transcription factor ChIP-Seq\" to identify TFBSs.\n\nTranscription factor ChIP-Seq involves the following steps:\n\n1. Chromatin immunoprecipitation (ChIP): The TF of interest is immunoprecipitated from the chromatin using an antibody specific to the TF. This isolates the TF-DNA complexes from the rest of the chromatin.\n2. DNA sequencing: The isolated TF-DNA complexes are then sequenced to obtain the DNA sequence around the TF binding site.\n3. Identification of TFBSs: The sequencing data is then analyzed to identify the TFBSs. The TALE-iD method uses a machine learning approach to identify TFBSs by comparing the sequencing data to a large database of known TFBSs.\n\nThe TALE-iD method has several advantages over other methods for the identification of TFBSs, including its ability to identify TFBSs with high specificity and sensitivity, and its ability to identify TFBSs in complex genomic regions. The TALE-iD method has been used to identify TFBSs in a variety of organisms, including humans, mice, and plants, and has been applied to a wide range of research areas, including gene regulation, epigenetics, and drug discovery.",
    "llama-7b_fact_raw": "1. The TALE-iD method is used for the identification of transcription factor binding sites in DNA sequences.\n2. Transcription factor binding sites play a key role in the regulation of gene expression.\n3. The TALE-iD method involves a transcription factor ChIP-Seq technique.\n4. Chromatin immunoprecipitation, or ChIP, involves immunoprecipitating the transcription factor of interest using a specific antibody.\n5. The TALE-iD method employs a machine learning approach to identify TFBSs by comparing sequencing data to known TFBSs databases.",
    "llama-7b_fact": [
      "The TALE-iD method is used for the identification of transcription factor binding sites in DNA sequences.",
      "Transcription factor binding sites play a key role in the regulation of gene expression.",
      "The TALE-iD method involves a transcription factor ChIP-Seq technique.",
      "Chromatin immunoprecipitation, or ChIP, involves immunoprecipitating the transcription factor of interest using a specific antibody.",
      "The TALE-iD method employs a machine learning approach to identify TFBSs by comparing sequencing data to known TFBSs databases."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The TALE-iD method is not commonly associated with identifying transcription factor binding sites; TALEN (Transcription Activator-Like Effector Nucleases) are engineered proteins that can be used for gene editing. Identification of transcription factor binding sites is often performed using techniques such as ChIP-Seq or DNA footprinting.\n2. TRUE\n3. FALSE [correction]: TALE-iD does not involve a transcription factor ChIP-Seq technique. ChIP-Seq is a separate method that can be used for identifying transcription factor binding sites, but it is not related to the TALE technology directly.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "You MUST give a detailed answer to the following question: Which Lisp framework has been developed for image processing?",
    "llama-7b_response": "There are several Lisp frameworks that have been developed for image processing, including:\n\n1. Common Lisp Image Processing Library (CLIP): CLIP is a Common Lisp library for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.\n2. Lisp Machine Image Processing Library (LMIP): LMIP is a Lisp machine library for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.\n3. Lisp Image Processing Library (LIP): LIP is a Lisp library for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.\n4. Lisp Image Processing System (LIPS): LIPS is a Lisp system for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.\n5. Lisp Image Processing Toolkit (LIPT): LIPT is a Lisp toolkit for image processing and analysis. It provides a wide range of image processing functions, including image filtering, morphological operations, and feature extraction.",
    "llama-7b_fact_raw": "1. The Common Lisp Image Processing Library (CLIP) is a library developed for image processing in Common Lisp.\n2. The Lisp Machine Image Processing Library (LMIP) is a Lisp machine library designed for image processing and analysis.\n3. The Lisp Image Processing Library (LIP) is a Lisp library that focuses on image processing and analysis.\n4. The Lisp Image Processing System (LIPS) is a system that has been developed for image processing and analysis in Lisp.\n5. The Lisp Image Processing Toolkit (LIPT) is a toolkit created for image processing and analysis in Lisp.",
    "llama-7b_fact": [
      "The Common Lisp Image Processing Library (CLIP) is a library developed for image processing in Common Lisp.",
      "The Lisp Machine Image Processing Library (LMIP) is a Lisp machine library designed for image processing and analysis.",
      "The Lisp Image Processing Library (LIP) is a Lisp library that focuses on image processing and analysis.",
      "The Lisp Image Processing System (LIPS) is a system that has been developed for image processing and analysis in Lisp.",
      "The Lisp Image Processing Toolkit (LIPT) is a toolkit created for image processing and analysis in Lisp."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information on CLIP, its development, and purpose, it's not possible to confirm its existence or its use in image processing within Common Lisp.\n2. UNKNOWN: The existence of the Lisp Machine Image Processing Library (LMIP) and its design for image processing and analysis cannot be confirmed without further context.\n3. UNKNOWN: The Lisp Image Processing Library (LIP) might exist, but without additional information, it's not possible to verify this statement.\n4. UNKNOWN: To confirm the existence and purpose of the Lisp Image Processing System (LIPS), specific details or additional context would be needed.\n5. UNKNOWN: The statement regarding the Lisp Image Processing Toolkit (LIPT) cannot be confirmed as true or false without additional information.\n\nNote: Unless specific and commonly accepted libraries, systems, or toolkits are referenced, such claims are challenging to verify without additional context or sources. Lisp has been used in the past for various purposes, including image processing, but the precise naming and existence of these given entities cannot be confirmed without more details.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "You MUST give a detailed answer to the following question: How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-7b_response": "30",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2763,
    "user_query": "You MUST give a detailed answer to the following question: Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-7b_response": "estradiol",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2842,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of ZCCHC17?",
    "llama-7b_response": "ZCCHC17 (zinc finger CCCH-type containing 17) is a gene that encodes a protein with a zinc finger domain and a coiled-coil domain. The function of ZCCHC17 is not well understood, but it has been suggested to play a role in the regulation of gene expression.\n\nZinc finger proteins are known to bind to specific DNA sequences, and the zinc finger domain of ZCCHC17 is thought to be involved in binding to DNA. The coiled-coil domain of ZCCHC17 is thought to be involved in protein-protein interactions, and it has been suggested that ZCCHC17 may interact with other proteins to regulate gene expression.\n\nSeveral studies have suggested that ZCCHC17 may play a role in the regulation of immune response and inflammation. For example, one study found that ZCCHC17 was upregulated in the blood of patients with systemic lupus erythematosus, a chronic autoimmune disorder characterized by inflammation. Another study found that ZCCHC17 was upregulated in the brains of mice with experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis, a chronic inflammatory disorder of the central nervous system.\n\nOverall, while the function of ZCCHC17 is not well understood, it is clear that it plays a role in the regulation of gene expression and may be involved in the regulation of immune response and inflammation. Further research is needed to fully understand the role of ZCCHC17 in human health and disease.",
    "llama-7b_fact_raw": "1. ZCCHC17 is a gene that encodes a protein with a zinc finger domain and a coiled-coil domain.\n2. The zinc finger domain of ZCCHC17 is thought to be involved in binding to DNA.\n3. The coiled-coil domain of ZCCHC17 is thought to be involved in protein-protein interactions.\n4. ZCCHC17 has been suggested to play a role in the regulation of immune response and inflammation.\n5. ZCCHC17 was found to be upregulated in the blood of patients with systemic lupus erythematosus and in the brains of mice with experimental autoimmune encephalomyelitis.",
    "llama-7b_fact": [
      "ZCCHC17 is a gene that encodes a protein with a zinc finger domain and a coiled-coil domain.",
      "The zinc finger domain of ZCCHC17 is thought to be involved in binding to DNA.",
      "The coiled-coil domain of ZCCHC17 is thought to be involved in protein-protein interactions.",
      "ZCCHC17 has been suggested to play a role in the regulation of immune response and inflammation.",
      "ZCCHC17 was found to be upregulated in the blood of patients with systemic lupus erythematosus and in the brains of mice with experimental autoimmune encephalomyelitis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "You MUST give a detailed answer to the following question: Which proteins form the nuclear pore basket in human cells?",
    "llama-7b_response": "The nuclear pore complex (NPC) is a large protein complex that regulates the flow of molecules between the nucleus and the cytoplasm in eukaryotic cells. The NPC consists of two main components: the nucleoplasmic side and the cytoplasmic side. The nucleoplasmic side of the NPC is made up of a basket-like structure called the nuclear pore basket, which is formed by a group of proteins called the nucleoporins.\n\nThe nucleoporins are a family of highly conserved proteins that are essential for the proper functioning of the NPC. There are 19 different nucleoporins that have been identified in humans, and they can be divided into three main classes: nucleoporin 100 (Nup100), nucleoporin 153 (Nup153), and nucleoporin 180 (Nup180).\n\nThe nucleoporin 100 (Nup100) proteins are the most abundant nucleoporins in the NPC and are responsible for forming the basket-like structure of the nucleoplasmic side of the NPC. The Nup100 proteins are made up of two subunits, Nup100a and Nup100b, which interact with each other to form a ring-like structure. The Nup100 proteins also interact with other nucleoporins, such as Nup153 and Nup180, to form the nucleoplasmic side of the NPC.\n\nThe nucleoporin 153 (Nup153) proteins are also important components of the NPC and are responsible for regulating the transport of molecules through the NPC. Nup153 proteins interact with both Nup100 and Nup180 proteins to form the nucleoplasmic side of the NPC.\n\nThe nucleoporin 180 (Nup180) proteins are also important components of the NPC and are responsible for regulating the transport of molecules through the NPC. Nup180 proteins interact with both Nup100 and Nup153 proteins to form the nucleoplasmic side of the NPC.",
    "llama-7b_fact_raw": "1. The nuclear pore complex (NPC) in eukaryotic cells consists of a basket-like structure known as the nuclear pore basket on the nucleoplasmic side.\n2. The nuclear pore basket is formed by a group of proteins called nucleoporins.\n3. There have been 19 different nucleoporins identified in humans.\n4. Nucleoporins are divided into three main classes: nucleoporin 100 (Nup100), nucleoporin 153 (Nup153), and nucleoporin 180 (Nup180).\n5. Nup100 proteins form the basket-like structure of the nucleoplasmic side of the NPC and are composed of two subunits, Nup100a and Nup100b, which interact to form a ring-like structure.",
    "llama-7b_fact": [
      "The nuclear pore complex (NPC) in eukaryotic cells consists of a basket-like structure known as the nuclear pore basket on the nucleoplasmic side.",
      "The nuclear pore basket is formed by a group of proteins called nucleoporins.",
      "There have been 19 different nucleoporins identified in humans.",
      "Nucleoporins are divided into three main classes: nucleoporin 100 (Nup100), nucleoporin 153 (Nup153), and nucleoporin 180 (Nup180).",
      "Nup100 proteins form the basket-like structure of the nucleoplasmic side of the NPC and are composed of two subunits, Nup100a and Nup100b, which interact to form a ring-like structure."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There are around 30 different nucleoporins that have been identified in humans, not 19.\n4. FALSE [correction]: Nucleoporins are not specifically divided into these three classes. Instead, there are multiple types of nucleoporins identified by their approximate molecular weight (e.g., Nup98, Nup153, etc.), but the classes are not limited to Nup100, Nup153, and Nup180.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2919,
    "user_query": "You MUST give a detailed answer to the following question: What type of topoisomerase inhibitor is gepotidacin?",
    "llama-7b_response": "Topoisomerase inhibitor",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2943,
    "user_query": "You MUST give a detailed answer to the following question: Describe Canvas SPW",
    "llama-7b_response": "I'm sorry, but I am not familiar with Canvas SPW. Can you provide more context or information about what you are looking for?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2960,
    "user_query": "You MUST give a detailed answer to the following question: List STING agonists.",
    "llama-7b_response": "STING (Stimulator of Interferon Genes) is a cytosolic DNA sensor that plays a crucial role in the innate immune response against viral infections. Upon binding to double-stranded DNA, STING activates a signaling cascade that leads to the activation of interferon (IFN) genes, resulting in the production of type I interferons (IFN-alpha and IFN-beta) and other antiviral cytokines.\n\nAgonists of STING, also known as STING activators or STING agonists, are compounds or agents that stimulate the activity of STING and induce an immune response against viral infections. Here are some examples of STING agonists:\n\n1. Cyclic di-GMP (c-di-GMP): c-di-GMP is a bacterial second messenger that regulates various cellular processes, including DNA repair, biofilm formation, and virulence. Recent studies have shown that c-di-GMP can activate STING and induce an antiviral response in mammalian cells.\n2. CpG oligodeoxynucleotides: CpG oligodeoxynucleotides are short, unmethylated DNA sequences that contain a high proportion of cytosine-phosphate-guanine (CpG) dinucleotides. CpG oligodeoxynucleotides have been shown to activate STING and induce an antiviral response in various cell types.\n3. Poly(I:C): Poly(I:C) is a synthetic analog of double-stranded RNA that can activate STING and induce an antiviral response in mammalian cells. Poly(I:C) has been used in various preclinical and clinical studies as a potential therapeutic agent for the treatment of viral infections.\n4. Resveratrol: Resveratrol is a polyphenolic compound found in various plants, including grapes, berries, and peanuts. Recent studies have shown that resveratrol can activate STING and induce an antiviral response in mammalian cells.\n5.",
    "llama-7b_fact_raw": "1. Cyclic di-GMP (c-di-GMP) is known to activate STING and induce an antiviral response in mammalian cells.\n2. CpG oligodeoxynucleotides are capable of activating STING and inducing an antiviral response in various cell types.\n3. Poly(I:C) is a synthetic analog of double-stranded RNA that can activate STING.\n4. Resveratrol, found in plants like grapes and berries, has been found to activate STING and induce an antiviral response in mammalian cells.\n5. STING is a cytosolic DNA sensor involved in the innate immune response against viral infections.",
    "llama-7b_fact": [
      "Cyclic di-GMP (c-di-GMP) is known to activate STING and induce an antiviral response in mammalian cells.",
      "CpG oligodeoxynucleotides are capable of activating STING and inducing an antiviral response in various cell types.",
      "Poly(I:C) is a synthetic analog of double-stranded RNA that can activate STING.",
      "Resveratrol, found in plants like grapes and berries, has been found to activate STING and induce an antiviral response in mammalian cells.",
      "STING is a cytosolic DNA sensor involved in the innate immune response against viral infections."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclic di-GMP (c-di-GMP) is known to activate the second messenger cyclic GMP-AMP synthase (cGAS), not STING directly. cGAS produces cGAMP which then activates STING.\n2. TRUE\n3. FALSE [correction]: Poly(I:C) is a synthetic analog of double-stranded RNA that can activate Toll-like receptor 3 (TLR3), MDA5, and RIG-I like receptors, but not STING directly.\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2964,
    "user_query": "You MUST give a detailed answer to the following question: Describe SLIC-CAGE",
    "llama-7b_response": "SLIC-CAGE is an acronym that stands for \"Single Layer Integrated Circuit - Computer-Aided Geometric Engineering.\" It is a computer-aided design (CAD) software tool that is used for the design and analysis of integrated circuits (ICs) and other microelectronic devices.\n\nThe SLIC-CAGE software is used to create detailed 2D and 3D models of ICs and other microelectronic devices. These models can be used to simulate and analyze the performance of the devices, including their electrical characteristics, thermal behavior, and reliability.\n\nThe SLIC-CAGE software is designed to be user-friendly and intuitive, making it easy for designers and engineers to create accurate and detailed models of ICs and other microelectronic devices. The software includes a range of features and tools that can be used to customize and optimize the design of the devices, including the ability to import and export data in a variety of formats.\n\nOverall, SLIC-CAGE is a valuable tool for the design and analysis of integrated circuits and other microelectronic devices, and it is widely used in the semiconductor industry.",
    "llama-7b_fact_raw": "1. SLIC-CAGE stands for \"Single Layer Integrated Circuit - Computer-Aided Geometric Engineering.\"\n2. SLIC-CAGE is a computer-aided design (CAD) software tool.\n3. The software is used in the design and analysis of integrated circuits (ICs) and other microelectronic devices.\n4. SLIC-CAGE enables the simulation and analysis of device performance, including electrical characteristics, thermal behavior, and reliability.\n5. The software offers features and tools for customization and optimization in the design process of microelectronic devices.",
    "llama-7b_fact": [
      "SLIC-CAGE stands for \"Single Layer Integrated Circuit - Computer-Aided Geometric Engineering.\"",
      "SLIC-CAGE is a computer-aided design (CAD) software tool.",
      "The software is used in the design and analysis of integrated circuits (ICs) and other microelectronic devices.",
      "SLIC-CAGE enables the simulation and analysis of device performance, including electrical characteristics, thermal behavior, and reliability.",
      "The software offers features and tools for customization and optimization in the design process of microelectronic devices."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: There is no well-known acronym or technology known as SLIC-CAGE that stands for \"Single Layer Integrated Circuit - Computer-Aided Geometric Engineering.\" \n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: Without any widely recognized information about something referred to as SLIC-CAGE, the veracity of the statements relating to specifics of the software is not possible to ascertain. The initial definition provided in statement 1 appears to be fabricated or incorrect, which means there is not enough information to accurately judge the following statements.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "You MUST give a detailed answer to the following question: What are the roles of LEM-3?",
    "llama-7b_response": "LEM-3, also known as leucine-rich repeat-containing G protein-coupled receptor 3, is a protein that belongs to the family of G protein-coupled receptors (GPCRs). GPCRs are a large family of receptors that are activated by a variety of extracellular signals, including hormones, neurotransmitters, and other signaling molecules.\n\nThe exact function of LEM-3 is not fully understood, but it is thought to play a role in the regulation of various physiological processes, including cell growth, differentiation, and apoptosis (programmed cell death). Studies have shown that LEM-3 may be involved in the regulation of the Wnt signaling pathway, which plays a crucial role in the control of cell proliferation, differentiation, and tissue development.\n\nIn addition to its role in the Wnt signaling pathway, LEM-3 has also been implicated in the regulation of other signaling pathways, including the TGF-β signaling pathway, which is involved in the regulation of cell growth, differentiation, and apoptosis.\n\nOverall, LEM-3 appears to play a critical role in the regulation of various physiological processes, and its dysregulation has been implicated in the development of various diseases, including cancer. Further research is needed to fully understand the functions of LEM-3 and its role in human health and disease.",
    "llama-7b_fact_raw": "1. LEM-3 is a protein that belongs to the family of G protein-coupled receptors (GPCRs).\n2. G protein-coupled receptors (GPCRs) are activated by a variety of extracellular signals such as hormones, neurotransmitters, and other signaling molecules.\n3. LEM-3 is thought to play a role in regulating cell growth, differentiation, and apoptosis (programmed cell death).\n4. LEM-3 may be involved in the regulation of the Wnt signaling pathway, which is important for cell proliferation, differentiation, and tissue development.\n5. LEM-3 has also been implicated in the regulation of the TGF-β signaling pathway.",
    "llama-7b_fact": [
      "LEM-3 is a protein that belongs to the family of G protein-coupled receptors (GPCRs).",
      "G protein-coupled receptors (GPCRs) are activated by a variety of extracellular signals such as hormones, neurotransmitters, and other signaling molecules.",
      "LEM-3 is thought to play a role in regulating cell growth, differentiation, and apoptosis (programmed cell death).",
      "LEM-3 may be involved in the regulation of the Wnt signaling pathway, which is important for cell proliferation, differentiation, and tissue development.",
      "LEM-3 has also been implicated in the regulation of the TGF-β signaling pathway."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: LEM-3 is not a protein that belongs to the family of G protein-coupled receptors (GPCRs). LEM domain-containing protein 3 (LEM-3) is actually a nuclease involved in DNA repair processes.\n2. TRUE\n3. FALSE [correction]: While LEM-3 is involved in cellular processes related to DNA repair, the statement that it regulates cell growth, differentiation, and apoptosis is too specific without the context of LEM-3's DNA repair function, and typically such functions are not attributed to LEM-3.\n4. UNKNOWN: Without specific references to scientific studies, it is difficult to verify the involvement of LEM-3 in the Wnt signaling pathway. However, LEM-3 is not well known for regulating this pathway.\n5. UNKNOWN: Similar to the above, the role of LEM-3 in the TGF-β signaling pathway cannot be determined without specific scientific literature references. Typically, proteins well-characterized in TGF-β pathway regulation are distinct from those in DNA repair pathways.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of tmVar",
    "llama-7b_response": "I'm sorry, but I don't have information on the releases of tmVar. Can you provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3018,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of somatic mutations in normal cells?",
    "llama-7b_response": "1000 Genomes Project",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3037,
    "user_query": "You MUST give a detailed answer to the following question: Are there graph kernel libraries available implemented in JAVA?",
    "llama-7b_response": "Yes, there are several graph kernel libraries available implemented in Java. Some of the popular ones include:\n\n1. JGraphT: JGraphT is a Java library for working with graphs and networks. It provides a high-level API for creating and manipulating graphs, as well as for querying and analyzing their properties. JGraphT supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs.\n2. NetworkX: NetworkX is a Python library for working with graphs and networks. It provides a high-level API for creating and manipulating graphs, as well as for querying and analyzing their properties. NetworkX supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs. NetworkX has a Java port called NetworkX-Java, which provides a Java API for working with graphs and networks.\n3. Graph5J: Graph5J is a Java library for working with graphs and networks. It provides a high-level API for creating and manipulating graphs, as well as for querying and analyzing their properties. Graph5J supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs.\n4. JUNG: JUNG is a Java library for working with graphs and networks. It provides a high-level API for creating and manipulating graphs, as well as for querying and analyzing their properties. JUNG supports various types of graphs, including undirected and directed graphs, weighted and unweighted graphs, and multigraphs.\n\nThese are just a few examples of the many graph kernel libraries available in Java. Each library has its own strengths and weaknesses, and the choice of which one to use will depend on the specific requirements of the application.",
    "llama-7b_fact_raw": "1. JGraphT is a Java library designed for working with graphs and networks.\n2. JGraphT includes features for creating, manipulating, querying, and analyzing properties of various graph types.\n3. Although NetworkX is primarily a Python library, it has a Java port called NetworkX-Java.\n4. Graph5J is another Java library for graph-related operations.\n5. JUNG is a Java library that supports the handling of graphs and networks, including multiple graph types.\n\nNote: The listed fact about NetworkX having a Java port may be incorrect as of the knowledge cutoff date. There is no widely-known or officially supported Java port of the NetworkX library. Therefore, the statement about NetworkX-Java providing a Java API may not be a verifiable fact.",
    "llama-7b_fact": [
      "JGraphT is a Java library designed for working with graphs and networks.",
      "JGraphT includes features for creating, manipulating, querying, and analyzing properties of various graph types.",
      "Although NetworkX is primarily a Python library, it has a Java port called NetworkX-Java.",
      "Graph5J is another Java library for graph-related operations.",
      "JUNG is a Java library that supports the handling of graphs and networks, including multiple graph types.",
      "te: The listed fact about NetworkX having a Java port may be incorrect as of the knowledge cutoff date. There is no widely-known or officially supported Java port of the NetworkX library. Therefore, the statement about NetworkX-Java providing a Java API may not be a verifiable fact."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: As of the knowledge cutoff date, there is no widely-known or officially supported Java port of the NetworkX library known as NetworkX-Java.\n4. UNKNOWN: Without additional context, it is not possible to verify the existence or the features of a library called Graph5J.\n5. TRUE\n6. TRUE: This note correctly identifies a potential error concerning the existence of a Java port for NetworkX.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3045,
    "user_query": "You MUST give a detailed answer to the following question: List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-7b_response": "Sure, here are the four advances integrated into the SHERLOCKv2 platform:\n\n1. Machine learning algorithms: The SHERLOCKv2 platform uses machine learning algorithms to analyze large amounts of data and identify patterns and anomalies. These algorithms are integrated into the platform to provide real-time threat detection and response capabilities.\n2. Behavioral analytics: The SHERLOCKv2 platform uses behavioral analytics to detect and respond to advanced threats. Behavioral analytics involves analyzing the behavior of users, devices, and applications to identify anomalies and potential threats.\n3. User and entity behavior analytics (UEBA): The SHERLOCKv2 platform uses user and entity behavior analytics (UEBA) to detect and respond to advanced threats. UEBA involves analyzing the behavior of users and entities within an organization to identify potential threats and anomalies.\n4. Artificial intelligence (AI): The SHERLOCKv2 platform uses artificial intelligence (AI) to analyze large amounts of data and identify patterns and anomalies. AI is integrated into the platform to provide real-time threat detection and response capabilities.\n\nOverall, the SHERLOCKv2 platform integrates these four advances to provide a comprehensive solution for detecting and responding to advanced threats. By leveraging machine learning algorithms, behavioral analytics, UEBA, and AI, the platform is able to provide real-time threat detection and response capabilities to help organizations protect their networks and data from advanced threats.",
    "llama-7b_fact_raw": "1. The SHERLOCKv2 platform integrates machine learning algorithms to provide real-time threat detection and response capabilities.\n2. Behavioral analytics are used in the SHERLOCKv2 platform to detect and respond to advanced threats by analyzing user, device, and application behavior.\n3. The SHERLOCKv2 platform employs user and entity behavior analytics (UEBA) to identify potential threats and anomalies within an organization.\n4. Artificial intelligence (AI) is integrated into the SHERLOCKv2 platform to analyze data and identify patterns and anomalies for real-time threat detection and response.",
    "llama-7b_fact": [
      "The SHERLOCKv2 platform integrates machine learning algorithms to provide real-time threat detection and response capabilities.",
      "Behavioral analytics are used in the SHERLOCKv2 platform to detect and respond to advanced threats by analyzing user, device, and application behavior.",
      "The SHERLOCKv2 platform employs user and entity behavior analytics (UEBA) to identify potential threats and anomalies within an organization.",
      "Artificial intelligence (AI) is integrated into the SHERLOCKv2 platform to analyze data and identify patterns and anomalies for real-time threat detection and response."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific context or additional information about the SHERLOCKv2 platform, it is not possible to determine the veracity of this statement.\n2. UNKNOWN: Similarly, the use of behavioral analytics in the SHERLOCKv2 platform cannot be confirmed or denied without further information.\n3. UNKNOWN: The implementation of user and entity behavior analytics (UEBA) in the SHERLOCKv2 platform is also unknown without more details.\n4. UNKNOWN: The integration of artificial intelligence (AI) and its role in data analysis for threat detection in the SHERLOCKv2 platform cannot be verified without additional context.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "You MUST give a detailed answer to the following question: Describe the bartender algorithm",
    "llama-7b_response": "The bartender algorithm, also known as the bartender problem, is a classic problem in computer science that involves scheduling tasks in a way that minimizes the total time required to complete them.\n\nThe problem is inspired by the task of a bartender who has to serve drinks to a group of patrons in a bar. Each patron has a preference for a specific type of drink, and the bartender has to serve the drinks in a way that satisfies all the patrons' preferences.\n\nThe bartender problem can be modeled as a scheduling problem, where the tasks are the different types of drinks, and the preferences of the patrons are the constraints. The goal is to find a schedule that minimizes the total time required to serve all the drinks.\n\nThe bartender algorithm is a simple greedy algorithm that solves the bartender problem. The algorithm works as follows:\n\n1. Start with an empty schedule, which means that no drinks have been served yet.\n2. For each patron, find the earliest time at which their preferred drink can be served.\n3. Add the patron's preferred drink to the schedule at the earliest time found in step 2.\n4. Repeat steps 2 and 3 for all patrons.\n5. The resulting schedule is the optimal solution to the bartender problem.\n\nThe bartender algorithm has a time complexity of O(n\\*m), where n is the number of patrons and m is the number of drinks. This is because the algorithm visits each patron and each drink once, and the time complexity of each visit is O(n) and O(m), respectively.\n\nThe bartender algorithm is a simple and efficient solution to the bartender problem, but it may not always produce the optimal solution. In some cases, a more sophisticated algorithm may be needed to find the optimal solution.",
    "llama-7b_fact_raw": "1. The bartender algorithm, also known as the bartender problem, is a computer science problem focused on minimizing the total time for task completion.\n2. The problem is based on a bartender who needs to serve drinks according to patrons' preferences.\n3. The bartender problem is modeled as a scheduling problem with the tasks being different types of drinks.\n4. The bartender algorithm is a greedy algorithm that seeks to find the earliest time a patron's preferred drink can be served and adds it to the schedule.\n5. The time complexity of the bartender algorithm is O(n*m), where n is the number of patrons and m is the number of drinks.",
    "llama-7b_fact": [
      "The bartender algorithm, also known as the bartender problem, is a computer science problem focused on minimizing the total time for task completion.",
      "The problem is based on a bartender who needs to serve drinks according to patrons' preferences.",
      "The bartender problem is modeled as a scheduling problem with the tasks being different types of drinks.",
      "The bartender algorithm is a greedy algorithm that seeks to find the earliest time a patron's preferred drink can be served and adds it to the schedule.",
      "The time complexity of the bartender algorithm is O(n*m), where n is the number of patrons and m is the number of drinks."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided seem to describe a hypothetical or metaphorical algorithm and do not correspond to any known standard problem or algorithm in computer science under the \"bartender algorithm\" or \"bartender problem\" names. Without a specific context or reference, it is not possible to verify the provided details as either true or false.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "You MUST give a detailed answer to the following question: Which web-based pedigree editors are available?",
    "llama-7b_response": "There are several web-based pedigree editors available, including:\n\n1. MyHeritage: MyHeritage is a popular web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n2. Ancestry: Ancestry is another popular web-based genealogy platform that offers a range of tools for creating and managing family trees, searching for ancestors, and sharing information with other family members.\n3. My Family: My Family is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n4. Geni: Geni is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n5. WeRelate: WeRelate is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n6. WikiTree: WikiTree is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.\n7. My Life: My Life is a web-based genealogy platform that allows users to create and manage their family trees, search for ancestors, and collaborate with other family members.",
    "llama-7b_fact_raw": "1. MyHeritage is a web-based genealogy platform.\n2. Ancestry provides tools for creating and managing family trees and searching for ancestors online.\n3. Geni is a web-based platform for creating, managing, and collaborating on family trees.\n4. WeRelate is an online genealogy platform that allows family tree creation and management.\n5. WikiTree is a web-based genealogy platform where users can collaborate on family trees.",
    "llama-7b_fact": [
      "MyHeritage is a web-based genealogy platform.",
      "Ancestry provides tools for creating and managing family trees and searching for ancestors online.",
      "Geni is a web-based platform for creating, managing, and collaborating on family trees.",
      "WeRelate is an online genealogy platform that allows family tree creation and management.",
      "WikiTree is a web-based genealogy platform where users can collaborate on family trees."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "You MUST give a detailed answer to the following question: Which curated databases exist for spider-venom toxins?",
    "llama-7b_response": "There are several curated databases that exist for spider venom toxins. Here are some of the most notable ones:\n\n1. Spider Toxin Database (STD): The Spider Toxin Database is a comprehensive database of spider venom toxins that was developed by researchers at the University of Melbourne in Australia. The database contains information on the chemical structure, biological activity, and pharmacological effects of spider venom toxins. It also includes information on the species of spider that produces the toxin and the prey species that the spider targets. The database is available online and can be accessed through the University of Melbourne website.\n2. World Spider Catalog (WSC): The World Spider Catalog (WSC) is a comprehensive database of spider species that was developed by researchers at the American Museum of Natural History in New York City. The database includes information on the biology, distribution, and taxonomy of spider species, as well as information on the venom of some species. The database is available online and can be accessed through the American Museum of Natural History website.\n3. Arachnology Database: The Arachnology Database is a comprehensive database of spider species that was developed by researchers at the University of California, Riverside. The database includes information on the biology, distribution, and taxonomy of spider species, as well as information on the venom of some species. The database is available online and can be accessed through the University of California, Riverside website.\n4. VenomDB: VenomDB is a database of venom peptides and proteins that was developed by researchers at the University of Melbourne in Australia. The database contains information on the chemical structure, biological activity, and pharmacological effects of venom peptides and proteins from a wide range of organisms, including spiders. The database is available online and can be accessed through the University of Melbourne website.\n\nThese are just a few examples of the many curated databases that exist for spider venom toxins. Each of these databases provides valuable information for researchers studying the biology and pharmacology of spider venom toxins.",
    "llama-7b_fact_raw": "1. The Spider Toxin Database (STD) was developed by researchers at the University of Melbourne in Australia and provides information on spider venom toxins.\n2. The World Spider Catalog (WSC) is a comprehensive database developed by researchers at the American Museum of Natural History in New York City and includes venom information for some spider species.\n3. The Arachnology Database provides information on spider biology, distribution, taxonomy, and venom, and was developed by researchers at the University of California, Riverside.\n4. VenomDB is a database containing information on venom peptides and proteins from various organisms, including spiders, and was developed by researchers at the University of Melbourne in Australia.",
    "llama-7b_fact": [
      "The Spider Toxin Database (STD) was developed by researchers at the University of Melbourne in Australia and provides information on spider venom toxins.",
      "The World Spider Catalog (WSC) is a comprehensive database developed by researchers at the American Museum of Natural History in New York City and includes venom information for some spider species.",
      "The Arachnology Database provides information on spider biology, distribution, taxonomy, and venom, and was developed by researchers at the University of California, Riverside.",
      "VenomDB is a database containing information on venom peptides and proteins from various organisms, including spiders, and was developed by researchers at the University of Melbourne in Australia."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE – While the primary focus of the World Spider Catalog is taxonomy, references within can contain venom information for some species.\n3. UNKNOWN – There isn't a well-known \"Arachnology Database\" specifically attributed to researchers at the University of California, Riverside, so the accuracy of this statement cannot be confirmed. The University of California, Riverside does have an Entomology department with expertise in arachnology, but specific database details are unclear.\n4. FALSE [correction]: VenomKB (Venom Knowledge Base), not VenomDB, is a comprehensive database containing information on venom peptides and proteins from various organisms, including spiders. VenomKB was developed by researchers at the Institute for Immunology and Informatics at the University of Rhode Island, not the University of Melbourne in Australia.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3111,
    "user_query": "You MUST give a detailed answer to the following question: Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-7b_response": "Axitinib is a tyrosine kinase inhibitor that is used to treat advanced renal cell carcinoma and advanced melanoma. It works by inhibiting the activity of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, which can help to reduce the growth and spread of cancer cells.\n\nThere have been several clinical trials that have investigated the use of axitinib in the treatment of pancreatic cancer. One study, known as the PANCH trial, found that the use of axitinib in combination with gemcitabine and nab-paclitaxel did not improve overall survival compared to gemcitabine and nab-paclitaxel alone in patients with metastatic pancreatic ductal adenocarcinoma.\n\nAnother study, known as the AXIS trial, found that the use of axitinib in combination with gemcitabine and nab-paclitaxel did not improve overall survival compared to gemcitabine and nab-paclitaxel alone in patients with metastatic pancreatic ductal adenocarcinoma. However, the study also found that axitinib did improve progression-free survival compared to gemcitabine and nab-paclitaxel alone.\n\nOverall, the evidence regarding the use of axitinib in the treatment of pancreatic cancer is mixed. While some studies have found that it may improve progression-free survival, other studies have not found any benefit in terms of overall survival. More research is needed to fully understand the role of axitinib in the treatment of pancreatic cancer.",
    "llama-7b_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor used to treat advanced renal cell carcinoma and advanced melanoma.\n2. Axitinib works by inhibiting the activity of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors.\n3. The PANCH trial investigated the use of axitinib in combination with gemcitabine and nab-paclitaxel for pancreatic cancer treatment.\n4. The PANCH trial concluded that axitinib with gemcitabine and nab-paclitaxel did not improve overall survival in metastatic pancreatic ductal adenocarcinoma compared to the control.\n5. The AXIS trial found that axitinib improved progression-free survival but not overall survival in metastatic pancreatic ductal adenocarcinoma when compared to gemcitabine and nab-paclitaxel alone.",
    "llama-7b_fact": [
      "Axitinib is a tyrosine kinase inhibitor used to treat advanced renal cell carcinoma and advanced melanoma.",
      "Axitinib works by inhibiting the activity of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors.",
      "The PANCH trial investigated the use of axitinib in combination with gemcitabine and nab-paclitaxel for pancreatic cancer treatment.",
      "The PANCH trial concluded that axitinib with gemcitabine and nab-paclitaxel did not improve overall survival in metastatic pancreatic ductal adenocarcinoma compared to the control.",
      "The AXIS trial found that axitinib improved progression-free survival but not overall survival in metastatic pancreatic ductal adenocarcinoma when compared to gemcitabine and nab-paclitaxel alone."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Axitinib is a tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, but it is not typically used to treat advanced melanoma.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The AXIS trial found that axitinib improved progression-free survival but not overall survival in patients with advanced renal cell carcinoma when compared to sorafenib, not to gemcitabine and nab-paclitaxel for pancreatic cancer.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3113,
    "user_query": "You MUST give a detailed answer to the following question: Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-7b_response": "Myosin-light-chain phosphatase (MLP) is an enzyme that dephosphorylates and inactivates myosin-light-chain kinase (MLCK), which is involved in the regulation of actin-myosin interactions in smooth muscle cells. MLP has been shown to play a role in the regulation of F-actin dynamics in various cell types, including smooth muscle cells.\n\nOne mechanism by which MLP regulates F-actin dynamics is through its interaction with the Arp2/3 complex, which is a key regulator of actin polymerization. The Arp2/3 complex is activated by WASP (Wiskott-Aldrich Syndrome Protein) and WASP-like proteins, which are proteins that bind to and activate the Arp2/3 complex. MLP has been shown to bind to and inhibit the activity of the Arp2/3 complex, which in turn inhibits the polymerization of F-actin.\n\nAnother mechanism by which MLP regulates F-actin dynamics is through its interaction with the formin family of proteins, which are involved in the assembly and elongation of F-actin. MLP has been shown to bind to and inhibit the activity of the formin family of proteins, which in turn inhibits the assembly and elongation of F-actin.\n\nIn summary, MLP regulates F-actin dynamics through its interaction with the Arp2/3 complex and the formin family of proteins, which are key regulators of actin-myosin interactions in smooth muscle cells.",
    "llama-7b_fact_raw": "1. Myosin-light-chain phosphatase (MLP) dephosphorylates and inactivates myosin-light-chain kinase (MLCK), which is involved in regulating actin-myosin interactions in smooth muscle cells.\n2. MLP plays a role in the regulation of F-actin dynamics in various cell types, including smooth muscle cells.\n3. MLP regulates F-actin dynamics through its interaction with the Arp2/3 complex, inhibiting the complex's activity and thus polymerization of F-actin.\n4. The Arp2/3 complex is activated by WASP and WASP-like proteins, which are involved in actin polymerization.\n5. MLP also interacts with the formin family of proteins, binding to them to inhibit their activity, which affects the assembly and elongation of F-actin.",
    "llama-7b_fact": [
      "Myosin-light-chain phosphatase (MLP) dephosphorylates and inactivates myosin-light-chain kinase (MLCK), which is involved in regulating actin-myosin interactions in smooth muscle cells.",
      "MLP plays a role in the regulation of F-actin dynamics in various cell types, including smooth muscle cells.",
      "MLP regulates F-actin dynamics through its interaction with the Arp2/3 complex, inhibiting the complex's activity and thus polymerization of F-actin.",
      "The Arp2/3 complex is activated by WASP and WASP-like proteins, which are involved in actin polymerization.",
      "MLP also interacts with the formin family of proteins, binding to them to inhibit their activity, which affects the assembly and elongation of F-actin."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Myosin-light-chain phosphatase (MLP) dephosphorylates and inactivates myosin light chain (MLC), which is involved in regulating actin-myosin interactions in smooth muscle cells. Myosin-light-chain kinase (MLCK) phosphorylates and activates MLC.\n2. TRUE\n3. FALSE [correction]: Myosin-light-chain phosphatase (MLP) has not been primarily known to regulate F-actin dynamics through direct interaction with the Arp2/3 complex. Its primary function is to dephosphorylate MLC. Regulation of F-actin dynamics through Arp2/3 complex would typically involve other proteins.\n4. TRUE\n5. FALSE [correction]: While MLP does interact with proteins to regulate muscular contractions, there is no well-established evidence that it directly interacts with the formin family of proteins to inhibit their activity. Formins are indeed involved in the assembly and elongation of F-actin, but their regulation is typically separate from the function of MLP.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3125,
    "user_query": "You MUST give a detailed answer to the following question: How many pseudokinases are there in the human kinome?",
    "llama-7b_response": "There are approximately 500 pseudokinases in the human kinome.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3139,
    "user_query": "You MUST give a detailed answer to the following question: List 3 apoE mimetics.",
    "llama-7b_response": "ApoE (apolipoprotein E) is a protein that plays an important role in the transport and metabolism of lipids in the bloodstream. It is a major protein component of high-density lipoproteins (HDL), which are responsible for transporting cholesterol from the liver to the liver for excretion.\n\nApoE mimetics are compounds that mimic the function of apoE in the transport and metabolism of lipids. Here are three examples of apoE mimetics:\n\n1. Pravastatin: Pravastatin is a cholesterol-lowering medication that works by inhibiting the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. Pravastatin has been shown to increase the levels of HDL cholesterol and reduce the levels of low-density lipoprotein (LDL) cholesterol, both of which are beneficial for cardiovascular health.\n2. Resveratrol: Resveratrol is a compound found in the skin of red grapes and other fruits and vegetables. It has been shown to have anti-inflammatory and antioxidant properties, and has been suggested to have potential benefits for cardiovascular health. Resveratrol has been shown to increase the levels of HDL cholesterol and reduce the levels of LDL cholesterol, both of which are beneficial for cardiovascular health.\n3. Curcumin: Curcumin is a compound found in the spice turmeric. It has been shown to have anti-inflammatory and antioxidant properties, and has been suggested to have potential benefits for cardiovascular health. Curcumin has been shown to increase the levels of HDL cholesterol and reduce the levels of LDL cholesterol, both of which are beneficial for cardiovascular health.\n\nOverall, apoE mimetics are compounds that mimic the function of apoE in the transport and metabolism of lipids. Pravastatin, resveratrol, and curcumin are examples of apoE mimetics that have been shown to have potential benefit",
    "llama-7b_fact_raw": "1. Pravastatin is a cholesterol-lowering medication that inhibits the enzyme HMG-CoA reductase.\n2. Resveratrol is a compound found in the skin of red grapes that has been shown to have anti-inflammatory and antioxidant properties.\n3. Curcumin is a compound found in turmeric that has been shown to have anti-inflammatory and antioxidant properties.\n4. ApoE mimetics are compounds that mimic the function of apolipoprotein E in lipid transport and metabolism.\n5. Pravastatin, resveratrol, and curcumin are examples of compounds that have been identified as apoE mimetics.",
    "llama-7b_fact": [
      "Pravastatin is a cholesterol-lowering medication that inhibits the enzyme HMG-CoA reductase.",
      "Resveratrol is a compound found in the skin of red grapes that has been shown to have anti-inflammatory and antioxidant properties.",
      "Curcumin is a compound found in turmeric that has been shown to have anti-inflammatory and antioxidant properties.",
      "ApoE mimetics are compounds that mimic the function of apolipoprotein E in lipid transport and metabolism.",
      "Pravastatin, resveratrol, and curcumin are examples of compounds that have been identified as apoE mimetics."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Pravastatin, resveratrol, and curcumin have not all been identified as apoE mimetics. Pravastatin is a statin drug for cholesterol management, resveratrol is a compound found in red grapes with potential health benefits, and curcumin is a compound in turmeric with anti-inflammatory and antioxidant properties. ApoE mimetics specifically mimic apolipoprotein E functions, which is not a known attribute of resveratrol and curcumin.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "You MUST give a detailed answer to the following question: What are there sex differences in SAMHD1 activity?",
    "llama-7b_response": "Sex differences in SAMHD1 activity have not been extensively studied, but there is some evidence to suggest that there may be differences between men and women.\n\nSAMHD1 is an important regulator of the HIV-1 life cycle, and its activity is critical for controlling viral replication. Studies have shown that SAMHD1 inhibits HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs), which are required for HIV-1 reverse transcription.\n\nWhile the overall function of SAMHD1 is similar in men and women, there may be some differences in the regulation of SAMHD1 activity between the two sexes. For example, studies have shown that estrogen can regulate SAMHD1 activity in certain cell types, such as breast cancer cells. In these cells, estrogen has been shown to increase SAMHD1 activity, which in turn inhibits HIV-1 replication.\n\nHowever, the role of estrogen in regulating SAMHD1 activity in other cell types, such as immune cells, has not been well studied. It is also possible that there may be other factors that influence SAMHD1 activity in men and women differently.\n\nOverall, while there is some evidence to suggest that there may be sex differences in SAMHD1 activity, more research is needed to fully understand the role of SAMHD1 in the regulation of HIV-1 replication in men and women.",
    "llama-7b_fact_raw": "1. SAMHD1 is an important regulator of the HIV-1 life cycle.\n2. SAMHD1 inhibits HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs) necessary for HIV-1 reverse transcription.\n3. Studies suggest that estrogen can regulate SAMHD1 activity in certain cell types, like breast cancer cells.\n4. In breast cancer cells, estrogen has been shown to increase SAMHD1 activity, which inhibits HIV-1 replication.\n5. The effect of estrogen on SAMHD1 activity in immune cells has not been well studied.",
    "llama-7b_fact": [
      "SAMHD1 is an important regulator of the HIV-1 life cycle.",
      "SAMHD1 inhibits HIV-1 replication by depleting the intracellular pool of deoxynucleoside triphosphates (dNTPs) necessary for HIV-1 reverse transcription.",
      "Studies suggest that estrogen can regulate SAMHD1 activity in certain cell types, like breast cancer cells.",
      "In breast cancer cells, estrogen has been shown to increase SAMHD1 activity, which inhibits HIV-1 replication.",
      "The effect of estrogen on SAMHD1 activity in immune cells has not been well studied."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWhile statements 1 and 2 are generally consistent with scientific knowledge about SAMHD1's role in HIV-1 replication, statements 3 to 5 involve more specific claims about the interaction between estrogen and SAMHD1, especially in specific cell types or contexts like breast cancer or immune cells. Without specific references to relevant scientific research that supports these claims, we cannot determine the veracity of statements 3 to 5; thus, they remain UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "You MUST give a detailed answer to the following question: Does RUNX2 inhibit astrocyte differentiation?",
    "llama-7b_response": "Yes, RUNX2 has been shown to inhibit astrocyte differentiation.\n\nRUNX2 is a transcription factor that plays a crucial role in the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes, which are responsible for myelin formation in the central nervous system (CNS). However, the role of RUNX2 in the differentiation of astrocytes, which are the most abundant glial cells in the CNS, is less clear.\n\nSeveral studies have shown that RUNX2 can inhibit astrocyte differentiation. For example, a study published in the journal Molecular and Cellular Biology in 2003 found that overexpression of RUNX2 in OPCs inhibited their differentiation into mature oligodendrocytes and promoted their differentiation into astrocytes in vitro. Another study published in the journal Glia in 2011 found that RUNX2 was downregulated during the differentiation of OPCs into mature oligodendrocytes, and that overexpression of RUNX2 in OPCs inhibited their differentiation into mature oligodendrocytes and promoted their differentiation into astrocytes in vitro.\n\nThese findings suggest that RUNX2 may play a role in the regulation of astrocyte differentiation by inhibiting the differentiation of OPCs into mature oligodendrocytes and promoting their differentiation into astrocytes. However, further studies are needed to fully understand the mechanisms by which RUNX2 regulates astrocyte differentiation.",
    "llama-7b_fact_raw": "1. RUNX2 is a transcription factor involved in the differentiation of oligodendrocyte progenitor cells into mature oligodendrocytes for myelin formation in the CNS.\n2. RUNX2 inhibition of astrocyte differentiation has been supported by several studies.\n3. A study published in the journal Molecular and Cellular Biology in 2003 found that overexpression of RUNX2 inhibited the differentiation of OPCs into mature oligodendrocytes.\n4. The same 2003 study reported that RUNX2 overexpression promoted differentiation into astrocytes in vitro.\n5. In 2011, a study published in the journal Glia discovered that RUNX2 was downregulated during the differentiation of OPCs into mature oligodendrocytes.",
    "llama-7b_fact": [
      "RUNX2 is a transcription factor involved in the differentiation of oligodendrocyte progenitor cells into mature oligodendrocytes for myelin formation in the CNS.",
      "RUNX2 inhibition of astrocyte differentiation has been supported by several studies.",
      "A study published in the journal Molecular and Cellular Biology in 2003 found that overexpression of RUNX2 inhibited the differentiation of OPCs into mature oligodendrocytes.",
      "The same 2003 study reported that RUNX2 overexpression promoted differentiation into astrocytes in vitro.",
      "In 2011, a study published in the journal Glia discovered that RUNX2 was downregulated during the differentiation of OPCs into mature oligodendrocytes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: RUNX2 is a transcription factor involved in osteoblast differentiation and bone formation, not differentiation of oligodendrocyte progenitor cells into mature oligodendrocytes. The transcription factor typically associated with oligodendrocyte differentiation is Olig1 or Olig2.\n2. UNKNOWN: Without specific studies to reference, it is difficult to ascertain whether this statement is true, though RUNX2 is generally not associated with astrocyte differentiation.\n3. FALSE [correction]: This statement is based on the incorrect assumption from statement 1. Therefore, any findings about overexpression of RUNX2 inhibiting the differentiation of OPCs into mature oligodendrocytes would not be accurate as RUNX2 is not directly involved in this process.\n4. UNKNOWN: Since RUNX2 is not known to be directly involved in oligodendrocyte differentiation, findings related to its overexpression promoting differentiation into astrocytes in vitro cannot be confirmed without the actual study reference.\n5. UNKNOWN: The role of RUNX2 downregulation in OPC differentiation into mature oligodendrocytes is questionable given that RUNX2 is not typically associated with oligodendrocyte differentiation; therefore, without the specific study, the accuracy of this statement cannot be confirmed.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "You MUST give a detailed answer to the following question: Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-7b_response": "wrist",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3243,
    "user_query": "You MUST give a detailed answer to the following question: Does GRHL2 over-expression lead to EMT?",
    "llama-7b_response": "Yes, GRHL2 over-expression has been shown to lead to epithelial-to-mesenchymal transition (EMT) in certain cell types.\n\nEpithelial-to-mesenchymal transition (EMT) is a process by which epithelial cells lose their cell-cell adhesion and acquire a mesenchymal phenotype, characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal genes, and the downregulation of epithelial genes. This process is crucial for embryonic development, tissue repair, and cancer progression.\n\nGRHL2 is a transcription factor that plays a crucial role in regulating the expression of genes involved in EMT. Over-expression of GRHL2 has been shown to induce EMT in various cell types, including epithelial cells, by activating the transcription of genes involved in the mesenchymal phenotype, such as N-cadherin and vimentin.\n\nIn summary, GRHL2 over-expression can lead to EMT in certain cell types by activating the transcription of genes involved in the mesenchymal phenotype. This process is crucial for embryonic development, tissue repair, and cancer progression.",
    "llama-7b_fact_raw": "1. GRHL2 over-expression leads to epithelial-to-mesenchymal transition (EMT) in certain cell types.\n2. EMT is characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal genes, and the downregulation of epithelial genes.\n3. GRHL2 is a transcription factor that regulates the expression of genes involved in EMT.\n4. GRHL2 over-expression induces EMT by activating the transcription of genes such as N-cadherin and vimentin.\n5. The EMT process is vital for embryonic development, tissue repair, and cancer progression.",
    "llama-7b_fact": [
      "GRHL2 over-expression leads to epithelial-to-mesenchymal transition (EMT) in certain cell types.",
      "EMT is characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal genes, and the downregulation of epithelial genes.",
      "GRHL2 is a transcription factor that regulates the expression of genes involved in EMT.",
      "GRHL2 over-expression induces EMT by activating the transcription of genes such as N-cadherin and vimentin.",
      "The EMT process is vital for embryonic development, tissue repair, and cancer progression."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in lung cancer?",
    "llama-7b_response": "There are several T-cell receptors (TCRs) that have been implicated in lung cancer. T-cell receptors are a type of immune cell receptor that is expressed on the surface of T cells, a type of immune cell that plays a key role in the immune system's response to infections and cancer.\n\nOne T-cell receptor that has been implicated in lung cancer is the T-cell receptor alpha (TCRα). TCRα is a type of T-cell receptor that is expressed on the surface of T cells and plays a key role in the immune system's response to infections and cancer.\n\nAnother T-cell receptor that has been implicated in lung cancer is the T-cell receptor gamma (TCRγ). TCRγ is a type of T-cell receptor that is expressed on the surface of T cells and plays a key role in the immune system's response to infections and cancer.\n\nThere are also other T-cell receptors that have been implicated in lung cancer, such as the T-cell receptor delta (TCRδ). TCRδ is a type of T-cell receptor that is expressed on the surface of T cells and plays a key role in the immune system's response to infections and cancer.\n\nOverall, T-cell receptors play a key role in the immune system's response to infections and cancer, and several T-cell receptors have been implicated in the development and progression of lung cancer.",
    "llama-7b_fact_raw": "1. T-cell receptors (TCRs) have been implicated in lung cancer.\n2. T-cell receptors are expressed on the surface of T cells.\n3. The T-cell receptor alpha (TCRα) has been implicated in lung cancer.\n4. The T-cell receptor gamma (TCRγ) has been implicated in lung cancer.\n5. The T-cell receptor delta (TCRδ) has been implicated in lung cancer.",
    "llama-7b_fact": [
      "T-cell receptors (TCRs) have been implicated in lung cancer.",
      "T-cell receptors are expressed on the surface of T cells.",
      "The T-cell receptor alpha (TCRα) has been implicated in lung cancer.",
      "The T-cell receptor gamma (TCRγ) has been implicated in lung cancer.",
      "The T-cell receptor delta (TCRδ) has been implicated in lung cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE: T-cell receptors (TCRs) have been implicated in the immune response to various cancers, including lung cancer.\n2. TRUE: T-cell receptors are indeed expressed on the surface of T cells and are crucial for their ability to recognize antigens.\n3. UNKNOWN: Without specific research data or findings, it is not possible to determine whether T-cell receptor alpha (TCRα) has been specifically implicated in lung cancer.\n4. UNKNOWN: As with TCRα, without specific research data or findings, it is not possible to determine whether the T-cell receptor gamma (TCRγ) has been specifically implicated in lung cancer.\n5. UNKNOWN: Similarly, without specific findings, it is not possible to determine whether the T-cell receptor delta (TCRδ) has been specifically implicated in lung cancer.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "You MUST give a detailed answer to the following question: What is known about the orphan receptor GPR151?",
    "llama-7b_response": "GPR151 (G-protein-coupled receptor 151) is an orphan receptor that belongs to the G-protein-coupled receptor (GPCR) family. GPCRs are a large family of transmembrane proteins that are activated by a variety of extracellular signals, including hormones, neurotransmitters, and drugs. GPR151 is primarily expressed in the brain, particularly in the hippocampus, and has been implicated in several neurological processes, including learning and memory, anxiety, and depression.\n\nTo date, very little is known about the function of GPR151. However, several studies have suggested that it may play a role in the regulation of anxiety and depression. For example, research has shown that GPR151 is highly expressed in the hippocampus, a region of the brain known to be involved in the regulation of anxiety and mood. Additionally, studies using animal models have shown that manipulating the expression of GPR151 can affect anxiety-like behavior and depression-like behavior.\n\nDespite these findings, more research is needed to fully understand the function of GPR151 and its potential as a therapeutic target for the treatment of neurological disorders.",
    "llama-7b_fact_raw": "1. GPR151 is an orphan receptor that is part of the G-protein-coupled receptor (GPCR) family.\n2. G-protein-coupled receptors are activated by external signals such as hormones, neurotransmitters, and drugs.\n3. GPR151 is primarily located in the brain and is notably expressed in the hippocampus.\n4. The receptor has been implicated in neurological processes including learning, memory, anxiety, and depression.\n5. Research using animal models indicates that manipulation of GPR151 expression can influence anxiety-like and depression-like behaviors.",
    "llama-7b_fact": [
      "GPR151 is an orphan receptor that is part of the G-protein-coupled receptor (GPCR) family.",
      "G-protein-coupled receptors are activated by external signals such as hormones, neurotransmitters, and drugs.",
      "GPR151 is primarily located in the brain and is notably expressed in the hippocampus.",
      "The receptor has been implicated in neurological processes including learning, memory, anxiety, and depression.",
      "Research using animal models indicates that manipulation of GPR151 expression can influence anxiety-like and depression-like behaviors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN (While the statement could be plausible given the location and function of many GPCRs, it's impossible to confirm the accuracy without specific research references.)\n5. UNKNOWN (Again, this statement sounds plausible, but without specific studies or experimental evidence provided, the truthfulness of the statement cannot be determined.)",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "You MUST give a detailed answer to the following question: List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-7b_response": "The Fluzone intradermal quadrivalent vaccine is a live attenuated influenza vaccine (LAIV) that contains four different strains of influenza virus: influenza A (H1N1), influenza A (H3N2), influenza B (Yamagata lineage), and influenza B (Victoria lineage). The vaccine is administered by intradermal injection, which involves injecting the vaccine into the top layer of the skin.\n\nThe specific strains of influenza virus contained in the Fluzone intradermal quadrivalent vaccine are:\n\n* Influenza A (H1N1) strain: A/California/7/2009 (H1N1)\n* Influenza A (H3N2) strain: A/Switzerland/9715233/2013 (H3N2)\n* Influenza B (Yamagata lineage) strain: B/Phuket/3073/2013 (Yamagata lineage)\n* Influenza B (Victoria lineage) strain: B/Brisbane/60/2008 (Victoria lineage)\n\nThe Fluzone intradermal quadrivalent vaccine is approved for use in adults and children aged 18 years and older. It is intended for use as an annual influenza vaccine to prevent influenza disease caused by the strains contained in the vaccine.",
    "llama-7b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine is a live attenuated influenza vaccine (LAIV).\n2. The vaccine contains the influenza A (H1N1) strain A/California/7/2009 (H1N1).\n3. The vaccine also contains the influenza A (H3N2) strain A/Switzerland/9715233/2013 (H3N2).\n4. The vaccine includes the influenza B (Yamagata lineage) strain B/Phuket/3073/2013.\n5. It additionally comprises the influenza B (Victoria lineage) strain B/Brisbane/60/2008.",
    "llama-7b_fact": [
      "The Fluzone intradermal quadrivalent vaccine is a live attenuated influenza vaccine (LAIV).",
      "The vaccine contains the influenza A (H1N1) strain A/California/7/2009 (H1N1).",
      "The vaccine also contains the influenza A (H3N2) strain A/Switzerland/9715233/2013 (H3N2).",
      "The vaccine includes the influenza B (Yamagata lineage) strain B/Phuket/3073/2013.",
      "It additionally comprises the influenza B (Victoria lineage) strain B/Brisbane/60/2008."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine is not a live attenuated influenza vaccine (LAIV). It is an inactivated vaccine.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Since the vaccine is quadrivalent, it would include an influenza B strain from the Victoria lineage, but the strain B/Brisbane/60/2008 is from the Yamagata lineage. The correct Victoria lineage strain needs to be identified, and it may not be B/Brisbane/60/2008.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3345,
    "user_query": "You MUST give a detailed answer to the following question: Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-7b_response": "promoter",
    "llama-7b_fact_raw": "1. The promoter part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus.",
    "llama-7b_fact": [
      "The promoter part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n\nThe association between a specific gene's promoter region and a disease like Systemic Lupus Erythematosus (SLE) would require specific scientific evidence which is not provided in the context of the given task. Without a reference to a specific study or scientific finding, the truth of the statement cannot be determined.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "You MUST give a detailed answer to the following question: Is there a vaccine for peanut allergy?",
    "llama-7b_response": "Yes, there is a vaccine for peanut allergy. The vaccine is called Palivizumab and it is used to prevent severe allergic reactions to peanuts in people who are at high risk of having an allergic reaction. The vaccine is given as an injection and is usually given to children who have a history of severe allergic reactions to peanuts or who have a family history of peanut allergy. The vaccine works by increasing the body's immunity to peanuts, making it less likely that the person will have a severe allergic reaction if they come into contact with peanuts. The vaccine is not a cure for peanut allergy, but it can help to reduce the risk of severe allergic reactions in people who are at high risk of having an allergic reaction.",
    "llama-7b_fact_raw": "1. Palivizumab is a vaccine used to prevent severe allergic reactions to peanuts.\n2. The vaccine is specifically for individuals at high risk of an allergic reaction to peanuts.\n3. Palivizumab is administered via injection.\n4. The vaccine is typically given to children with a history of severe peanut allergy or those with a family history of peanut allergy.\n5. Palivizumab increases the body's immunity to peanuts to decrease the likelihood of severe allergic reactions.",
    "llama-7b_fact": [
      "Palivizumab is a vaccine used to prevent severe allergic reactions to peanuts.",
      "The vaccine is specifically for individuals at high risk of an allergic reaction to peanuts.",
      "Palivizumab is administered via injection.",
      "The vaccine is typically given to children with a history of severe peanut allergy or those with a family history of peanut allergy.",
      "Palivizumab increases the body's immunity to peanuts to decrease the likelihood of severe allergic reactions."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Palivizumab is not a vaccine for preventing allergic reactions to peanuts. It is a monoclonal antibody used to prevent severe respiratory disease caused by Respiratory Syncytial Virus (RSV) in infants and young children at high risk.\n2. FALSE [correction]: Palivizumab is specifically for individuals at high risk of severe respiratory disease caused by RSV, not allergic reactions to peanuts.\n3. TRUE\n4. FALSE [correction]: Palivizumab is typically given to children with a high risk of severe RSV disease, which may include premature infants, children with certain heart conditions, or those with chronic lung disease, not specifically those with a history or family history of peanut allergy.\n5. FALSE [correction]: Palivizumab works by boosting the body's immunity to RSV, not peanuts, to decrease the likelihood of severe respiratory infections.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3365,
    "user_query": "You MUST give a detailed answer to the following question: What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-7b_response": "The Fxy gene is located on the X chromosome.",
    "llama-7b_fact_raw": "1. The Fxy gene is located on the X chromosome.",
    "llama-7b_fact": [
      "The Fxy gene is located on the X chromosome."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-7b_response": "The basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method is the incorporation of the nucleotide analog methidiumpropyl-EDTA (MP-EDTA) into DNA during replication. MPE-seq is a high-throughput sequencing method that can be used to sequence large numbers of DNA molecules simultaneously.\n\nThe MPE-seq method is based on the ability of the nucleotide analog MP-EDTA to incorporate into DNA during replication. MP-EDTA is a modified form of the nucleotide analog EDTA, which is a chelating agent that binds to metal ions. MP-EDTA is similar to EDTA, but it has a methyl group attached to one of the nitrogen atoms. This methyl group allows MP-EDTA to incorporate into DNA more easily than EDTA.\n\nIn the MPE-seq method, a DNA template is incubated with a solution containing MP-EDTA and DNA polymerase. During replication, the DNA polymerase incorporates MP-EDTA into the growing DNA strand, resulting in the formation of modified DNA molecules. These modified DNA molecules can then be sequenced using standard DNA sequencing techniques, such as Illumina sequencing.\n\nThe MPE-seq method has several advantages over other sequencing methods, including high throughput, low cost, and the ability to sequence large numbers of DNA molecules simultaneously. It has been used to sequence large numbers of DNA molecules from a variety of sources, including bacteria, archaea, and eukaryotic cells.\n\nOverall, the basis of the MPE-seq method is the incorporation of the nucleotide analog MP-EDTA into DNA during replication, which allows for the sequencing of large numbers of DNA molecules using standard DNA sequencing techniques.",
    "llama-7b_fact_raw": "1. Methidiumpropyl-EDTA sequencing (MPE-seq) involves the incorporation of the nucleotide analog methidiumpropyl-EDTA into DNA during replication.\n2. Methidiumpropyl-EDTA (MP-EDTA) is a modified form of the nucleotide analog EDTA, with a methyl group attached to one of the nitrogen atoms.\n3. The MPE-seq method uses a solution containing MP-EDTA and DNA polymerase to produce modified DNA molecules during DNA replication.\n4. Modified DNA molecules created through MPE-seq can be sequenced using standard DNA sequencing techniques.\n5. MPE-seq is characterized by its high throughput, low cost, and capability to sequence large numbers of DNA molecules simultaneously.",
    "llama-7b_fact": [
      "Methidiumpropyl-EDTA sequencing (MPE-seq) involves the incorporation of the nucleotide analog methidiumpropyl-EDTA into DNA during replication.",
      "Methidiumpropyl-EDTA (MP-EDTA) is a modified form of the nucleotide analog EDTA, with a methyl group attached to one of the nitrogen atoms.",
      "The MPE-seq method uses a solution containing MP-EDTA and DNA polymerase to produce modified DNA molecules during DNA replication.",
      "Modified DNA molecules created through MPE-seq can be sequenced using standard DNA sequencing techniques.",
      "MPE-seq is characterized by its high throughput, low cost, and capability to sequence large numbers of DNA molecules simultaneously."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Methidiumpropyl-EDTA sequencing (MPE-seq) does not involve the incorporation of a nucleotide analog into DNA during replication. Instead, MPE-seq generally refers to a footprinting technique that uses methidiumpropyl-EDTA-Fe(II) as a cleaving agent to break DNA at specific sites.\n2. FALSE [correction]: Methidiumpropyl-EDTA (MP-EDTA) is not a modified nucleotide analog. It is a metallointercalator and a chemical cleaving agent that, when combined with iron (Fe), is used to break DNA at specific sites, not a nucleotide analog modified with a methyl group.\n3. FALSE [correction]: The MPE-seq method does not use a solution of MP-EDTA with DNA polymerase to produce modified DNA molecules. It typically uses methidiumpropyl-EDTA-Fe(II) with a reducing agent to cleave DNA.\n4. UNKNOWN: Without specific details on MPE-seq as the term is not standard in the context provided, I cannot determine the accuracy of this statement. If MPE-seq referred to a hypothetical sequencing technology, then the characteristics of the modified DNA molecules and their compatibility with standard sequencing techniques would have to be specified.\n5. UNKNOWN: The statement seems to describe attributes of a DNA sequencing technology, but because MPE-seq as a sequencing technique involving methidiumpropyl-EDTA isn't standard or well-known, the accuracy of these characteristics can't be determined without further context. Methidiumpropyl-EDTA is usually associated with DNA footprinting, not sequencing.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "You MUST give a detailed answer to the following question: Which programming language has been used for implementing GWAR?",
    "llama-7b_response": "C++",
    "llama-7b_fact_raw": "1. C++ is the programming language used for implementing GWAR.",
    "llama-7b_fact": [
      "C++ is the programming language used for implementing GWAR."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n\n[Explanation]: GWAR is not a widely known acronym in relation to programming or software development, at least as of my last update. Without additional context or clarification, it is not possible to determine whether C++ is indeed used for implementing GWAR or what GWAR refers to in this context.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "You MUST give a detailed answer to the following question: Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-7b_response": "Xaliproden is a drug that has been studied for its potential to slow the progression of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. However, there is currently insufficient evidence to determine whether xaliproden improves the prognosis of ALS.\n\nXaliproden is a selective adenosine A2A receptor antagonist, which means that it blocks the action of adenosine A2A receptors in the body. Adenosine is a molecule that plays a role in several physiological processes, including the regulation of inflammation and the function of immune cells. Some studies have suggested that adenosine may play a role in the progression of ALS by promoting inflammation and the death of motor neurons, which are the nerve cells that control muscle movement.\n\nXaliproden has been studied in several clinical trials as a potential treatment for ALS. Some studies have suggested that xaliproden may slow the progression of ALS by reducing inflammation and preserving the function of motor neurons. However, other studies have found no benefit from xaliproden treatment.\n\nIn summary, while xaliproden has shown some promise as a potential treatment for ALS, there is currently insufficient evidence to determine whether it improves the prognosis of the disease. Further research is needed to fully understand the potential benefits and risks of xaliproden in the treatment of ALS.",
    "llama-7b_fact_raw": "1. Xaliproden has been studied for its potential to slow the progression of amyotrophic lateral sclerosis (ALS).\n2. Xaliproden functions as a selective adenosine A2A receptor antagonist.\n3. Adenosine plays a role in inflammation and the function of immune cells.\n4. Clinical trials have been conducted to analyze the efficacy of xaliproden in treating ALS.\n5. There is currently insufficient evidence to conclude that xaliproden improves the prognosis of ALS.",
    "llama-7b_fact": [
      "Xaliproden has been studied for its potential to slow the progression of amyotrophic lateral sclerosis (ALS).",
      "Xaliproden functions as a selective adenosine A2A receptor antagonist.",
      "Adenosine plays a role in inflammation and the function of immune cells.",
      "Clinical trials have been conducted to analyze the efficacy of xaliproden in treating ALS.",
      "There is currently insufficient evidence to conclude that xaliproden improves the prognosis of ALS."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Xaliproden is not a selective adenosine A2A receptor antagonist; it is a serotonergic compound with neurotrophic effects that has been studied for ALS.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "You MUST give a detailed answer to the following question: In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-7b_response": "In the LiPS-A3S line, transgenes are inserted in the X chromosome.",
    "llama-7b_fact_raw": "1. Transgenes in the LiPS-A3S line are inserted in the X chromosome.",
    "llama-7b_fact": [
      "Transgenes in the LiPS-A3S line are inserted in the X chromosome."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nWithout additional context regarding what the \"LiPS-A3S line\" refers to, it is impossible to determine the accuracy of the statement about transgenes being inserted in the X chromosome.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "You MUST give a detailed answer to the following question: Which tool exist for predicting drug synergy with deep learning?",
    "llama-7b_response": "There are several tools available for predicting drug synergy using deep learning, including:\n\n1. DeepDive: DeepDive is a deep learning model developed by researchers at the University of California, San Francisco (UCSF) that can predict the synergy between two drugs. The model uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks to analyze drug activity data and predict the likelihood of synergy.\n2. DrugB6: DrugB6 is a machine learning model developed by researchers at the University of California, San Diego (UCSD) that can predict the synergy between two drugs. The model uses a combination of decision trees and support vector machines (SVMs) to analyze drug activity data and predict the likelihood of synergy.\n3. SynergyNet: SynergyNet is a deep learning model developed by researchers at the University of California, San Francisco (UCSF) that can predict the synergy between two drugs. The model uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks to analyze drug activity data and predict the likelihood of synergy.\n\nThese are just a few examples of the many tools available for predicting drug synergy using deep learning. Each tool has its own strengths and weaknesses, and the choice of tool will depend on the specific needs and goals of the researcher.",
    "llama-7b_fact_raw": "1. DeepDive is a deep learning model designed to predict drug synergy and was developed by researchers at the University of California, San Francisco (UCSF).\n2. DeepDive uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks for analysis.\n3. DrugB6 is a machine learning model developed by researchers at the University of California, San Diego (UCSD) to predict drug synergy.\n4. DrugB6 employs decision trees and support vector machines (SVMs) in its predictive analysis.\n5. SynergyNet is another deep learning model from researchers at the University of California, San Francisco (UCSF) and also predicts drug synergy using a combination of CNNs and LSTM networks.",
    "llama-7b_fact": [
      "DeepDive is a deep learning model designed to predict drug synergy and was developed by researchers at the University of California, San Francisco (UCSF).",
      "DeepDive uses a combination of convolutional neural networks (CNNs) and long short-term memory (LSTM) networks for analysis.",
      "DrugB6 is a machine learning model developed by researchers at the University of California, San Diego (UCSD) to predict drug synergy.",
      "DrugB6 employs decision trees and support vector machines (SVMs) in its predictive analysis.",
      "SynergyNet is another deep learning model from researchers at the University of California, San Francisco (UCSF) and also predicts drug synergy using a combination of CNNs and LSTM networks."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific access to current or past research publications or databases that confirm the development and methodologies of the models DeepDive, DrugB6, and SynergyNet by the mentioned universities, it is not possible to ascertain the accuracy of the statements provided. These details are quite specific and would require verification through credible sources in the biomedical field, such as peer-reviewed papers or official university research announcements.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "You MUST give a detailed answer to the following question: Which cloud-based platform has been developed for comparing GWAS?",
    "llama-7b_response": "There are several cloud-based platforms that have been developed for comparing genome-wide association studies (GWAS), including:\n\n1. The National Center for Biotechnology Information's (NCBI) dbGaP (https://www.ncbi.nlm.nih.gov/gap): dbGaP is a public database of genetic association data for human traits and diseases. It provides a platform for storing, analyzing, and sharing GWAS data.\n2. The National Human Genome Research Institute's (NHGRI) Genome Variation Server (GVS) (https://www.ncbi.nlm.nih.gov/gvs): GVS is a web-based platform for storing, analyzing, and sharing genetic variation data, including GWAS data.\n3. The European Bioinformatics Institute's (EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n4. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n5. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n6. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n7. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a public database of functional genomics experiments, including GWAS data.\n8. The European Molecular Biology Laboratory's (EMBL-EBI) ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>): ArrayExpress is a",
    "llama-7b_fact_raw": "1. The National Center for Biotechnology Information's (NCBI) dbGaP is a cloud-based platform for genome-wide association studies.\n2. dbGaP provides a platform for storing, analyzing, and sharing GWAS data.\n3. The National Human Genome Research Institute's (NHGRI) Genome Variation Server (GVS) is a web-based platform that also supports storing, analyzing, and sharing GWAS data.\n4. The European Bioinformatics Institute's (EBI) ArrayExpress is a public database of functional genomics experiments that includes GWAS data.\n5. The European Molecular Biology Laboratory (EMBL-EBI) also supports ArrayExpress for public access to functional genomics experiments and GWAS data.",
    "llama-7b_fact": [
      "The National Center for Biotechnology Information's (NCBI) dbGaP is a cloud-based platform for genome-wide association studies.",
      "dbGaP provides a platform for storing, analyzing, and sharing GWAS data.",
      "The National Human Genome Research Institute's (NHGRI) Genome Variation Server (GVS) is a web-based platform that also supports storing, analyzing, and sharing GWAS data.",
      "The European Bioinformatics Institute's (EBI) ArrayExpress is a public database of functional genomics experiments that includes GWAS data.",
      "The European Molecular Biology Laboratory (EMBL-EBI) also supports ArrayExpress for public access to functional genomics experiments and GWAS data."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The National Center for Biotechnology Information's (NCBI) dbGaP is not specifically a cloud-based platform but a repository that stores and provides access to the results of studies that have investigated the interaction of genotype and phenotype.\n2. TRUE\n3. FALSE [correction]: The Genome Variation Server (GVS) was hosted by the SeattleSNPs project at the University of Washington, which provided tools for the analysis of high-density SNP genotype data, but this is not specified as an initiative by the National Human Genome Research Institute (NHGRI) nor is the server currently maintained.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "You MUST give a detailed answer to the following question: Can CMB305 be used against sarcomas?",
    "llama-7b_response": "Yes, CMB305 can be used against sarcomas.\n\nSarcomas are a type of cancer that affects the soft tissues of the body, including muscles, tendons, ligaments, and fat. They can also affect the bones and joints. Sarcomas are relatively rare cancers, accounting for only about 1% of all cancers.\n\nCMB305 is a type of immunotherapy drug that works by stimulating the body's immune system to attack cancer cells. It is made from a patient's own white blood cells, which are collected and modified in the laboratory to produce chimeric antigen receptors (CARs) on their surface. These CARs allow the modified white blood cells to recognize and attack cancer cells that express a specific protein called CD19.\n\nCMB305 has been shown to be effective in treating B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), which are both types of cancer that express the CD19 protein. However, it is not clear whether CMB305 is effective against sarcomas, as there have been no clinical trials specifically testing its use against this type of cancer.\n\nIt is possible that CMB305 could be effective against sarcomas, as the CD19 protein is expressed on the surface of some sarcoma cells. However, more research would be needed to determine the safety and effectiveness of using CMB305 to treat sarcomas.\n\nIn summary, while CMB305 has been shown to be effective against certain types of cancer, such as B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma, it is not clear whether it is effective against sarcomas. Further research is needed to determine the safety and effectiveness of using CMB305 to treat sarcomas.",
    "llama-7b_fact_raw": "1. Sarcomas are cancers that affect the soft tissues, including muscles, tendons, ligaments, and fat, or the bones and joints.\n2. Sarcomas account for about 1% of all cancers.\n3. CMB305 is a type of immunotherapy drug that works by stimulating the immune system to attack cancer cells.\n4. CMB305 is made from a patient's own white blood cells modified to produce chimeric antigen receptors (CARs) targeting the CD19 protein.\n5. CMB305's effectiveness has been shown in B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), but its efficacy against sarcomas has not been clinically tested.",
    "llama-7b_fact": [
      "Sarcomas are cancers that affect the soft tissues, including muscles, tendons, ligaments, and fat, or the bones and joints.",
      "Sarcomas account for about 1% of all cancers.",
      "CMB305 is a type of immunotherapy drug that works by stimulating the immune system to attack cancer cells.",
      "CMB305 is made from a patient's own white blood cells modified to produce chimeric antigen receptors (CARs) targeting the CD19 protein.",
      "CMB305's effectiveness has been shown in B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), but its efficacy against sarcomas has not been clinically tested."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: CMB305 is not made from a patient's own white blood cells modified to produce CARs targeting CD19 protein. CMB305 is actually an investigational cancer vaccine targeting the NY-ESO-1 protein expressed on cancer cells, not a CAR-T therapy like those targeting CD19.\n5. FALSE [correction]: The provided statement regarding CMB305's effectiveness cannot be confirmed as true without clinical evidence. Additionally, CMB305, as a cancer vaccine targeting NY-ESO-1, would not be used for B-ALL and DLBCL, diseases typically linked to CD19-targeted CAR-T therapies. Instead, CMB305's clinical testing has been directed towards sarcomas, specifically those expressing the NY-ESO-1 protein.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "You MUST give a detailed answer to the following question: What are manifestations of the Saint's Triad?",
    "llama-7b_response": "The manifestations of the Saint's Triad, also known as the Three Saints, are the physical, emotional, and mental aspects of a person's being. These aspects are interconnected and influence each other, and when in balance, they contribute to a person's overall well-being and happiness.\n\nThe physical aspect of the Saint's Triad refers to the body and its functions. This includes things like physical health, energy levels, and the ability to perform physical tasks. A balanced physical aspect is important for overall health and well-being.\n\nThe emotional aspect of the Saint's Triad refers to a person's emotions and feelings. This includes things like happiness, sadness, anger, and fear. A balanced emotional aspect is important for maintaining positive relationships and good mental health.\n\nThe mental aspect of the Saint's Triad refers to a person's thoughts, beliefs, and understanding of the world. This includes things like intelligence, creativity, and problem-solving skills. A balanced mental aspect is important for making informed decisions and achieving personal and professional goals.\n\nWhen all three aspects of the Saint's Triad are in balance, a person is said to be in a state of equilibrium. However, when one or more aspects are out of balance, a person may experience imbalance or disharmony, which can lead to physical, emotional, or mental distress.\n\nIn conclusion, the manifestations of the Saint's Triad are the physical, emotional, and mental aspects of a person's being, which are interconnected and influence each other. When in balance, they contribute to a person's overall well-being and happiness, but when out of balance, they can lead to imbalance or disharmony.",
    "llama-7b_fact_raw": "1. The Saint's Triad, also known as the Three Saints, includes the physical, emotional, and mental aspects of a person's being.\n2. The physical aspect of the Saint's Triad encompasses physical health, energy levels, and the ability to perform physical tasks.\n3. The emotional aspect of the Saint's Triad involves a person's emotions and feelings, such as happiness, sadness, anger, and fear.\n4. The mental aspect of the Saint's Triad includes a person's thoughts, beliefs, and understanding of the world, as well as their intelligence, creativity, and problem-solving skills.\n5. If any aspect of the Saint's Triad is out of balance, a person may experience physical, emotional, or mental distress.",
    "llama-7b_fact": [
      "The Saint's Triad, also known as the Three Saints, includes the physical, emotional, and mental aspects of a person's being.",
      "The physical aspect of the Saint's Triad encompasses physical health, energy levels, and the ability to perform physical tasks.",
      "The emotional aspect of the Saint's Triad involves a person's emotions and feelings, such as happiness, sadness, anger, and fear.",
      "The mental aspect of the Saint's Triad includes a person's thoughts, beliefs, and understanding of the world, as well as their intelligence, creativity, and problem-solving skills.",
      "If any aspect of the Saint's Triad is out of balance, a person may experience physical, emotional, or mental distress."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: The correctness of statement 1 is dependent on the definition established by a specific doctrine or philosophy which was not provided here. Assuming the term \"Saint's Triad\" is used within a certain context that defines it as such, the rest of the statements follow that definition and are considered true. If \"Saint's Triad\" does not exist within the referenced framework or has a different definition, then the first statement could be false.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "You MUST give a detailed answer to the following question: Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-7b_response": "Yes, overexpression of LY6K has been associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n\nLY6K, also known as podoplanin, is a transmembrane glycoprotein that belongs to the immunoglobulin superfamily. It is expressed on the surface of platelets, endothelial cells, and certain tumor cells, including those of NSCLC.\n\nSeveral studies have investigated the prognostic significance of LY6K expression in NSCLC. These studies have found that high levels of LY6K expression are associated with improved overall survival (OS) and progression-free survival (PFS) in NSCLC patients.\n\nFor example, a study published in the Journal of Thoracic Oncology in 2016 found that high LY6K expression was associated with better OS and PFS in patients with NSCLC. The study included 182 patients with NSCLC and found that those with high LY6K expression had a significantly better OS and PFS compared to those with low LY6K expression.\n\nAnother study published in the Journal of Clinical Oncology in 2018 found that high LY6K expression was associated with improved OS and PFS in patients with advanced NSCLC. The study included 306 patients with advanced NSCLC and found that those with high LY6K expression had a significantly better OS and PFS compared to those with low LY6K expression.\n\nThese findings suggest that overexpression of LY6K may be associated with better prognosis for NSCLC patients. However, further research is needed to confirm these findings and to better understand the role of LY6K in the development and progression of NSCLC.",
    "llama-7b_fact_raw": "1. Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. LY6K is a transmembrane glycoprotein that is expressed on the surface of tumor cells, including those of NSCLC.\n3. High levels of LY6K expression are associated with improved overall survival (OS) and progression-free survival (PFS) in NSCLC patients.\n4. A study published in the Journal of Thoracic Oncology in 2016 found a positive association between high LY6K expression and better OS and PFS in patients with NSCLC.\n5. A study published in the Journal of Clinical Oncology in 2018 reported that patients with advanced NSCLC and high LY6K expression had significantly better OS and PFS than those with low LY6K expression.",
    "llama-7b_fact": [
      "Overexpression of LY6K is associated with better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "LY6K is a transmembrane glycoprotein that is expressed on the surface of tumor cells, including those of NSCLC.",
      "High levels of LY6K expression are associated with improved overall survival (OS) and progression-free survival (PFS) in NSCLC patients.",
      "A study published in the Journal of Thoracic Oncology in 2016 found a positive association between high LY6K expression and better OS and PFS in patients with NSCLC.",
      "A study published in the Journal of Clinical Oncology in 2018 reported that patients with advanced NSCLC and high LY6K expression had significantly better OS and PFS than those with low LY6K expression."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Overexpression of LY6K is generally associated with a poor prognosis for non-small cell lung cancer (NSCLC) patients.\n2. TRUE\n3. FALSE [correction]: High levels of LY6K expression are generally associated with poor overall survival (OS) and progression-free survival (PFS) in NSCLC patients.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3473,
    "user_query": "You MUST give a detailed answer to the following question: List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-7b_response": "Cdk targets that are dephosphorylated during cytokinesis include the following:\n\n1. Cyclin B1: Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n2. Cyclin A: Cyclin A is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n3. Cyclin B2: Cyclin B2 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n4. Cyclin A2: Cyclin A2 is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n5. Cyclin B3: Cyclin B3 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n6. Cyclin A3: Cyclin A3 is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n7. Cyclin B4: Cyclin B4 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n8. Cyclin A4: Cyclin A4 is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n9. Cyclin B5: Cyclin B5 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n10. Cyclin A5: Cyclin A5 is dephosphorylated by Cdk2 during cytokinesis, leading to its degradation by the ubi",
    "llama-7b_fact_raw": "1. Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.\n2. Cyclin A is dephosphorylated by Cdk2 during cytokinesis.\n3. The dephosphorylation of Cyclins by Cdks during cytokinesis leads to their degradation via the ubiquitin-proteasome pathway.\n4. Cyclin B2 is another target of Cdk1 dephosphorylation during cytokinesis.\n5. Cyclin A2 undergoes dephosphorylation by Cdk2 during cytokinesis.",
    "llama-7b_fact": [
      "Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Cyclin A is dephosphorylated by Cdk2 during cytokinesis.",
      "The dephosphorylation of Cyclins by Cdks during cytokinesis leads to their degradation via the ubiquitin-proteasome pathway.",
      "Cyclin B2 is another target of Cdk1 dephosphorylation during cytokinesis.",
      "Cyclin A2 undergoes dephosphorylation by Cdk2 during cytokinesis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclin B1 is phosphorylated by Cdk1 during the transition from G2 to M phase, and it is not during cytokinesis where its levels decrease leading to its degradation.\n2. FALSE [correction]: Cyclin A is targeted for degradation before mitosis is completed and thus its levels typically decrease before cytokinesis. It is not dephosphorylated by Cdk2 during cytokinesis.\n3. TRUE: The decrease in cyclin levels typically triggers their degradation via the ubiquitin-proteasome pathway, although the statement slightly simplifies the complex regulation of cyclin degradation.\n4. UNKNOWN: This statement is unclear because while Cyclin B2 is involved in the cell cycle and does interact with Cdk1, the specific details of its dephosphorylation during cytokinesis are not common knowledge without specific sources or research context.\n5. FALSE [correction]: Cyclin A2 is associated with the regulation of the cell cycle before mitosis, and its degradation typically occurs before cytokinesis is initiated, not during; thus it would not be undergoing dephosphorylation by Cdk2 during cytokinesis.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "You MUST give a detailed answer to the following question: What is Xanamem?",
    "llama-7b_response": "Xanamem is a drug that is used to treat the symptoms of mild to moderate Alzheimer's disease. It belongs to a class of drugs called cholinergic agonists, which work by increasing the levels of a chemical called acetylcholine in the brain. Acetylcholine is a neurotransmitter that is important for memory and cognitive function.\n\nXanamem is available in the form of a tablet that is taken orally. It is usually taken once daily, with or without food. The dosage of Xanamem that is recommended for the treatment of Alzheimer's disease varies depending on the individual and the severity of their symptoms. It is important for patients to follow their doctor's instructions carefully when taking Xanamem, as the dosage may need to be adjusted based on the individual's response to the medication.\n\nIt is important for patients to note that Xanamem is not a cure for Alzheimer's disease, and it may not completely reverse the symptoms of the condition. However, it can help to improve memory and cognitive function, and may help to slow the progression of the disease.\n\nIt is also important for patients to be aware of the potential side effects of Xanamem, which may include nausea, vomiting, diarrhea, and constipation. In rare cases, Xanamem may also cause muscle spasms, restlessness, and insomnia. It is important for patients to let their doctor know if they experience any side effects while taking Xanamem.",
    "llama-7b_fact_raw": "1. Xanamem is a drug used to treat symptoms of mild to moderate Alzheimer's disease.\n2. It belongs to a class of drugs called cholinergic agonists.\n3. Cholinergic agonists, like Xanamem, increase levels of acetylcholine in the brain.\n4. Xanamem is administered orally in tablet form, typically taken once daily.\n5. Common side effects of Xanamem may include nausea, vomiting, diarrhea, and constipation.",
    "llama-7b_fact": [
      "Xanamem is a drug used to treat symptoms of mild to moderate Alzheimer's disease.",
      "It belongs to a class of drugs called cholinergic agonists.",
      "Cholinergic agonists, like Xanamem, increase levels of acetylcholine in the brain.",
      "Xanamem is administered orally in tablet form, typically taken once daily.",
      "Common side effects of Xanamem may include nausea, vomiting, diarrhea, and constipation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific information on a drug named \"Xanamem,\" it is impossible to verify whether it is used to treat symptoms of mild to moderate Alzheimer's disease. This name does not correspond to a widely recognized pharmaceutical product as of my knowledge cutoff date.\n2. UNKNOWN: Similarly, without confirmation that \"Xanamem\" is an actual drug, we cannot determine whether it belongs to the class of drugs called cholinergic agonists.\n3. TRUE: In general, cholinergic agonists are known to increase levels of acetylcholine in the brain, which is consistent with the intended effect of drugs used to treat Alzheimer's disease.\n4. UNKNOWN: The method of administration and dosage regimen for Xanamem cannot be confirmed without specific information about the drug.\n5. UNKNOWN: Side effects listed are common among many medications, but without confirmation that Xanamem is a real drug and information about its properties, it's impossible to accurately state these are its side effects.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-7b_response": "The Hof1-Cyk3 interaction plays a crucial role in the regulation of cytokinesis in yeast. Hof1 is a protein that is involved in the regulation of the actin cytoskeleton, while Cyk3 is a protein that is involved in the regulation of the microtubule cytoskeleton. The Hof1-Cyk3 interaction allows for the coordination of the actin and microtubule cytoskeletons during cytokinesis, which is the process of dividing the cell into two daughter cells.\n\nDuring cytokinesis, the actin and microtubule cytoskeletons work together to divide the cell into two daughter cells. The Hof1-Cyk3 interaction allows for the coordination of these two cytoskeletons, as Cyk3 interacts with the actin cytoskeleton through its interaction with the Arp2/3 complex, while Hof1 interacts with the microtubule cytoskeleton through its interaction with the Kip3 protein.\n\nThe Hof1-Cyk3 interaction is also involved in the regulation of the actin cytoskeleton during the cell cycle. During interphase, the actin cytoskeleton is involved in the formation of the mitotic spindle, while during metaphase, the actin cytoskeleton is involved in the separation of the chromosomes. The Hof1-Cyk3 interaction allows for the coordination of the actin cytoskeleton during these different stages of the cell cycle.\n\nOverall, the Hof1-Cyk3 interaction plays a crucial role in the regulation of the actin and microtubule cytoskeletons during cytokinesis and the cell cycle in yeast. The coordination of these two cytoskeletons allows for the proper division of the cell into two daughter cells, and the regulation of the actin cytoskeleton during different stages of the cell cycle.",
    "llama-7b_fact_raw": "1. The Hof1-Cyk3 interaction is involved in the regulation of cytokinesis in yeast.\n2. Hof1 is a protein that regulates the actin cytoskeleton in yeast.\n3. Cyk3 is a protein that regulates the microtubule cytoskeleton in yeast.\n4. The coordination of the actin and microtubule cytoskeletons during cytokinesis is facilitated by the Hof1-Cyk3 interaction.\n5. The Hof1-Cyk3 interaction is involved in the regulation of the actin cytoskeleton during different stages of the yeast cell cycle, including interphase and metaphase.",
    "llama-7b_fact": [
      "The Hof1-Cyk3 interaction is involved in the regulation of cytokinesis in yeast.",
      "Hof1 is a protein that regulates the actin cytoskeleton in yeast.",
      "Cyk3 is a protein that regulates the microtubule cytoskeleton in yeast.",
      "The coordination of the actin and microtubule cytoskeletons during cytokinesis is facilitated by the Hof1-Cyk3 interaction.",
      "The Hof1-Cyk3 interaction is involved in the regulation of the actin cytoskeleton during different stages of the yeast cell cycle, including interphase and metaphase."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Cyk3 is not primarily known for regulating the microtubule cytoskeleton in yeast; it is involved in cell wall remodeling during cytokinesis.\n4. TRUE\n5. FALSE [correction]: The Hof1-Cyk3 interaction is specifically involved in the regulation of cytokinesis, which occurs at the end of the cell cycle, rather than during different stages such as interphase and metaphase.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3598,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in gastric cancer?",
    "llama-7b_response": "There are several T-UCRs that have been implicated in gastric cancer, including:\n\n1. TNF-alpha: TNF-alpha is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of TNF-alpha have been found in the stomach tissue of patients with gastric cancer, and TNF-alpha has been shown to promote the growth and survival of gastric cancer cells in vitro.\n2. IL-1beta: IL-1beta is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-1beta have been found in the stomach tissue of patients with gastric cancer, and IL-1beta has been shown to promote the growth and survival of gastric cancer cells in vitro.\n3. IFN-gamma: IFN-gamma is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IFN-gamma have been found in the stomach tissue of patients with gastric cancer, and IFN-gamma has been shown to promote the growth and survival of gastric cancer cells in vitro.\n4. IL-6: IL-6 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-6 have been found in the stomach tissue of patients with gastric cancer, and IL-6 has been shown to promote the growth and survival of gastric cancer cells in vitro.\n5. IL-8: IL-8 is a pro-inflammatory cytokine that has been implicated in the development of gastric cancer. High levels of IL-8 have been found in the stomach tissue of patients with gastric cancer, and IL-8 has been shown to promote the growth and survival of gastric cancer cells in vitro.\n6. TGF-beta: TGF-beta is a cytokine that has been implicated in the development of gastric cancer. High levels of TGF-beta have been found in the stomach tissue of patients with gastric cancer, and TG",
    "llama-7b_fact_raw": "1. TNF-alpha has been implicated in gastric cancer development, with increased levels found in the stomach tissue of patients.\n2. IL-1beta is another pro-inflammatory cytokine linked to the development of gastric cancer.\n3. IFN-gamma levels are elevated in the stomach tissue of patients with gastric cancer and are implicated in the disease's development.\n4. IL-6 is a pro-inflammatory cytokine that promotes the growth and survival of gastric cancer cells.\n5. IL-8 has been shown to have a role in gastric cancer, with high levels found in the stomach tissue of patients with the disease.",
    "llama-7b_fact": [
      "TNF-alpha has been implicated in gastric cancer development, with increased levels found in the stomach tissue of patients.",
      "IL-1beta is another pro-inflammatory cytokine linked to the development of gastric cancer.",
      "IFN-gamma levels are elevated in the stomach tissue of patients with gastric cancer and are implicated in the disease's development.",
      "IL-6 is a pro-inflammatory cytokine that promotes the growth and survival of gastric cancer cells.",
      "IL-8 has been shown to have a role in gastric cancer, with high levels found in the stomach tissue of patients with the disease."
    ],
    "llama-7b_judge_raw": "1. TRUE: TNF-alpha is a pro-inflammatory cytokine that has been implicated in the development of various cancers, including gastric cancer, with increased levels often found in the affected tissue.\n2. TRUE: IL-1beta is a pro-inflammatory cytokine that has been linked to the development and progression of gastric cancer, as it can contribute to the inflammatory environment that promotes cancer growth.\n3. TRUE: IFN-gamma is a cytokine that plays a role in immune responses and has also been found at elevated levels in the stomach tissue of patients with gastric cancer, suggesting its involvement in the disease's development.\n4. TRUE: IL-6 is a pro-inflammatory cytokine known to promote tumor growth and survival, and it has been associated with the progression of gastric cancer.\n5. TRUE: IL-8 is a pro-inflammatory cytokine that has been shown to be involved in gastric cancer, with higher levels often detected in patients with the condition, contributing to angiogenesis and tumor growth.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "You MUST give a detailed answer to the following question: What is the Lupus Severity Index (LSI)?",
    "llama-7b_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disorder that can affect various organs and systems in the body. The LSI was developed in the 1970s by a team of researchers led by Dr. Wallace McDermott at the National Institutes of Health (NIH) in Bethesda, Maryland.\n\nThe LSI is based on a comprehensive review of the medical history and physical examination findings of patients with SLE. The index assigns a score to each organ system affected by the disease, ranging from 0 to 4, with higher scores indicating more severe disease. The LSI also takes into account the presence and severity of certain clinical manifestations, such as malar rash, discoid rash, photosensitivity, lupus nephritis, and serositis.\n\nThe LSI has been widely used in clinical practice and research to assess the severity of SLE and to monitor the response to treatment. It is also used to predict the likelihood of disease flares and the risk of organ damage over time.\n\nIn summary, the Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disorder that can affect various organs and systems in the body. It is based on a comprehensive review of the medical history and physical examination findings of patients with SLE and assigns a score to each organ system affected by the disease, ranging from 0 to 4, with higher scores indicating more severe disease. The LSI has been widely used in clinical practice and research to assess the severity of SLE and to monitor the response to treatment, and it is also used to predict the likelihood of disease flares and the risk of organ damage over time.",
    "llama-7b_fact_raw": "1. The Lupus Severity Index (LSI) is a tool designed to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed in the 1970s by a team led by Dr. Wallace McDermott at the National Institutes of Health (NIH) in Bethesda, Maryland.\n3. The LSI assigns a numerical score to each organ system affected by SLE, with the scores ranging from 0 to 4.\n4. The Lupus Severity Index takes into account clinical manifestations such as malar rash, discoid rash, photosensitivity, lupus nephritis, and serositis.\n5. The LSI is used in clinical practice and research to monitor SLE patients' response to treatment and to predict the likelihood of disease flares and organ damage risk over time.",
    "llama-7b_fact": [
      "The Lupus Severity Index (LSI) is a tool designed to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed in the 1970s by a team led by Dr. Wallace McDermott at the National Institutes of Health (NIH) in Bethesda, Maryland.",
      "The LSI assigns a numerical score to each organ system affected by SLE, with the scores ranging from 0 to 4.",
      "The Lupus Severity Index takes into account clinical manifestations such as malar rash, discoid rash, photosensitivity, lupus nephritis, and serositis.",
      "The LSI is used in clinical practice and research to monitor SLE patients' response to treatment and to predict the likelihood of disease flares and organ damage risk over time."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely recognized tool called the Lupus Severity Index developed in the 1970s by Dr. Wallace McDermott at the NIH. However, several tools such as the SLE Disease Activity Index (SLEDAI) have been developed to assess the severity of SLE, but not specifically by the mentioned person or at that time.\n3. UNKNOWN (This might be true for specific SLE assessment scales, but it cannot be confirmed for the LSI without specific knowledge of such a tool.)\n4. TRUE (While the statement is true for common tools used to assess SLE, it cannot be confirmed for the nonexistent LSI mentioned. However, in the context of SLE assessment, these are typical clinical manifestations that would be included in such tools.)\n5. TRUE (The statement is generally true for SLE severity assessment tools, but again, assuming that the LSI exists and has these functions cannot be confirmed due to the lack of information about the LSI.)",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3615,
    "user_query": "You MUST give a detailed answer to the following question: Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-7b_response": "De novo mutations are genetic changes that occur for the first time in an individual and are not inherited from the parents. ZSWIM6 is a gene that has been associated with several disorders that are caused by de novo mutations.\n\nOne of the disorders caused by de novo mutations in ZSWIM6 is Charcot-Marie-Tooth disease (CMT). CMT is a group of genetic disorders that affect the peripheral nervous system, which is responsible for transmitting signals between the brain and the rest of the body. CMT can cause a range of symptoms, including muscle weakness, muscle atrophy, and loss of sensation in the feet and hands.\n\nAnother disorder caused by de novo mutations in ZSWIM6 is autism spectrum disorder (ASD). ASD is a neurodevelopmental disorder that is characterized by social communication difficulties, repetitive behaviors, and restricted interests. While the exact causes of ASD are not fully understood, genetic factors are thought to play a role in the development of the disorder.\n\nOther disorders that have been associated with de novo mutations in ZSWIM6 include intellectual disability, epilepsy, and cardiac arrhythmias. However, more research is needed to fully understand the role of ZSWIM6 in these disorders and the specific mechanisms by which de novo mutations in the gene contribute to their development.",
    "llama-7b_fact_raw": "1. De novo mutations in ZSWIM6 can cause Charcot-Marie-Tooth disease.\n2. Charcot-Marie-Tooth disease affects the peripheral nervous system with symptoms like muscle weakness and atrophy.\n3. Autism spectrum disorder, which includes social communication difficulties and repetitive behaviors, has been associated with de novo mutations in ZSWIM6.\n4. Intellectual disability is one of the disorders linked to de novo mutations in ZSWIM6.\n5. Cardiac arrhythmias have also been associated with de novo mutations in the ZSWIM6 gene.",
    "llama-7b_fact": [
      "De novo mutations in ZSWIM6 can cause Charcot-Marie-Tooth disease.",
      "Charcot-Marie-Tooth disease affects the peripheral nervous system with symptoms like muscle weakness and atrophy.",
      "Autism spectrum disorder, which includes social communication difficulties and repetitive behaviors, has been associated with de novo mutations in ZSWIM6.",
      "Intellectual disability is one of the disorders linked to de novo mutations in ZSWIM6.",
      "Cardiac arrhythmias have also been associated with de novo mutations in the ZSWIM6 gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: De novo mutations in ZSWIM6 are associated with developmental disorders that could include intellectual disability and autism, but Charcot-Marie-Tooth disease is typically associated with mutations in other genes such as PMP22, MFN2, MPZ, and others.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "You MUST give a detailed answer to the following question: Which disease can be classified using the Koos Classification?",
    "llama-7b_response": "osteoarthriti",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3628,
    "user_query": "You MUST give a detailed answer to the following question: What are the in vivo effects of AZD8601?",
    "llama-7b_response": "AZD8601 is a potent and selective inhibitor of the c-Met receptor tyrosine kinase, which is overexpressed in various types of cancer, including non-small cell lung cancer (NSCLC). In vivo studies have shown that AZD8601 has antitumor activity in preclinical models of cancer, including NSCLC.\n\nOne study published in the Journal of Clinical Oncology in 2015 evaluated the safety and efficacy of AZD8601 in patients with advanced solid tumors. The study enrolled 110 patients with various types of solid tumors, including NSCLC, and treated them with AZD8601 at doses ranging from 100 mg to 600 mg per day. The results showed that AZD8601 was well-tolerated and had antitumor activity in patients with advanced solid tumors, including those with NSCLC.\n\nAnother study published in the Journal of Clinical Oncology in 2017 evaluated the safety and efficacy of AZD8601 in combination with erlotinib, an EGFR inhibitor, in patients with advanced NSCLC. The study enrolled 152 patients with advanced NSCLC and treated them with AZD8601 and erlotinib or erlotinib alone. The results showed that the combination of AZD8601 and erlotinib was well-tolerated and had improved antitumor activity compared to erlotinib alone in patients with advanced NSCLC harboring EGFR-activating mutations.\n\nOverall, the in vivo effects of AZD8601 have been shown to include antitumor activity in preclinical models of cancer, including NSCLC, and improved antitumor activity in combination with erlotinib in patients with advanced NSCLC harboring EGFR-activating mutations. However, further clinical trials are needed to fully evaluate the safety and efficacy of AZD8601 in patients with NSCLC.",
    "llama-7b_fact_raw": "1. AZD8601 is an inhibitor of the c-Met receptor tyrosine kinase, which is often overexpressed in several types of cancer, including non-small cell lung cancer.\n2. In vivo studies indicate that AZD8601 has antitumor activity in preclinical models of cancer, including NSCLC.\n3. A study published in the Journal of Clinical Oncology in 2015 reported that AZD8601 was well-tolerated and showed antitumor activity in 110 patients with various types of advanced solid tumors.\n4. Another study published in the Journal of Clinical Oncology in 2017 revealed that the combination of AZD8601 and erlotinib improved antitumor activity compared to erlotinib alone in patients with advanced NSCLC with EGFR-activating mutations.\n5. Based on the given answer, additional clinical trials are suggested to be necessary to fully assess the safety and efficacy of AZD8601 in patients with NSCLC.",
    "llama-7b_fact": [
      "AZD8601 is an inhibitor of the c-Met receptor tyrosine kinase, which is often overexpressed in several types of cancer, including non-small cell lung cancer.",
      "In vivo studies indicate that AZD8601 has antitumor activity in preclinical models of cancer, including NSCLC.",
      "A study published in the Journal of Clinical Oncology in 2015 reported that AZD8601 was well-tolerated and showed antitumor activity in 110 patients with various types of advanced solid tumors.",
      "Another study published in the Journal of Clinical Oncology in 2017 revealed that the combination of AZD8601 and erlotinib improved antitumor activity compared to erlotinib alone in patients with advanced NSCLC with EGFR-activating mutations.",
      "Based on the given answer, additional clinical trials are suggested to be necessary to fully assess the safety and efficacy of AZD8601 in patients with NSCLC."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of the c-Met receptor tyrosine kinase; it is actually a developmental drug that encodes a modified mRNA for the vascular endothelial growth factor A (VEGF-A), intended for regenerative therapy.\n2. FALSE [correction]: Since AZD8601 is not an inhibitor of the c-Met receptor tyrosine kinase but rather a VEGF-A mRNA therapy, it is not accurate to make claims about its antitumor activity without the correct context. If there are in vivo studies for AZD8601, they would not be related to its role as a c-Met inhibitor.\n3. UNKNOWN: Without access to the actual study from the Journal of Clinical Oncology, the results concerning AZD8601 cannot be confirmed as true or false.\n4. UNKNOWN: Similar to the above statement, without access to the specific study from the Journal of Clinical Oncology, the results regarding the combination of AZD8601 (assuming it's the correct drug being referred to) and erlotinib cannot be confirmed as true or false.\n5. TRUE: Typically, additional clinical trials would indeed be necessary to fully assess the safety and efficacy of any developmental drug like AZD8601 in patients with a particular condition such as NSCLC.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "You MUST give a detailed answer to the following question: How are SAHFS created?",
    "llama-7b_response": "SAHFs (Secure Attestation of Hardware Functionality) are created through a process called \"attestation.\" Attestation is the process of verifying the authenticity and integrity of a hardware device, such as a smart card or a secure element, to ensure that it is functioning as intended and has not been tampered with.\n\nThe attestation process typically involves the following steps:\n\n1. Device Enrollment: The device, such as a smart card or a secure element, is enrolled in the attestation system. This involves generating a unique identifier for the device and storing it in a secure database.\n2. Attestation Request: The attestation request is sent to the device by the attestation system. The request contains information about the services that the device is expected to provide, as well as any constraints or requirements that need to be met.\n3. Device Response: The device responds to the attestation request by providing information about its hardware and software components, as well as its current state and configuration. This information is used to verify the authenticity and integrity of the device.\n4. Attestation Report: The attestation system generates an attestation report that contains the results of the attestation process. This report includes information about the device's hardware and software components, as well as its current state and configuration.\n5. Certificate Generation: If the attestation process is successful, the attestation system generates a digital certificate that certifies the authenticity and integrity of the device. This certificate can be used to verify the identity of the device and ensure that it is functioning as intended.\n\nOverall, the process of creating a SAHF involves attesting the authenticity and integrity of a hardware device, such as a smart card or a secure element, to ensure that it is functioning as intended and has not been tampered with. The attestation process typically involves enrolling the device in the attestation system, sending an attestation request to the device, receiving a device response, generating an attestation report, and generating a digital certificate if the attestation process is successful.",
    "llama-7b_fact_raw": "1. SAHFs (Secure Attestation of Hardware Functionality) are created through a process called \"attestation.\"\n2. Attestation verifies the authenticity and integrity of a hardware device to ensure it hasn't been tampered with.\n3. Device enrollment in the attestation process involves generating a unique identifier for the device and storing it in a secure database.\n4. The attestation system generates an attestation report that includes information about the device's hardware and software components, as well as its current state and configuration.\n5. A digital certificate is generated if the attestation process is successful, certifying the device's authenticity and integrity.",
    "llama-7b_fact": [
      "SAHFs (Secure Attestation of Hardware Functionality) are created through a process called \"attestation.\"",
      "Attestation verifies the authenticity and integrity of a hardware device to ensure it hasn't been tampered with.",
      "Device enrollment in the attestation process involves generating a unique identifier for the device and storing it in a secure database.",
      "The attestation system generates an attestation report that includes information about the device's hardware and software components, as well as its current state and configuration.",
      "A digital certificate is generated if the attestation process is successful, certifying the device's authenticity and integrity."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - However, it's worth noting that the specifics of device enrollment can vary depending on the attestation system. The concept of generating a unique identifier and storing it securely would be a common aspect of the process.\n4. TRUE\n5. TRUE - If the attestation process is successful, a type of digital certificate or attestation report can be generated as evidence of the device's authenticity and integrity. However, it's important to note the term \"digital certificate\" is not exclusively used in the context of hardware attestation, and it might refer to different things in different contexts.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the PDZ domain in SATB1?",
    "llama-7b_response": "The PDZ domain is a protein interaction domain found in many proteins, including the transcription factor SATB1 (Special AT-rich sequence binding protein 1). The function of the PDZ domain in SATB1 is to mediate protein-protein interactions with other proteins.\n\nThe PDZ domain in SATB1 specifically interacts with other proteins that contain a PDZ-binding motif, which is a specific sequence of amino acids that is recognized by the PDZ domain. These proteins include other transcription factors, scaffold proteins, and signaling molecules.\n\nThe PDZ domain in SATB1 plays a crucial role in the regulation of gene expression by SATB1. By interacting with other proteins, SATB1 can recruit these proteins to specific regions of the genome, where they can regulate the expression of genes involved in a variety of biological processes.\n\nFor example, SATB1 has been shown to interact with other transcription factors, such as E2F1 and YY1, which are involved in the regulation of cell proliferation and differentiation. By interacting with these proteins through its PDZ domain, SATB1 can help to coordinate the expression of genes involved in these processes.\n\nIn addition to its role in transcriptional regulation, the PDZ domain in SATB1 also plays a role in the post-translational modification of SATB1. For example, the PDZ domain in SATB1 has been shown to interact with the ubiquitin ligase Nedd4-1, which can target SATB1 for degradation through the ubiquitin-proteasome pathway.\n\nOverall, the PDZ domain in SATB1 is an important protein interaction domain that plays a critical role in the regulation of gene expression and the post-translational modification of SATB1.",
    "llama-7b_fact_raw": "1. The PDZ domain in SATB1 mediates protein-protein interactions with other proteins that contain a PDZ-binding motif.\n2. SATB1, which stands for Special AT-rich sequence binding protein 1, is a transcription factor with a PDZ domain.\n3. SATB1 recruits proteins to specific regions of the genome to regulate gene expression involved in biological processes such as cell proliferation and differentiation.\n4. SATB1 interacts with the transcription factors E2F1 and YY1 through its PDZ domain.\n5. The PDZ domain in SATB1 interacts with the ubiquitin ligase Nedd4-1, which can target SATB1 for degradation through the ubiquitin-proteasome pathway.",
    "llama-7b_fact": [
      "The PDZ domain in SATB1 mediates protein-protein interactions with other proteins that contain a PDZ-binding motif.",
      "SATB1, which stands for Special AT-rich sequence binding protein 1, is a transcription factor with a PDZ domain.",
      "SATB1 recruits proteins to specific regions of the genome to regulate gene expression involved in biological processes such as cell proliferation and differentiation.",
      "SATB1 interacts with the transcription factors E2F1 and YY1 through its PDZ domain.",
      "The PDZ domain in SATB1 interacts with the ubiquitin ligase Nedd4-1, which can target SATB1 for degradation through the ubiquitin-proteasome pathway."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation for statement 4 and 5: The statements regarding specific interactions of SATB1 through its PDZ domain with E2F1, YY1, and ubiquitin ligase Nedd4-1 would require direct evidence or specific literature citations to confirm their accuracy. Without additional context or specific references, we cannot accurately determine the veracity of these interactions, hence the classification as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the BLISS technique?",
    "llama-7b_response": "The BLISS technique is based on the idea that the brain can be trained to produce different states of consciousness.",
    "llama-7b_fact_raw": "1. The BLISS technique is intended to train the brain to produce different states of consciousness.",
    "llama-7b_fact": [
      "The BLISS technique is intended to train the brain to produce different states of consciousness."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "You MUST give a detailed answer to the following question: List 3 NK3R antagonists.",
    "llama-7b_response": "NK3 receptor antagonists are medications that block the action of the NK3 receptor, which is a subtype of the neurokinin-1 (NK1) receptor. The NK3 receptor is found primarily in the central nervous system and is involved in the regulation of pain, inflammation, and other physiological processes. Here are three examples of NK3R antagonists:\n\n1. Aprepitant: Aprepitant is a medication that is used to prevent nausea and vomiting caused by chemotherapy. It works by blocking the NK3 receptor and other receptors involved in the regulation of nausea and vomiting.\n2. Sitagliptin: Sitagliptin is a medication that is used to treat type 2 diabetes. It works by increasing the amount of insulin produced by the pancreas and by decreasing the amount of glucose produced by the liver. Sitagliptin also blocks the NK3 receptor, which may contribute to its effects on glucose metabolism.\n3. Pregabalin: Pregabalin is a medication that is used to treat neuropathic pain and anxiety disorders. It works by blocking the NK3 receptor and other receptors involved in the regulation of pain and anxiety. Pregabalin is also a member of a class of medications called gabapentinoids, which are structurally related to the neurotransmitter gamma-aminobutyric acid (GABA).",
    "llama-7b_fact_raw": "1. Aprepitant is a medication used to prevent chemotherapy-induced nausea and vomiting and acts as an NK3 receptor antagonist.\n2. Sitagliptin is a medication used to treat type 2 diabetes and has an effect on the NK3 receptor.\n3. Pregabalin is a medication used to treat neuropathic pain and anxiety disorders, and it functions as an NK3 receptor antagonist.\n4. NK3 receptor antagonists are used in the regulation of pain, inflammation, and other physiological processes.\n5. The NK3 receptor is a subtype of the neurokinin-1 (NK1) receptor and is primarily found in the central nervous system.",
    "llama-7b_fact": [
      "Aprepitant is a medication used to prevent chemotherapy-induced nausea and vomiting and acts as an NK3 receptor antagonist.",
      "Sitagliptin is a medication used to treat type 2 diabetes and has an effect on the NK3 receptor.",
      "Pregabalin is a medication used to treat neuropathic pain and anxiety disorders, and it functions as an NK3 receptor antagonist.",
      "NK3 receptor antagonists are used in the regulation of pain, inflammation, and other physiological processes.",
      "The NK3 receptor is a subtype of the neurokinin-1 (NK1) receptor and is primarily found in the central nervous system."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Aprepitant is a medication used to prevent chemotherapy-induced nausea and vomiting and acts as an NK1 receptor antagonist, not an NK3 receptor antagonist.\n2. FALSE [correction]: Sitagliptin is a medication used to treat type 2 diabetes but it does not have an effect on NK3 receptors; instead, it inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which increases the levels of incretin hormones.\n3. FALSE [correction]: Pregabalin is a medication used to treat neuropathic pain and anxiety disorders, but it does not function as an NK3 receptor antagonist; it works by inhibiting certain calcium channels.\n4. UNKNOWN: While NK receptor antagonists can potentially affect processes such as pain and inflammation, the statement is vague regarding which NK receptor subtype is involved and how they are regulated.\n5. FALSE [correction]: The NK3 receptor is not a subtype of the neurokinin-1 (NK1) receptor; rather, it is a separate receptor that is part of the tachykinin receptor family, which includes NK1, NK2, and NK3 receptors. The NK1 receptor is primarily involved in the central nervous system functions such as nausea and vomiting.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "You MUST give a detailed answer to the following question: Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-7b_response": "liraglutide",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3693,
    "user_query": "You MUST give a detailed answer to the following question: What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-7b_response": "Vaxchora is a vaccine that is approved for the prevention of cholera caused by the serogroup Ogawa in adults aged 18 years and older. The vaccine is administered as a single-dose subcutaneous injection.\n\nThe protective efficacy of Vaxchora against moderate to severe cholera was evaluated in a randomized, double-blind, placebo-controlled trial conducted in Bangladesh. The trial enrolled adults aged 18 years and older who were at risk of exposure to cholera. The participants were randomly assigned to receive either Vaxchora or placebo, and were followed for up to 12 months.\n\nThe results of the trial showed that Vaxchora was highly effective in protecting against cholera caused by the serogroup Ogawa. The vaccine was estimated to be 86% effective in preventing moderate to severe cholera cases, and 92% effective in preventing severe cholera cases. The vaccine was also found to be well-tolerated and had a good safety profile.\n\nIn summary, the protective efficacy of Vaxchora against moderate to severe cholera is high, with the vaccine estimated to be 86% effective in preventing moderate to severe cholera cases and 92% effective in preventing severe cholera cases. The vaccine is recommended for use in adults aged 18 years and older who are at risk of exposure to cholera.",
    "llama-7b_fact_raw": "1. Vaxchora is approved for the prevention of cholera caused by serogroup Ogawa in adults aged 18 years and older.\n2. Vaxchora is administered as a single-dose subcutaneous injection.\n3. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Vaxchora was conducted in Bangladesh with adults aged 18 and older.\n4. The trial estimated Vaxchora's protective efficacy against moderate to severe cholera to be 86%.\n5. Vaxchora was estimated to be 92% effective in preventing severe cholera cases.",
    "llama-7b_fact": [
      "Vaxchora is approved for the prevention of cholera caused by serogroup Ogawa in adults aged 18 years and older.",
      "Vaxchora is administered as a single-dose subcutaneous injection.",
      "A randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Vaxchora was conducted in Bangladesh with adults aged 18 and older.",
      "The trial estimated Vaxchora's protective efficacy against moderate to severe cholera to be 86%.",
      "Vaxchora was estimated to be 92% effective in preventing severe cholera cases."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Vaxchora is administered as a single-dose oral vaccine, not as a subcutaneous injection.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "You MUST give a detailed answer to the following question: Which was the first cholera vaccine approved in the US?",
    "llama-7b_response": "cholera vaccine",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3737,
    "user_query": "You MUST give a detailed answer to the following question: Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-7b_response": "adenosine deaminase deficiency",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3743,
    "user_query": "You MUST give a detailed answer to the following question: Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-7b_response": "The IFIT1 (Interferon, alpha-inducible) gene is a member of the type I interferon (IFN) gene family, which plays a crucial role in the immune response against viral infections. The IFIT1 gene encodes for a protein that is involved in the antiviral response by inducing the expression of other IFN-stimulated genes (ISGs).\n\nIn the context of Systemic Lupus Erythematosus (SLE), the role of the IFIT1 gene is not well understood. However, there is some evidence to suggest that the IFIT1 gene may be involved in the pathogenesis of SLE.\n\nFor example, a study published in the journal Arthritis & Rheumatology in 2018 found that individuals with SLE had lower levels of IFIT1 mRNA expression in their peripheral blood mononuclear cells compared to healthy controls. This suggests that the IFIT1 gene may be dysregulated in SLE.\n\nAdditionally, a study published in the journal PLoS One in 2016 found that the IFIT1 gene was downregulated in SLE patients compared to healthy controls. This suggests that the IFIT1 gene may play a role in the pathogenesis of SLE.\n\nHowever, further research is needed to fully understand the role of the IFIT1 gene in SLE.",
    "llama-7b_fact_raw": "1. The IFIT1 (Interferon, alpha-inducible) gene is a member of the type I interferon (IFN) gene family.\n2. The IFIT1 gene is involved in the antiviral response by inducing the expression of other IFN-stimulated genes (ISGs).\n3. A study published in Arthritis & Rheumatology in 2018 reported that individuals with Systemic Lupus Erythematosus (SLE) had lower levels of IFIT1 mRNA expression in their peripheral blood mononuclear cells than healthy controls.\n4. A study published in PLoS One in 2016 found that the IFIT1 gene was downregulated in patients with SLE.\n5. There is evidence suggesting the IFIT1 gene may be involved in the pathogenesis of Systemic Lupus Erythematosus.",
    "llama-7b_fact": [
      "The IFIT1 (Interferon, alpha-inducible) gene is a member of the type I interferon (IFN) gene family.",
      "The IFIT1 gene is involved in the antiviral response by inducing the expression of other IFN-stimulated genes (ISGs).",
      "A study published in Arthritis & Rheumatology in 2018 reported that individuals with Systemic Lupus Erythematosus (SLE) had lower levels of IFIT1 mRNA expression in their peripheral blood mononuclear cells than healthy controls.",
      "A study published in PLoS One in 2016 found that the IFIT1 gene was downregulated in patients with SLE.",
      "There is evidence suggesting the IFIT1 gene may be involved in the pathogenesis of Systemic Lupus Erythematosus."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The IFIT1 (Interferon-induced protein with tetratricopeptide repeats 1) gene is not a member of the type I interferon (IFN) gene family; it is stimulated by type I interferons and is part of the interferon-stimulated genes (ISGs).\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "You MUST give a detailed answer to the following question: What is the use of the Liverpool Elbow Score?",
    "llama-7b_response": "​",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3763,
    "user_query": "You MUST give a detailed answer to the following question: Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-7b_response": "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with cancer or rare diseases. As part of this project, efforts have been made to sequence genomes of patients with sarcoma, a type of cancer that affects the soft tissues and bones.\n\nOne of the key objectives of the 100,000 Genomes Project is to use genomic data to improve diagnosis, treatment, and care for patients with cancer and rare diseases. In the case of sarcoma, genomic data can be used to identify specific subtypes of the disease, which can then be targeted with more effective treatments.\n\nTo sequence the genomes of patients with sarcoma as part of the 100,000 Genomes Project, researchers used a combination of next-generation sequencing (NGS) technologies, including whole-exome sequencing and targeted sequencing. Whole-exome sequencing involves sequencing only the protein-coding regions of the genome, while targeted sequencing involves sequencing specific genes or regions of the genome that are known to be associated with a particular disease.\n\nIn addition to sequencing the genomes of patients with sarcoma, the 100,000 Genomes Project is also analyzing the data to identify genomic variants that may be associated with the disease. These variants can then be used to develop targeted therapies and personalized treatment plans for patients with sarcoma.\n\nOverall, the efforts on sarcoma from the 100,000 Genomes Project are aimed at improving diagnosis, treatment, and care for patients with this type of cancer. By sequencing the genomes of patients with sarcoma and analyzing the data, researchers hope to identify specific subtypes of the disease and develop targeted therapies that can improve patient outcomes.",
    "llama-7b_fact_raw": "1. The 100,000 Genomes Project is an initiative in the UK that sequences whole genomes from NHS patients with cancer or rare diseases, including those with sarcoma.\n2. The project seeks to use genomic data to enhance diagnosis, treatment, and patient care for conditions like sarcoma.\n3. Researchers involved in the project use next-generation sequencing technologies such as whole-exome sequencing and targeted sequencing for patients with sarcoma.\n4. Whole-exome sequencing sequences only the protein-coding regions of the genome.\n5. The project aims to identify genomic variants associated with sarcoma to develop targeted therapies and personalized treatment plans.",
    "llama-7b_fact": [
      "The 100,000 Genomes Project is an initiative in the UK that sequences whole genomes from NHS patients with cancer or rare diseases, including those with sarcoma.",
      "The project seeks to use genomic data to enhance diagnosis, treatment, and patient care for conditions like sarcoma.",
      "Researchers involved in the project use next-generation sequencing technologies such as whole-exome sequencing and targeted sequencing for patients with sarcoma.",
      "Whole-exome sequencing sequences only the protein-coding regions of the genome.",
      "The project aims to identify genomic variants associated with sarcoma to develop targeted therapies and personalized treatment plans."
    ],
    "llama-7b_judge_raw": "1. TRUE: The 100,000 Genomes Project is indeed an initiative in the UK that focuses on sequencing whole genomes of NHS patients with cancer, including those with sarcoma, or rare diseases.\n2. TRUE: One of the key goals of the project is to use genomic data to improve diagnosis, treatment, and care for patients with various conditions, which includes sarcoma.\n3. FALSE [correction]: While the researchers may use next-generation sequencing technologies, the core of the 100,000 Genomes Project is whole-genome sequencing rather than whole-exome sequencing or targeted sequencing.\n4. TRUE: Whole-exome sequencing is a technique that sequences only the protein-coding regions of the genome, which constitute about 1-2% of the human genome but contain the majority of known disease-related variants.\n5. TRUE: An objective of the project is to identify genomic variants that may be associated with various conditions, including sarcoma, to inform the development of targeted therapies and personalized treatment plans.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "You MUST give a detailed answer to the following question: Does protein ALEX1 contain armadillo repeats?",
    "llama-7b_response": "Yes, protein ALEX1 contains armadillo repeats.",
    "llama-7b_fact_raw": "1. Protein ALEX1 contains armadillo repeats.",
    "llama-7b_fact": [
      "Protein ALEX1 contains armadillo repeats."
    ],
    "llama-7b_judge_raw": "UNKNOWN",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "You MUST give a detailed answer to the following question: List enzymes that removes histone modifications.",
    "llama-7b_response": "There are several enzymes that can remove histone modifications, including:\n\n1. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histones, leading to a decrease in histone acetylation and an increase in histone deacetylation.\n2. Histone methyltransferases (HMTs): These enzymes add methyl groups to histones, leading to a decrease in histone methylation and an increase in histone demethylation.\n3. Histone demethylases: These enzymes remove methyl groups from histones, leading to a decrease in histone methylation and an increase in histone demethylation.\n4. Lysine-specific demethylase 1 (LSD1): This enzyme removes methyl groups from lysine residues on histones, leading to a decrease in histone methylation and an increase in histone demethylation.\n5. Jumonji domain-containing protein 3 (JMJD3): This enzyme removes methyl groups from lysine residues on histones, leading to a decrease in histone methylation and an increase in histone demethylation.",
    "llama-7b_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histones.\n2. Although listed, Histone methyltransferases (HMTs) do not remove methyl groups; instead, they add methyl groups to histones.\n3. Histone demethylases remove methyl groups from histones.\n4. Lysine-specific demethylase 1 (LSD1) removes methyl groups from lysine residues on histones.\n5. Jumonji domain-containing protein 3 (JMJD3) removes methyl groups from lysine residues on histones.",
    "llama-7b_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histones.",
      "Although listed, Histone methyltransferases (HMTs) do not remove methyl groups; instead, they add methyl groups to histones.",
      "Histone demethylases remove methyl groups from histones.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from lysine residues on histones.",
      "Jumonji domain-containing protein 3 (JMJD3) removes methyl groups from lysine residues on histones."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "You MUST give a detailed answer to the following question: Does head ct increase brain tumor risk?",
    "llama-7b_response": "The relationship between head CT scans and the risk of brain tumors is a complex one, and the answer is not straightforward.\n\nA head CT scan, also known as a computed tomography scan, is a medical imaging test that uses X-rays to create detailed images of the head and brain. It is commonly used to diagnose a variety of conditions, including brain tumors.\n\nWhile head CT scans are generally considered safe, there is some evidence to suggest that they may increase the risk of developing a brain tumor. This is because CT scans use X-rays, which are a form of ionizing radiation. Exposure to ionizing radiation has been linked to an increased risk of developing certain types of cancer, including brain tumors.\n\nHowever, it is worth noting that the risk of developing a brain tumor from a single head CT scan is relatively low. The risk is generally considered to be low enough that the benefits of the scan outweigh the potential risks for the vast majority of patients.\n\nIn addition, the risk of developing a brain tumor from a head CT scan depends on a number of factors, including the type and frequency of the scan, the patient's age and health status, and their exposure to other sources of ionizing radiation.\n\nOverall, while there is some evidence to suggest that head CT scans may increase the risk of developing a brain tumor, the risk is generally considered to be low, and the benefits of the scan may outweigh the potential risks for the vast majority of patients. It is important for patients to discuss the risks and benefits of a head CT scan with their healthcare provider before undergoing the procedure.",
    "llama-7b_fact_raw": "1. Head CT scans, known as computed tomography scans, use X-rays to create detailed images of the head and brain.\n2. There is evidence suggesting that exposure to ionizing radiation from CT scans may increase the risk of developing certain types of cancer, including brain tumors.\n3. The risk of developing a brain tumor from a single head CT scan is generally considered to be relatively low.\n4. The benefits of a head CT scan typically outweigh the potential risks for most patients.\n5. The risk of developing a brain tumor from head CT scans depends on various factors, such as the type and frequency of the scan, the patient's age and health status, and their exposure to other sources of ionizing radiation.",
    "llama-7b_fact": [
      "Head CT scans, known as computed tomography scans, use X-rays to create detailed images of the head and brain.",
      "There is evidence suggesting that exposure to ionizing radiation from CT scans may increase the risk of developing certain types of cancer, including brain tumors.",
      "The risk of developing a brain tumor from a single head CT scan is generally considered to be relatively low.",
      "The benefits of a head CT scan typically outweigh the potential risks for most patients.",
      "The risk of developing a brain tumor from head CT scans depends on various factors, such as the type and frequency of the scan, the patient's age and health status, and their exposure to other sources of ionizing radiation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "You MUST give a detailed answer to the following question: Which type of pluripotency is Otx2 associated with?",
    "llama-7b_response": "transcriptional",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3815,
    "user_query": "You MUST give a detailed answer to the following question: How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-7b_response": "The number of DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region is not a fixed number, as the number of DHS can vary depending on the experimental conditions and the method used to detect them. However, the beta globin locus region is known to have a relatively high number of DHS compared to other regions of the genome.\n\nIn general, DHS are regions of the genome that are more accessible to DNaseI enzymes, indicating that the DNA in these regions is more easily digested by the enzyme. The beta globin locus region, which contains the genes that encode the beta globin subunits of hemoglobin, is known to have a high number of DHS due to the presence of repetitive sequences and other factors that make the DNA in this region more accessible to DNaseI enzymes.\n\nThe exact number of DHS in the murine beta globin locus region can vary depending on the experimental conditions and the method used to detect them. For example, some studies have reported that the beta globin locus region contains hundreds or even thousands of DHS, while other studies have reported lower numbers.\n\nIn summary, the number of DHS that mark the murine beta globin locus region is not a fixed number and can vary depending on the experimental conditions and the method used to detect them. However, the beta globin locus region is known to have a relatively high number of DHS compared to other regions of the genome.",
    "llama-7b_fact_raw": "1. The number of DNaseI hypersensitive sites marking the murine beta globin locus region is variable.\n2. The variability in the number of DNaseI hypersensitive sites can be attributed to experimental conditions and detection methods used.\n3. DNaseI hypersensitive sites are genomic regions more accessible to DNaseI enzymes.\n4. The murine beta globin locus region is characterized by having a relatively high number of DNaseI hypersensitive sites compared to other genomic regions.\n5. The beta globin locus contains genes that encode for the beta globin subunits of hemoglobin.",
    "llama-7b_fact": [
      "The number of DNaseI hypersensitive sites marking the murine beta globin locus region is variable.",
      "The variability in the number of DNaseI hypersensitive sites can be attributed to experimental conditions and detection methods used.",
      "DNaseI hypersensitive sites are genomic regions more accessible to DNaseI enzymes.",
      "The murine beta globin locus region is characterized by having a relatively high number of DNaseI hypersensitive sites compared to other genomic regions.",
      "The beta globin locus contains genes that encode for the beta globin subunits of hemoglobin."
    ],
    "llama-7b_judge_raw": "1. TRUE: The number of DNaseI hypersensitive sites can indeed be variable. These sites are areas of the genome that are more open to transcription factors and are often associated with active regulatory regions such as promoters and enhancers. The number of these sites at a given locus, including the murine beta globin locus, can vary based on cell type, developmental stage, and other biological factors.\n\n2. TRUE: The variability in the number of DNaseI hypersensitive sites can be influenced by experimental conditions such as the concentration of DNaseI enzyme used, the duration of the digestion, and the sensitivity of the detection method. Different experimental setups can yield different profiles of hypersensitive sites.\n\n3. TRUE: DNaseI hypersensitive sites are indeed genomic regions that are more accessible to DNaseI and other enzymes. This is typically because the chromatin in these regions is less condensed, allowing for easier access by these enzymes.\n\n4. UNKNOWN: Without specific evidence from the supplied context, it is not possible to definitively say whether the murine beta globin locus has a relatively high number of DNaseI hypersensitive sites compared to other genomic regions. This can vary widely depending on many factors, and without context, the statement remains undetermined.\n\n5. TRUE: The beta globin locus does contain genes that encode for the beta globin subunits of hemoglobin. In humans and other mammals, the beta globin genes are an essential component of hemoglobin, the protein responsible for transporting oxygen in the blood.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "You MUST give a detailed answer to the following question: List as many European influenza vaccines as possible.",
    "llama-7b_response": "1. Fluarix (GlaxoSmithKline)\n2. FluLaval (Sanofi Pasteur)\n3. Fluvirin (Novartis)\n4. FluMist (MedImmune)\n5. Fluad (Novartis)\n6. Fluarix Quadrivalent (GlaxoSmithKline)\n7. FluLaval Quadrivalent (Sanofi Pasteur)\n8. Fluvirin Quadrivalent (Novartis)\n9. FluMist Quadrivalent (MedImmune)\n10. Fluad Quadrivalent (Novartis)\n11. Fluarix Tetravalent (GlaxoSmithKline)\n12. FluLaval Tetravalent (Sanofi Pasteur)\n13. Fluvirin Tetravalent (Novartis)\n14. FluMist Tetravalent (MedImmune)\n15. Fluad Tetravalent (Novartis)\n16. Fluarix High-Dose (GlaxoSmithKline)\n17. FluLaval High-Dose (Sanofi Pasteur)\n18. Fluvirin High-Dose (Novartis)\n19. FluMist High-Dose (MedImmune)\n20. Fluad High-Dose (Novartis)\n21. Fluarix Quadrivalent Adjuvanted (GlaxoSmithKline)\n22. FluLaval Quadrivalent Adjuvanted (Sanofi Pasteur)\n23. Fluvirin Quadrivalent Adjuvanted (Novartis)\n24. FluMist Quadrivalent Adjuvanted (MedImmune)\n25. Fluad Quadrivalent Adjuvanted (Novartis)\n26. Fluarix Tetravalent Adjuvanted (GlaxoSmithKline)\n27. FluLaval Tetravalent Adjuvanted (Sanofi Pasteur)\n28. Fluvirin Tetravalent Adjuvanted (Nov",
    "llama-7b_fact_raw": "1. Fluarix is a brand of influenza vaccine produced by GlaxoSmithKline.\n2. FluLaval is a brand of influenza vaccine produced by Sanofi Pasteur.\n3. Fluvirin is a brand of influenza vaccine produced by Novartis.\n4. FluMist is a brand of influenza vaccine produced by MedImmune.\n5. Fluad is a brand of influenza vaccine produced by Novartis.",
    "llama-7b_fact": [
      "Fluarix is a brand of influenza vaccine produced by GlaxoSmithKline.",
      "FluLaval is a brand of influenza vaccine produced by Sanofi Pasteur.",
      "Fluvirin is a brand of influenza vaccine produced by Novartis.",
      "FluMist is a brand of influenza vaccine produced by MedImmune.",
      "Fluad is a brand of influenza vaccine produced by Novartis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: FluLaval is a brand of influenza vaccine produced by GlaxoSmithKline.\n3. FALSE [correction]: Fluvirin was originally produced by Novartis, but as of my knowledge cutoff in 2023, the influenza vaccine portfolio of Novartis was acquired by CSL's Seqirus.\n4. TRUE\n5. FALSE [correction]: Fluad is a brand of influenza vaccine produced by Seqirus, which as of my knowledge cutoff in 2023, is part of the CSL Group.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "You MUST give a detailed answer to the following question: Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-7b_response": "Yes, the Paramyxovirus geneome is segmented and negative-sense RNA.\n\nParamyxoviruses are a family of viruses that cause a wide range of diseases in humans and animals, including the common cold, measles, mumps, and respiratory syncytial virus (RSV). The genome of paramyxoviruses is segmented, meaning that it is made up of multiple segments of negative-sense RNA.\n\nEach segment of the paramyxovirus genome encodes a specific protein that is necessary for the virus to replicate and cause infection. The negative-sense RNA means that the genetic information is read in the opposite direction to the usual sense RNA, from 3' to 5'.\n\nThe negative-sense RNA genome of paramyxoviruses is surrounded by a protein coat, which is made up of the proteins encoded by the other segments of the genome. This protein coat helps the virus to infect cells and to evade the immune system.\n\nOverall, the segmented, negative-sense RNA genome of paramyxoviruses is an important factor in their ability to cause disease and to evade the immune system.",
    "llama-7b_fact_raw": "1. The genome of paramyxoviruses is made up of multiple segments of RNA.\n2. Paramyxoviruses have a negative-sense RNA genome.\n3. The negative-sense RNA of paramyxoviruses means the genetic information is read from 3' to 5'.\n4. Each segment of the paramyxovirus genome encodes for a specific protein necessary for the virus to replicate and cause infection.\n5. The negative-sense RNA genome of paramyxoviruses is surrounded by a protein coat.",
    "llama-7b_fact": [
      "The genome of paramyxoviruses is made up of multiple segments of RNA.",
      "Paramyxoviruses have a negative-sense RNA genome.",
      "The negative-sense RNA of paramyxoviruses means the genetic information is read from 3' to 5'.",
      "Each segment of the paramyxovirus genome encodes for a specific protein necessary for the virus to replicate and cause infection.",
      "The negative-sense RNA genome of paramyxoviruses is surrounded by a protein coat."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The genome of paramyxoviruses is made up of a single strand of non-segmented negative-sense RNA.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Paramyxovirus have a non-segmented genome; thus, their single RNA strand encodes for multiple proteins necessary for the virus to replicate and cause infection.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "You MUST give a detailed answer to the following question: Roflumilast Cream is effective for which disease?",
    "llama-7b_response": "evere asthma",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3885,
    "user_query": "You MUST give a detailed answer to the following question: Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-7b_response": "There are several tools that have been developed for identifying and visualizing ncRNA promoters. Some of the most commonly used tools include:\n\n1. UCSC Genome Browser: The UCSC Genome Browser is a web-based genome annotation resource that provides a variety of tools for identifying and visualizing ncRNA promoters. The browser allows users to search for and view genomic features, including promoters, using a variety of annotation tracks and tools.\n2. ENCODE Project: The ENCODE (Encyclopedia of DNA Elements) Project is a large-scale effort to identify and characterize all functional elements in the human genome. As part of this project, the ENCODE Consortium has developed a variety of tools and resources for identifying and visualizing ncRNA promoters, including the UCSC Genome Browser track \"Human ENCODE Promoter Roadmap\".\n3. DNase-seq Viewer: The DNase-seq Viewer is a web-based tool developed by the ENCODE Project that allows users to visualize DNase I hypersensitivity sites, which are often associated with ncRNA promoters. The tool allows users to search for and view DNase I hypersensitivity sites in a variety of genomic contexts, including across different cell types and tissues.\n4. RNA-seq Viewer: The RNA-seq Viewer is a web-based tool developed by the ENCODE Project that allows users to visualize RNA-seq data, including ncRNA transcripts and their corresponding expression levels. The tool allows users to search for and view RNA-seq data in a variety of genomic contexts, including across different cell types and tissues.\n5. CisGenome: CisGenome is a web-based tool developed by the ENCODE Project that allows users to search for and view genomic features, including ncRNA promoters, using a variety of annotation tracks and tools. The tool allows users to search for and view ncRNA promoters in a variety of genomic contexts, including across different cell types and tissues.\n\nOverall, these tools provide researchers with a variety of resources for identifying and visualizing ncRNA promoters, and can be used in conjunction with other bioinformatic",
    "llama-7b_fact_raw": "1. The UCSC Genome Browser is a web-based annotation resource used for identifying and visualizing ncRNA promoters.\n2. The ENCODE Project has developed tools and resources for characterizing functional elements in the human genome, including ncRNA promoters.\n3. The DNase-seq Viewer developed by the ENCODE Project visualizes DNase I hypersensitivity sites that are often associated with ncRNA promoters.\n4. The RNA-seq Viewer developed by the ENCODE Project allows visualization of RNA-seq data, including ncRNA transcripts and their expression levels.\n5. CisGenome is a web-based tool that can be used to search for and view ncRNA promoters among other genomic features.",
    "llama-7b_fact": [
      "The UCSC Genome Browser is a web-based annotation resource used for identifying and visualizing ncRNA promoters.",
      "The ENCODE Project has developed tools and resources for characterizing functional elements in the human genome, including ncRNA promoters.",
      "The DNase-seq Viewer developed by the ENCODE Project visualizes DNase I hypersensitivity sites that are often associated with ncRNA promoters.",
      "The RNA-seq Viewer developed by the ENCODE Project allows visualization of RNA-seq data, including ncRNA transcripts and their expression levels.",
      "CisGenome is a web-based tool that can be used to search for and view ncRNA promoters among other genomic features."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The UCSC Genome Browser is a web-based annotation resource used for a wide range of genomic data, not exclusively for identifying and visualizing ncRNA promoters.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "You MUST give a detailed answer to the following question: List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-7b_response": "The SWIM tool is a web-based tool developed by the National Center for Biotechnology Information (NCBI) that uses gene expression data to identify genes that are down-regulated in specific types of cancer, including glioblastoma. Here are some examples of genes that the SWIM tool has identified as being down-regulated in glioblastoma:\n\n1. CDKN2A: This gene encodes a protein that inhibits the activity of cyclin-dependent kinases, which are enzymes that regulate cell division. Mutations in the CDKN2A gene have been implicated in the development of several types of cancer, including glioblastoma.\n2. TP53: This gene encodes a protein called p53, which is a key regulator of cell growth and division. Mutations in the TP53 gene are common in glioblastoma and other types of cancer.\n3. PTEN: This gene encodes a protein that negatively regulates the PI3K/AKT signaling pathway, which is involved in cell growth and survival. Mutations in the PTEN gene have been implicated in the development of several types of cancer, including glioblastoma.\n4. CDKN1A: This gene encodes a protein that inhibits the activity of cyclin-dependent kinases, which are enzymes that regulate cell division. Mutations in the CDKN1A gene have been implicated in the development of several types of cancer, including glioblastoma.\n5. RB1: This gene encodes a protein called retinoblastoma protein, which is a key regulator of cell growth and division. Mutations in the RB1 gene have been implicated in the development of several types of cancer, including glioblastoma.\n\nThese are just a few examples of the many genes that the SWIM tool has identified as being down-regulated in glioblastoma. The tool provides a comprehensive list of genes that are down-regulated in glioblastoma and other types of cancer, and can be used to identify potential therapeutic targets for the treatment of these diseases.",
    "llama-7b_fact_raw": "1. The SWIM tool identifies genes that are down-regulated in specific types of cancer, including glioblastoma.\n2. CDKN2A is a gene identified by the SWIM tool as down-regulated in glioblastoma, and it encodes a protein that inhibits cyclin-dependent kinases.\n3. The TP53 gene, which encodes a protein called p53, is identified by the SWIM tool as being down-regulated in glioblastoma.\n4. PTEN is a gene identified by the SWIM tool that is down-regulated in glioblastoma, and it encodes a protein that regulates the PI3K/AKT signaling pathway.\n5. RB1, a gene encoding the retinoblastoma protein and identified as down-regulated in glioblastoma by the SWIM tool, is linked with the regulation of cell growth and division.",
    "llama-7b_fact": [
      "The SWIM tool identifies genes that are down-regulated in specific types of cancer, including glioblastoma.",
      "CDKN2A is a gene identified by the SWIM tool as down-regulated in glioblastoma, and it encodes a protein that inhibits cyclin-dependent kinases.",
      "The TP53 gene, which encodes a protein called p53, is identified by the SWIM tool as being down-regulated in glioblastoma.",
      "PTEN is a gene identified by the SWIM tool that is down-regulated in glioblastoma, and it encodes a protein that regulates the PI3K/AKT signaling pathway.",
      "RB1, a gene encoding the retinoblastoma protein and identified as down-regulated in glioblastoma by the SWIM tool, is linked with the regulation of cell growth and division."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nPlease note, the assessment of the statements about the SWIM tool is marked as UNKNOWN because the specifics of what the SWIM tool identifies are not common knowledge and cannot be verified without additional context or access to relevant scientific literature. Statements that are generally understood and accepted in the scientific community concerning gene functions are marked as TRUE.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3926,
    "user_query": "You MUST give a detailed answer to the following question: Which R packages have been developed for studying TADs?",
    "llama-7b_response": "There are several R packages that have been developed for studying TADs (topologically associating domains). Some of the most commonly used R packages for studying TADs include:\n\n1. TADMatrix: TADMatrix is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n2. TADView: TADView is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n3. TADStack: TADStack is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n4. TADTree: TADTree is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n5. TADCover: TADCover is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n6. TADPlot: TADPlot is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.\n7. TADFusion: TADFusion is an R package for visualizing and analyzing TADs. It allows users to visualize TADs in 2D and 3D, and to perform various analyses on the TAD data.",
    "llama-7b_fact_raw": "1. TADMatrix is an R package designed for visualizing and analyzing topologically associating domains (TADs).\n2. TADView is an R package that provides tools for visualizing and analyzing TADs in 2D and 3D.\n3. TADStack is an R package that supports visualization and analysis of TADs.\n4. TADTree is an R package created for the purposes of visualizing and analyzing TADs.\n5. TADCover is an R package that includes functionality for TAD visualization and analysis.",
    "llama-7b_fact": [
      "TADMatrix is an R package designed for visualizing and analyzing topologically associating domains (TADs).",
      "TADView is an R package that provides tools for visualizing and analyzing TADs in 2D and 3D.",
      "TADStack is an R package that supports visualization and analysis of TADs.",
      "TADTree is an R package created for the purposes of visualizing and analyzing TADs.",
      "TADCover is an R package that includes functionality for TAD visualization and analysis."
    ],
    "llama-7b_judge_raw": "1. TRUE: TADMatrix is indeed an R package designed for visualizing and analyzing Topologically Associating Domains (TADs).\n2. UNKNOWN: Without specific information about an R package named TADView, it is not possible to verify its existence or functions.\n3. UNKNOWN: Without specific information about an R package named TADStack, it is not possible to verify its existence or functions.\n4. UNKNOWN: Without specific information about an R package named TADTree, it is not possible to verify its existence or functions.\n5. UNKNOWN: Without specific information about an R package named TADCover, it is not possible to verify its existence or functions.\n\n[Note: As of the knowledge cutoff date in 2023, TADMatrix is a known R package for TAD analysis. The existence and functionality of the other packages may need verification as they may not be well-known or may not exist.]",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "You MUST give a detailed answer to the following question: Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-7b_response": "edgeR",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3933,
    "user_query": "You MUST give a detailed answer to the following question: What are the end products of the shikimate pathway?",
    "llama-7b_response": "aromatic amino acid",
    "llama-7b_fact_raw": "1. The end products of the shikimate pathway are aromatic amino acids.",
    "llama-7b_fact": [
      "The end products of the shikimate pathway are aromatic amino acids."
    ],
    "llama-7b_judge_raw": "1. TRUE",
    "llama-7b_judge": [
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "You MUST give a detailed answer to the following question: Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-7b_response": "Yes, it is.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3939,
    "user_query": "You MUST give a detailed answer to the following question: What is the main manifestation of Liebenberg syndrome?",
    "llama-7b_response": "Liebenberg syndrome is a rare genetic disorder caused by mutations in the PIK3R1 gene, which encodes for the regulatory subunit of the phosphatidylinositol 3-kinase (PI3K) enzyme. The PI3K enzyme plays a crucial role in regulating various cellular processes, including cell growth, survival, and metabolism. Mutations in the PIK3R1 gene result in reduced expression or function of the PI3K enzyme, leading to the development of Liebenberg syndrome.\n\nThe main manifestation of Liebenberg syndrome is intellectual disability, which can range from mild to severe. Intellectual disability in Liebenberg syndrome is caused by abnormal brain development and function, which can result in impaired cognitive, social, and adaptive skills. Other common features of Liebenberg syndrome include delayed motor milestones, such as walking and talking, as well as speech and language delays. Some individuals with Liebenberg syndrome may also have feeding difficulties, gastrointestinal problems, and seizures.\n\nIn addition to intellectual disability and developmental delays, individuals with Liebenberg syndrome may also have characteristic physical features, such as a small head (microcephaly), wide-set eyes (hypertelorism), and a flat nasal bridge. Some individuals with Liebenberg syndrome may also have hearing loss, heart defects, and kidney abnormalities.\n\nLiebenberg syndrome is a genetic disorder that is inherited in an autosomal recessive manner. This means that an individual must inherit two copies of the mutated PIK3R1 gene, one from each parent, in order to develop the syndrome. If an individual only inherits one mutated copy of the gene, they will be a carrier of the condition but will not exhibit any symptoms themselves.\n\nDiagnosis of Liebenberg syndrome typically involves a combination of genetic testing and clinical evaluation. Treatment for Liebenberg syndrome is primarily supportive and focuses on managing the symptoms and complications associated with the condition. Speech and language therapy, occupational therapy, and physical therapy may be helpful in improving cognitive, motor, and adaptive skill",
    "llama-7b_fact_raw": "1. Liebenberg syndrome is caused by mutations in the PIK3R1 gene.\n2. The main manifestation of Liebenberg syndrome is intellectual disability.\n3. Other common features of Liebenberg syndrome can include delayed motor milestones, speech and language delays, feeding difficulties, gastrointestinal problems, and seizures.\n4. Characteristic physical features of individuals with Liebenberg syndrome may include microcephaly, hypertelorism, and a flat nasal bridge.\n5. Liebenberg syndrome is inherited in an autosomal recessive manner, meaning both parents must contribute a mutated gene for a child to have the syndrome.",
    "llama-7b_fact": [
      "Liebenberg syndrome is caused by mutations in the PIK3R1 gene.",
      "The main manifestation of Liebenberg syndrome is intellectual disability.",
      "Other common features of Liebenberg syndrome can include delayed motor milestones, speech and language delays, feeding difficulties, gastrointestinal problems, and seizures.",
      "Characteristic physical features of individuals with Liebenberg syndrome may include microcephaly, hypertelorism, and a flat nasal bridge.",
      "Liebenberg syndrome is inherited in an autosomal recessive manner, meaning both parents must contribute a mutated gene for a child to have the syndrome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Liebenberg syndrome (also known as Leiber's syndrome) is not associated with mutations in the PIK3R1 gene. Liebenberg syndrome is a rare congenital disorder characterized by the fusion of the elbow joints and developmental anomalies of the forearms and hands. The genetic causes, if any, are not well characterized in available literature as of my last update. \n2. FALSE [correction]: The main manifestation of Liebenberg syndrome is not intellectual disability. Liebenberg syndrome primarily affects the development of the upper limbs, particularly the arms, elbows, and hands.\n3. FALSE [correction]: Common features of Liebenberg syndrome are related to the upper limb anomalies, and not necessarily to delayed motor milestones, speech and language delays, feeding difficulties, gastrointestinal problems, and seizures. These manifestations are not typically associated with Liebenberg syndrome.\n4. FALSE [correction]: While microcephaly, hypertelorism, and a flat nasal bridge are characteristic physical features of certain genetic syndromes, they are not specifically associated with Liebenberg syndrome. Liebenberg syndrome is characterized by limb malformations, particularly of the elbows and hands. \n5. UNKNOWN: The inheritance pattern of Liebenberg syndrome is not well defined in the available literature as of my last update. Without specific genetic information, the inheritance pattern cannot be accurately described.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "You MUST give a detailed answer to the following question: List orally bioavailable MPS1 kinase inhibitors",
    "llama-7b_response": "Sure, here are some orally bioavailable MPS1 kinase inhibitors:\n\n1. Sorafenib (Nexavar)\n2. Sunitinib (Sutent)\n3. Pazopanib (Votrient)\n4. Axitinib (Inlyta)\n5. Tofacitinib (Xeljanz)\n6. Cediranib (Cediranib Maleate)\n7. AZD8055 (ARQ 197)\n8. BAY 439001 (Sunitinib Malate)\n9. GSK2141795\n10. PF-04217903\n\nPlease note that this list is not exhaustive and there may be other orally bioavailable MPS1 kinase inhibitors that are not included here.",
    "llama-7b_fact_raw": "1. Sorafenib (Nexavar) is an orally bioavailable MPS1 kinase inhibitor.\n2. Sunitinib (Sutent) is an orally bioavailable MPS1 kinase inhibitor.\n3. Pazopanib (Votrient) is an orally bioavailable MPS1 kinase inhibitor.\n4. Axitinib (Inlyta) is an orally bioavailable MPS1 kinase inhibitor.\n5. Tofacitinib (Xeljanz) is an orally bioavailable MPS1 kinase inhibitor.",
    "llama-7b_fact": [
      "Sorafenib (Nexavar) is an orally bioavailable MPS1 kinase inhibitor.",
      "Sunitinib (Sutent) is an orally bioavailable MPS1 kinase inhibitor.",
      "Pazopanib (Votrient) is an orally bioavailable MPS1 kinase inhibitor.",
      "Axitinib (Inlyta) is an orally bioavailable MPS1 kinase inhibitor.",
      "Tofacitinib (Xeljanz) is an orally bioavailable MPS1 kinase inhibitor."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Sorafenib (Nexavar) is an orally bioavailable kinase inhibitor, but it primarily targets several receptor tyrosine kinases (RTKs), such as VEGFR and PDGFR, and the serine/threonine kinases Raf-1 and B-Raf, not specifically or primarily MPS1.\n2. FALSE [correction]: Sunitinib (Sutent) is an orally bioavailable kinase inhibitor that targets multiple receptor tyrosine kinases (RTKs), including VEGFR, PDGFR, and others. It is not specifically known as an MPS1 kinase inhibitor.\n3. FALSE [correction]: Pazopanib (Votrient) is an orally bioavailable kinase inhibitor for several receptor tyrosine kinases (RTKs), including VEGFR, PDGFR, and c-Kit. It is not specifically known as an MPS1 kinase inhibitor.\n4. FALSE [correction]: Axitinib (Inlyta) is an orally bioavailable kinase inhibitor that is selective for VEGFR receptors but is not specifically marketed or known as an MPS1 kinase inhibitor.\n5. FALSE [correction]: Tofacitinib (Xeljanz) is an orally bioavailable kinase inhibitor that primarily targets Janus kinases (JAKs), not MPS1.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4031,
    "user_query": "You MUST give a detailed answer to the following question: Was golimumab tested for diabetes?",
    "llama-7b_response": "Golimumab, also known as Simponi, is a monoclonal antibody drug that is used to treat several autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It works by targeting a specific protein called tumor necrosis factor-alpha (TNF-alpha), which is involved in the immune system's response to inflammation.\n\nTo my knowledge, there is no specific information available on whether golimumab has been tested for the treatment of diabetes. However, it is worth noting that some studies have suggested that TNF-alpha may play a role in the development of insulin resistance and type 2 diabetes. Therefore, it is possible that golimumab, or similar drugs that target TNF-alpha, could potentially be used to treat or prevent diabetes in the future. However, more research would be needed to determine the safety and effectiveness of golimumab for this purpose.",
    "llama-7b_fact_raw": "1. Golimumab, also known as Simponi, is a monoclonal antibody drug.\n2. Golimumab is used to treat autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n3. Golimumab targets the protein called tumor necrosis factor-alpha (TNF-alpha) to respond to inflammation.\n4. TNF-alpha is suggested to be involved in the development of insulin resistance and type 2 diabetes.",
    "llama-7b_fact": [
      "Golimumab, also known as Simponi, is a monoclonal antibody drug.",
      "Golimumab is used to treat autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "Golimumab targets the protein called tumor necrosis factor-alpha (TNF-alpha) to respond to inflammation.",
      "TNF-alpha is suggested to be involved in the development of insulin resistance and type 2 diabetes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "You MUST give a detailed answer to the following question: Is progeria caused by an autosomal recessive gene?",
    "llama-7b_response": "Yes, progeria is caused by an autosomal recessive gene.\n\nProgeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes premature aging in children. It is caused by a mutation in the LMNA gene, which is located on chromosome 1q21. The LMNA gene provides instructions for making a protein called lamin A, which is a key component of the nucleus of cells.\n\nIn individuals with progeria, the mutation in the LMNA gene leads to the production of an abnormal form of lamin A, which accumulates in the cells and causes them to become rigid and dysfunctional. This leads to the characteristic features of progeria, such as premature graying, hardening of the skin, and heart disease.\n\nProgeria is a very rare disorder, affecting only about 200 children worldwide. It is typically diagnosed in children between the ages of 18 months and 2 years, and most children with progeria do not survive beyond their early 20s. Despite its rarity, progeria has been extensively studied, and researchers have made significant progress in understanding its genetic basis and potential treatments.",
    "llama-7b_fact_raw": "1. Progeria is caused by a mutation in the LMNA gene, which is located on chromosome 1q21.\n2. The LMNA gene is responsible for making a protein called lamin A.\n3. The mutation in the LMNA gene results in an abnormal form of lamin A that accumulates in cells, contributing to premature aging in children with progeria.\n4. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), typically presents in children between the ages of 18 months and 2 years.\n5. Most children with progeria do not survive beyond their early 20s.",
    "llama-7b_fact": [
      "Progeria is caused by a mutation in the LMNA gene, which is located on chromosome 1q21.",
      "The LMNA gene is responsible for making a protein called lamin A.",
      "The mutation in the LMNA gene results in an abnormal form of lamin A that accumulates in cells, contributing to premature aging in children with progeria.",
      "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), typically presents in children between the ages of 18 months and 2 years.",
      "Most children with progeria do not survive beyond their early 20s."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "You MUST give a detailed answer to the following question: What are common variants at 12q14 and 12q24 associated with?",
    "llama-7b_response": "The common variants at 12q14 and 12q24 are associated with schizophrenia.",
    "llama-7b_fact_raw": "1. Genetic variants at the 12q14 chromosomal location are associated with schizophrenia.\n2. Genetic variants at the 12q24 chromosomal location are associated with schizophrenia.",
    "llama-7b_fact": [
      "Genetic variants at the 12q14 chromosomal location are associated with schizophrenia.",
      "Genetic variants at the 12q24 chromosomal location are associated with schizophrenia."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n\nWithout specific context or a reference to a research paper that makes a direct claim about the association of genetic variants at the 12q14 chromosomal location with schizophrenia, the statement remains unverified. However, studies have widely recognized that the 12q24 chromosomal location is associated with a higher risk of developing schizophrenia.",
    "llama-7b_judge": [
      "unknown",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "You MUST give a detailed answer to the following question: Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-7b_response": "The Roundabout (Robo) receptors are a family of G protein-coupled receptors (GPCRs) that play a critical role in the development and maintenance of the nervous system. These receptors are primarily expressed in the nervous system and are involved in a variety of processes, including axon guidance, synaptic plasticity, and neurodegeneration.\n\nThe ligands of the Roundabout (Robo) receptors are a diverse group of molecules that include proteins, peptides, and small molecules. Some of the known ligands of the Roundabout (Robo) receptors include:\n\n1. Robo proteins: The Roundabout (Robo) proteins are the primary ligands of the Roundabout (Robo) receptors. There are several isoforms of the Robo proteins, including Robo1, Robo2, Robo3, Robo4, and Robo5. These proteins are expressed in various tissues and play important roles in the development and maintenance of the nervous system.\n2. Neurexins: Neurexins are another group of ligands of the Roundabout (Robo) receptors. There are several isoforms of neurexins, including Neurexin1, Neurexin2, Neurexin3, and Neurexin4. These proteins are expressed in various tissues and play important roles in the development and maintenance of the nervous system.\n3. Slit proteins: Slit proteins are another group of ligands of the Roundabout (Robo) receptors. There are several isoforms of slit proteins, including Slit1, Slit2, Slit3, and Slit4. These proteins are expressed in various tissues and play important roles in the development and maintenance of the nervous system.\n4. Growth factors: Growth factors, such as epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF), have also been shown to act as ligands of the Roundabout (Robo) receptors.\n5. Small molecules: Small molecules, such as retinoic acid and thyroid hormones, have also been shown to act a",
    "llama-7b_fact_raw": "1. Roundabout (Robo) receptors are a family of G protein-coupled receptors (GPCRs).\n2. Robo receptors are primarily expressed in the nervous system and are involved in processes including axon guidance, synaptic plasticity, and neurodegeneration.\n3. Robo proteins (Robo1, Robo2, Robo3, Robo4, and Robo5) serve as primary ligands for Roundabout (Robo) receptors.\n4. Neurexins (Neurexin1, Neurexin2, Neurexin3, Neurexin4) are ligands of the Roundabout (Robo) receptors.\n5. Slit proteins, growth factors like EGF, FGF, PDGF, and small molecules such as retinoic acid and thyroid hormones can act as ligands of the Roundabout (Robo) receptors.",
    "llama-7b_fact": [
      "Roundabout (Robo) receptors are a family of G protein-coupled receptors (GPCRs).",
      "Robo receptors are primarily expressed in the nervous system and are involved in processes including axon guidance, synaptic plasticity, and neurodegeneration.",
      "Robo proteins (Robo1, Robo2, Robo3, Robo4, and Robo5) serve as primary ligands for Roundabout (Robo) receptors.",
      "Neurexins (Neurexin1, Neurexin2, Neurexin3, Neurexin4) are ligands of the Roundabout (Robo) receptors.",
      "Slit proteins, growth factors like EGF, FGF, PDGF, and small molecules such as retinoic acid and thyroid hormones can act as ligands of the Roundabout (Robo) receptors."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Roundabout (Robo) receptors are not a family of G protein-coupled receptors (GPCRs); they are a family of single-pass transmembrane receptors.\n2. TRUE\n3. FALSE [correction]: Robo proteins do not serve as ligands for Roundabout (Robo) receptors; instead, they are the receptors themselves. Slit proteins are known ligands for Robo receptors.\n4. FALSE [correction]: Neurexins are not ligands for Roundabout (Robo) receptors. They are cell adhesion molecules.\n5. PARTIALLY TRUE [correction]: Slit proteins are indeed known ligands for Robo receptors, but there is no consensus on EGF, FGF, PDGF, retinoic acid, and thyroid hormones serving as ligands specifically for Roundabout (Robo) receptors. Such growth factors and small molecules are ligands for other receptor types.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4112,
    "user_query": "You MUST give a detailed answer to the following question: Is there a role for TFII-I in megakaryopoiesis?",
    "llama-7b_response": "Yes, there is a role for TFII-I in megakaryopoiesis. TFII-I is a transcription factor that plays an important role in the regulation of gene expression during the process of megakaryopoiesis.\n\nMegakaryopoiesis is the process by which megakaryocytes, which are specialized bone marrow cells that produce platelets, are formed. This process involves the proliferation and differentiation of hematopoietic stem cells into megakaryocytes.\n\nTFII-I has been shown to play a crucial role in the regulation of genes involved in the differentiation of hematopoietic stem cells into megakaryocytes. For example, TFII-I has been shown to bind to the promoter region of the platelet-derived growth factor receptor alpha (PDGFRα) gene, which is a key regulator of megakaryopoiesis, and to activate its transcription.\n\nFurthermore, TFII-I has also been shown to play a role in the regulation of genes involved in the maturation of megakaryocytes. For example, TFII-I has been shown to bind to the promoter region of the glycoprotein Ibα (GPIbα) gene, which is a key regulator of platelet formation, and to activate its transcription.\n\nIn summary, TFII-I plays an important role in the regulation of gene expression during the process of megakaryopoiesis by binding to the promoter regions of genes involved in the differentiation and maturation of hematopoietic stem cells into megakaryocytes.",
    "llama-7b_fact_raw": "1. TFII-I is involved in the regulation of gene expression during megakaryopoiesis.\n2. Megakaryopoiesis is the process by which megakaryocytes are formed and is essential for the production of platelets.\n3. TFII-I binds to the promoter region of the platelet-derived growth factor receptor alpha (PDGFRα) gene, which plays a significant role in megakaryopoiesis.\n4. TFII-I is involved in activating the transcription of the PDGFRα gene.\n5. TFII-I also binds to the promoter region of the glycoprotein Ibα (GPIbα) gene, which is important for platelet formation.",
    "llama-7b_fact": [
      "TFII-I is involved in the regulation of gene expression during megakaryopoiesis.",
      "Megakaryopoiesis is the process by which megakaryocytes are formed and is essential for the production of platelets.",
      "TFII-I binds to the promoter region of the platelet-derived growth factor receptor alpha (PDGFRα) gene, which plays a significant role in megakaryopoiesis.",
      "TFII-I is involved in activating the transcription of the PDGFRα gene.",
      "TFII-I also binds to the promoter region of the glycoprotein Ibα (GPIbα) gene, which is important for platelet formation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements about TFII-I's involvement in megakaryopoiesis and the general process of megakaryopoiesis are generally accepted scientific facts. However, without specific scientific literature references or more detailed context regarding the roles of TFII-I binding to the promoter region of the PDGFRα and GPIbα genes and its involvement in their transcription activation, the veracity of statements 3, 4, and 5 cannot be determined as true or false from the given information alone. These are specific claims that require direct evidence from scientific studies.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "You MUST give a detailed answer to the following question: Is atenolol metabolized by CYP2D6?",
    "llama-7b_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6. Atenolol is a beta-adrenergic receptor blocker that is used to treat hypertension and angina pectoris. It works by blocking the beta-1 adrenergic receptors in the heart and blood vessels, which reduces the workload on the heart and lowers blood pressure.\n\nCYP2D6 is an enzyme that is involved in the metabolism of a wide range of drugs, including many cardiovascular medications. The metabolism of atenolol by CYP2D6 results in the formation of several metabolites, including tenoxicam and tenidap.\n\nThe metabolism of atenolol by CYP2D6 can be affected by genetic variations in the CYP2D6 gene. Some individuals may have reduced activity of the CYP2D6 enzyme, which can lead to reduced metabolism of atenolol and an increased risk of side effects. Conversely, some individuals may have increased activity of the CYP2D6 enzyme, which can lead to increased metabolism of atenolol and a reduced effectiveness of the medication.\n\nIn summary, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6, which is involved in the metabolism of many cardiovascular medications. The metabolism of atenolol by CYP2D6 can be affected by genetic variations in the CYP2D6 gene, which can lead to changes in the effectiveness and side effects of the medication.",
    "llama-7b_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. Atenolol is used to treat hypertension and angina pectoris by blocking beta-1 adrenergic receptors in the heart and blood vessels.\n3. Metabolism of atenolol by CYP2D6 results in the formation of metabolites such as tenoxicam and tenidap.\n4. Genetic variations in the CYP2D6 gene can affect the enzyme's activity, influencing the metabolism of atenolol.\n5. Differences in CYP2D6 enzyme activity can alter the effectiveness and side effects of atenolol.",
    "llama-7b_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "Atenolol is used to treat hypertension and angina pectoris by blocking beta-1 adrenergic receptors in the heart and blood vessels.",
      "Metabolism of atenolol by CYP2D6 results in the formation of metabolites such as tenoxicam and tenidap.",
      "Genetic variations in the CYP2D6 gene can affect the enzyme's activity, influencing the metabolism of atenolol.",
      "Differences in CYP2D6 enzyme activity can alter the effectiveness and side effects of atenolol."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the cytochrome P450 enzyme system; it is primarily excreted unchanged in the urine.\n2. TRUE\n3. FALSE [correction]: Tenoxicam and tenidap are not metabolites of atenolol. These are different drugs and not related to the metabolism of atenolol.\n4. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, genetic variations in the CYP2D6 gene would not be expected to influence the metabolism of atenolol to a clinically significant extent.\n5. FALSE [correction]: Because atenolol is not significantly metabolized by CYP2D6, variations in CYP2D6 activity are not likely to alter the effectiveness and side effects of atenolol significantly. However, other factors can influence the pharmacokinetics of atenolol, such as renal function.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "You MUST give a detailed answer to the following question: List versions of ExpansionHunter",
    "llama-7b_response": "I'm sorry, but I don't have any information about versions of ExpansionHunter. Can you provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 4164,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of Adamts18 in hormone receptor signaling?",
    "llama-7b_response": "Adamts18, also known as adamalysin-18, is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of proteins. The role of Adamts18 in hormone receptor signaling is not well understood, but it has been suggested that it may play a role in the regulation of hormone receptor trafficking and signaling.\n\nHormone receptors, such as estrogen receptors (ERs) and progesterone receptors (PRs), are transmembrane proteins that bind to hormones and regulate the expression of target genes involved in various physiological processes. Upon hormone binding, the receptors undergo a series of post-translational modifications, including phosphorylation, ubiquitination, and sumoylation, which regulate their stability, localization, and activity.\n\nAdamts18 has been shown to interact with several hormone receptors, including ERs, PRs, and androgen receptors (ARs). In vitro studies have demonstrated that Adamts18 can modulate the activity of these receptors by regulating their trafficking and signaling. For example, Adamts18 has been shown to promote the endocytic internalization of ERs and PRs, which can inhibit their signaling activity. Conversely, Adamts18 has also been shown to promote the recycling of ERs and PRs back to the plasma membrane, which can enhance their signaling activity.\n\nIn addition to its effects on hormone receptor trafficking, Adamts18 has also been implicated in the regulation of hormone receptor signaling. For example, Adamts18 has been shown to modulate the phosphorylation of ERs and PRs, which can regulate their transcriptional activity. Adamts18 has also been shown to modulate the ubiquitination and sumoylation of hormone receptors, which can regulate their stability and activity.\n\nOverall, the role of Adamts18 in hormone receptor signaling is complex and multifaceted, and further research is needed to fully understand",
    "llama-7b_fact_raw": "1. Adamts18, also known as adamalysin-18, is part of the ADAMTS family of proteins.\n2. Adamts18 may play a role in the regulation of hormone receptor trafficking and signaling.\n3. Adamts18 has been shown to interact with estrogen receptors (ERs), progesterone receptors (PRs), and androgen receptors (ARs).\n4. In vitro studies suggest that Adamts18 can modulate the activity of these hormone receptors by affecting their trafficking.\n5. Adamts18 has been indicated to influence the post-translational modifications of hormone receptors, such as phosphorylation, ubiquitination, and sumoylation.",
    "llama-7b_fact": [
      "Adamts18, also known as adamalysin-18, is part of the ADAMTS family of proteins.",
      "Adamts18 may play a role in the regulation of hormone receptor trafficking and signaling.",
      "Adamts18 has been shown to interact with estrogen receptors (ERs), progesterone receptors (PRs), and androgen receptors (ARs).",
      "In vitro studies suggest that Adamts18 can modulate the activity of these hormone receptors by affecting their trafficking.",
      "Adamts18 has been indicated to influence the post-translational modifications of hormone receptors, such as phosphorylation, ubiquitination, and sumoylation."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: ADAMTS proteins, including Adamts18, are generally involved in the processing of procollagen proteins and the cleavage of von Willebrand factor, but the specific role of Adamts18 in hormone receptor trafficking and signaling is not well established.\n3. FALSE [correction]: There is no widely accepted or direct evidence that Adamts18 interacts with hormone receptors such as estrogen, progesterone, and androgen receptors. Instead, these receptors interact with a different set of molecules that modulate their activity.\n4. FALSE [correction]: As there is no established evidence that Adamts18 interacts with these hormone receptors, it is incorrect to state in vitro studies suggest Adamts18's role in modulating receptor activity through trafficking.\n5. FALSE [correction]: Given that the specific interactions of Adamts18 with hormone receptors are not well-documented, the claim regarding its influence on post-translational modifications of these receptors is likely incorrect. Generally, the modulation of hormone receptors through post-translational modifications involves various other enzymes and regulatory proteins.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4208,
    "user_query": "You MUST give a detailed answer to the following question: What is the mode of action of Thiazovivin?",
    "llama-7b_response": "Thiazovivin is a chemotherapy drug that belongs to the class of alkylating agents. It works by interfering with the process of DNA replication, which is essential for the growth and survival of cancer cells.\n\nThe mechanism of action of thiazovivin involves the formation of a covalent adduct between the drug and the guanine base of DNA. This results in the inhibition of DNA replication and transcription, as well as the induction of apoptosis (programmed cell death) in cancer cells.\n\nThiazovivin also inhibits the enzyme topoisomerase II, which is involved in the relaxation of supercoiled DNA. This leads to the formation of DNA strand breaks and the accumulation of DNA damage, which further contributes to the cytotoxic effects of the drug.\n\nOverall, the mode of action of thiazovivin involves the interference with the processes of DNA replication, transcription, and repair, which are essential for the survival and proliferation of cancer cells.",
    "llama-7b_fact_raw": "1. Thiazovivin is a chemotherapy drug that interrupts the process of DNA replication.\n2. The drug acts by forming a covalent bond with the guanine base of DNA, disrupting replication and transcription.\n3. The mode of action of Thiazovivin results in the induction of apoptosis in cancer cells.\n4. Thiazovivin inhibits the enzyme topoisomerase II, which plays a role in the relaxation of supercoiled DNA.\n5. Interference with DNA replication, transcription, and repair by Thiazovivin contributes to its cytotoxic effects on cancer cells.",
    "llama-7b_fact": [
      "Thiazovivin is a chemotherapy drug that interrupts the process of DNA replication.",
      "The drug acts by forming a covalent bond with the guanine base of DNA, disrupting replication and transcription.",
      "The mode of action of Thiazovivin results in the induction of apoptosis in cancer cells.",
      "Thiazovivin inhibits the enzyme topoisomerase II, which plays a role in the relaxation of supercoiled DNA.",
      "Interference with DNA replication, transcription, and repair by Thiazovivin contributes to its cytotoxic effects on cancer cells."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is not a chemotherapy drug; it is actually a small molecule that enhances the survival of induced pluripotent stem cells (iPSCs) and is used in stem cell research.\n2. FALSE [correction]: Thiazovivin does not form a covalent bond with guanine bases in DNA, as that is not its mechanism of action. It promotes the survival of iPSCs generally by inhibiting Rho-associated kinase (ROCK).\n3. FALSE [correction]: Thiazovivin's mode of action is not the induction of apoptosis in cancer cells. Instead, it enhances the survival and reprogramming efficiency of stem cells through inhibition of the ROCK pathway.\n4. FALSE [correction]: Thiazovivin does not inhibit topoisomerase II; it exerts its effects by inhibiting the ROCK pathway, which is not directly related to topoisomerase II.\n5. FALSE [correction]: Since Thiazovivin is not a chemotherapy drug, its effects do not involve interference with DNA replication, transcription, and repair in the context of cytotoxicity against cancer cells. Instead, it aids in stem cell technology and research.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  }
]